U.S. patent application number 17/747384 was filed with the patent office on 2022-09-29 for pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations.
This patent application is currently assigned to Rigel Pharmaceuticals, Inc.. The applicant listed for this patent is Rigel Pharmaceuticals, Inc.. Invention is credited to Somasekhar Bhamidipati, Yan Chen, Lu Chou, Ihab Darwish, Matt Duan, Dazhong Fan, Zhushou Luo, Simon Shaw, Vanessa Taylor.
Application Number | 20220306620 17/747384 |
Document ID | / |
Family ID | 1000006349098 |
Filed Date | 2022-09-29 |
United States Patent
Application |
20220306620 |
Kind Code |
A1 |
Chou; Lu ; et al. |
September 29, 2022 |
PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING
THE COMPOUNDS AND/OR FORMULATIONS
Abstract
Disclosed herein are embodiments of a pyrazole compound
according to formula I. ##STR00001## Compositions comprising the
compound, and a method for making the composition also are
disclosed. The composition may comprise a carrier, such as a
polymer and/or the composition may be a spray-dried formulation.
Also disclosed is a method for using the compound and/or
composition. The compound and/or composition may be useful to
inhibit an IRAK protein and/or to ameliorate, treat and/or prevent
an IRAK-associated disease or condition in a subject.
Inventors: |
Chou; Lu; (Burlingame,
CA) ; Duan; Matt; (Foster City, CA) ; Darwish;
Ihab; (South San Francisco, CA) ; Shaw; Simon;
(Oakland, CA) ; Bhamidipati; Somasekhar; (Foster
City, CA) ; Taylor; Vanessa; (San Francisco, CA)
; Chen; Yan; (Foster City, CA) ; Fan; Dazhong;
(South San Francisco, CA) ; Luo; Zhushou; (South
San Francisco, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Rigel Pharmaceuticals, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
Rigel Pharmaceuticals, Inc.
South San Francisco
CA
|
Family ID: |
1000006349098 |
Appl. No.: |
17/747384 |
Filed: |
May 18, 2022 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
17006150 |
Aug 28, 2020 |
11370787 |
|
|
17747384 |
|
|
|
|
62894547 |
Aug 30, 2019 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 417/14
20130101 |
International
Class: |
C07D 417/14 20060101
C07D417/14 |
Claims
1. A compound that is sodium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate.
2. A composition comprising the compound of claim 1, and a
pharmaceutically acceptable excipient.
3. A method for treating a disease or condition for which an IRAK
inhibitor is indicated, comprising administering to a subject
having the disease or condition an effective amount of a compound
according to claim 1 or a composition thereof, wherein the disease
or condition comprises an auto-immune disease, inflammatory
disorder, cardiovascular disease, neurodegenerative disorder,
allergic disorder, multi-organ failure, kidney disease, platelet
aggregation, cancer, transplantation, sperm motility, erythrocyte
deficiency, graft rejection, lung injury, respiratory disease,
ischemic condition, bacterial infection, viral infection, immune
regulatory disorder or a combination thereof.
4. The method of claim 3, wherein the disease or condition
comprises an autoimmune disease, inflammatory disorder,
cardiovascular disease, cancer, ischemic condition, immune
regulatory disorder or a combination thereof.
5. The method of claim 3, wherein the disease or condition
comprises an autoimmune disease or inflammatory disorder.
6. The method of claim 3, wherein the disease or condition
comprises a proliferative disorder.
7. The method of claim 3, wherein the disease or condition
comprises transplant or organ rejection, a graft-versus-host
disease, rheumatoid arthritis, systemic lupus erythematosus,
Hashimoto's thyroiditis, multiple sclerosis, systemic sclerosis,
myasthenia gravis, type I diabetes, uveitis, posterior uveitis,
allergic encephalomyelitis, glomerulonephritis, rheumatic fever,
post-infectious glomerulonephritis, inflammatory skin disease,
hyperproliferative skin disease, psoriasis, atopic dermatitis,
contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis,
lichen planus, pemphigus, bullous pemphigoid, epidermolysis
bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous
eosinophilia, lupus erythematosus, acne, alopecia areata,
keratoconjunctivitis, vernal conjunctivitis, uveitis associated
with Behcet's disease, keratitis, herpetic keratitis, conical
cornea, dystrophia epithelialis corneae, corneal leukoma, ocular
pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy,
Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies,
reversible obstructive airway disease, bronchial asthma, allergic
asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or
inveterate asthma, late asthma and airway hyper-responsiveness,
bronchitis, gastric ulcers, vascular damage caused by ischemic
diseases and thrombosis, ischemic bowel diseases, inflammatory
bowel diseases, necrotizing enterocolitis, intestinal lesions
associated with thermal burns, celiac diseases, proctitis,
eosinophilic gastroenteritis, mastocytosis, Crohn's disease,
ulcerative colitis, migraine, rhinitis, eczema, interstitial
nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome,
diabetic nephropathy, multiple myositis, Guillain-Barre syndrome,
Meniere's disease, polyneuritis, multiple neuritis, mononeuritis,
radiculopathy, hyperthyroidism, Basedow's disease, pure red cell
aplasia, aplastic anemia, hypoplastic anemia, idiopathic
thrombocytopenic purpura, autoimmune hemolytic anemia,
agranulocytosis, pernicious anemia, megaloblastic anemia,
anerythroplasia, osteoporosis, sarcoidosis, fibroid lung,
idiopathic interstitial pneumonia, dermatomyositis, leukoderma
vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous
T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis,
atherosclerosis, aortitis syndrome, polyarteritis nodosa,
myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome,
adiposis, eosinophilic fascitis, lesions of gingiva, periodontium,
alveolar bone, substantia ossea dentis, glomerulonephritis, male
pattern alopecia or alopecia senilis by preventing epilation or
providing hair germination and/or promoting hair generation and
hair growth, muscular dystrophy, pyoderma and Sezary's syndrome,
Addison's disease, ischemia-reperfusion injury of organs which
occurs upon preservation, transplantation or ischemic disease,
endotoxin-shock, pseudomembranous colitis, colitis caused by drug
or radiation, ischemic acute renal insufficiency, chronic renal
insufficiency, toxinosis caused by lung-oxygen or drugs, lung
cancer, pulmonary emphysema, cataracta, siderosis, retinitis
pigmentosa, senile macular degeneration, vitreal scarring, corneal
alkali burn, dermatitis erythema multiforme, linear IgA ballous
dermatitis and cement dermatitis, gingivitis, periodontitis,
sepsis, pancreatitis, diseases caused by environmental pollution,
aging, carcinogenesis, metastasis of carcinoma and hypobaropathy,
disease caused by histamine or leukotriene-C4 release, Behcet's
disease, autoimmune hepatitis, primary biliary cirrhosis,
sclerosing cholangitis, partial liver resection, acute liver
necrosis, necrosis caused by toxin, viral hepatitis, shock, or
anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis,
alcoholic liver disease, including alcoholic cirrhosis,
non-alcoholic steatohepatitis (NASH), hepatic failure, fulminant
hepatic failure, late-onset hepatic failure, "acute-on-chronic"
liver failure, augmentation of chemotherapeutic effect,
cytomegalovirus infection, HCMV infection, AIDS, cancer, senile
dementia, Parkinson's disease, trauma, chronic bacterial infection,
or a combination thereof.
8. The method of claim 3, wherein the disease or condition
comprises a lymphoid neoplasm selected from myeloproliferative
neoplasms (MPN) excluding polycythemia vera, myeloid/lymphoid
neoplasms with PDGFRA rearrangement, myeloid/lymphoid neoplasms
with PDGFRB rearrangement, myeloid/lymphoid neoplasms with FGFR1
rearrangement, myeloid/lymphoid neoplasms with PCM1-JAK2,
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN), myeloid
sarcoma, myeloid proliferations related to Down syndrome, blastic
plasmacytoid dendritic cell neoplasm, B-lymphoblastic
leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, or a
combination thereof.
9. The method of claim 3, wherein the disease or condition
comprises rheumatoid arthritis, psoriatic arthritis,
osteoarthritis, systemic lupus erythematosus, lupus nephritis,
ankylosing spondylitis, osteoporosis, systemic sclerosis, multiple
sclerosis, psoriasis, in particular pustular psoriasis, type I
diabetes, type II diabetes, inflammatory bowel disease (Crohn's
disease and ulcerative colitis), hyperimmunoglobulinemia d and
periodic fever syndrome, cryopyrin-associated periodic syndromes,
Schnitzler's syndrome, systemic juvenile idiopathic arthritis,
adult-onset Still's disease, gout, gout flares, pseudogout, sapho
syndrome, Castleman's disease, sepsis, stroke, atherosclerosis,
celiac disease, DIRA (deficiency of Il-1 receptor antagonist),
Alzheimer's disease, Parkinson's disease or a combination
thereof.
10. The method of claim 6, wherein the proliferative disorder
comprises a disorder selected from benign tumors, malignant tumors,
solid tumor, carcinoma of the brain, kidney, liver, adrenal gland,
bladder, breast, stomach, gastric tumors, ovaries, colon, rectum,
prostate, pancreas, lung, vagina, cervix, testis, genitourinary
tract, esophagus, larynx, skin, bone or thyroid, sarcoma,
glioblastomas, neuroblastomas, multiple myeloma, gastrointestinal
cancer, colon carcinoma or colorectal adenoma, a tumor of the neck
and head, an epidermal hyperproliferation, psoriasis, prostate
hyperplasia, a neoplasia, a neoplasia of epithelial character,
adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma,
large cell carcinoma, non-small-cell lung carcinoma, lymphomas,
Hodgkins and non-Hodgkins, a mammary carcinoma, follicular
carcinoma, undifferentiated carcinoma, papillary carcinoma,
seminoma, melanoma, IL-1 driven disorders, a MyD88 driven disorder
(such as ABC diffuse large B-cell lymphoma (DLBCL), Waldenstrom's
macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell
lymphoma, smoldering or indolent multiple myeloma, hematological
malignancies, leukemia, acute myeloid leukemia (AML), DLBCL, ABC
DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic
lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia,
acute lymphocytic leukemia, B-cell prolymphocytic leukemia,
lymphoplasmacytic lymphoma, myelodysplastic syndromes (MDS),
myelofibrosis, polycythemia vera, Kaposi's sarcoma, Waldenstrom's
macroglobulinemia (WM), splenic marginal zone lymphoma, multiple
myeloma, plasmacytoma, intravascular large B-cell lymphoma, or a
combination thereof.
11. The method of claim 6, wherein the proliferative disorder
comprises psoriasis.
12. The method of claim 12, wherein the proliferative disorder
comprises a drug resistant malignancy.
13. The method of claim 12, wherein the drug resistant malignancy
comprises a malignancy selected from malignancies resistant to JAK
inhibitors, ibrutinib resistant malignancies, ibrutinib resistant
hematological malignancies, ibrutinib resistant CLL, ibrutinib
resistant, Waldenstrom's macroglobulinemia or a combination
thereof.
14. The method of claim 3, wherein the disease or condition
comprises a hematological malignancy.
15. The method of claim 14, wherein the hematological malignancy
comprises a malignancy selected from leukemia, acute myeloid
leukemia (AML), DLBCL, ABC DLBCL, chronic lymphocytic leukemia
(CLL), chronic lymphocytic lymphoma, primary effusion lymphoma,
Burkitt lymphoma/leukemia, acute lymphocytic leukemia, B-cell
prolymphocytic leukemia, lymphoplasmacytic lymphoma,
myelodysplastic syndromes (MDS), myelofibrosis, polycythemia vera,
Kaposi's sarcoma, Waldenstrom's macroglobulinemia (WM), splenic
marginal zone lymphoma, multiple myeloma, plasmacytoma, and
intravascular large B-cell lymphoma.
16. The method of claim 3, wherein the disease or condition
comprises a hyperproliferative skin disorder.
17. The method of claim 3, wherein the disease or condition
comprises an inflammatory skin disease, psoriasis, primary biliary
cirrhosis, sclerosing cholangitis, systemic juvenile idiopathic
arthritis, atopic dermatitis, contact dermatitis, eczematous
dermatitis, or seborrhoeic dermatitis.
18. The method of claim 3, further comprising administering a
second therapeutic agent.
19. The method of claim 18, wherein the second therapeutic agent is
an analgesic, an antibiotic, an anticoagulant, an antibody, an
anti-inflammatory agent, an immunosuppressant, a guanylate
cyclase-C agonist, an intestinal secretagogue, an antiviral,
anticancer, antifungal, or a combination thereof.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. patent
application Ser. No. 17/006,150, filed on Aug. 28, 2020, which
claims the benefit of the earlier filing date of U.S. provisional
patent application No. 62/894,547, filed Aug. 30, 2019, which is
incorporated herein by reference in its entirety.
FIELD
[0002] The present disclosure concerns compounds, formulations
thereof, and embodiments of a method using the compounds and/or
formulations, such as for inhibiting interleukin
receptor-associated kinase (IRAK) and/or delivering an IRAK
inhibitor to a subject, and for treating diseases and conditions
related to IRAK.
BACKGROUND
[0003] Interleukin-1 receptor-associated kinases (IRAKs) are
important mediators of signaling processes, such as toll-like
receptors (TLR) and interleukin-1 receptor (IL-1R) signaling
processes. IRAKs have been implicated in modulating signaling
networks that control inflammation, apoptosis, and cellular
differentiation. Four IRAK genes have been identified in the human
genome (IRAK1, IRAK2, IRAK3 and IRAK4), and studies have revealed
distinct, non-redundant biological roles. IRAK1 and IRAK4 have been
shown to exhibit kinase activity.
SUMMARY
[0004] Disclosed herein are compounds, and compositions comprising
such compounds that are useful as, inter alia, kinase inhibitors,
such as IRAK inhibitors and/or useful for delivering an IRAK
inhibitor to a subject in need thereof. In some embodiments, the
compounds are prodrugs and/or salts of IRAK inhibitor compounds.
Certain disclosed embodiments concern compounds having a formula
I.
##STR00002##
wherein R is hydrogen, aliphatic, acyl, heterocyclyl, carboxyl
ester, amide, alkyl phosphoramidate, or alkyl phosphate, such as
alkyl, acyl, carboxyl ester, amide, nonaromatic heterocyclyl, alkyl
phosphoramidate, or alkyl phosphate. Alternatively, R is hydrogen
and the compound is a salt. In some embodiments, R is
C.sub.1-4alkyl phosphate, C.sub.1-4alkyl phosphoramidate,
C.sub.1-6alkyl, C.sub.1-6acyl, --C(O)O--C.sub.1-6aliphatic,
--C(O)N(R.sup.b).sub.2, or 5- or 6-membered nonaromatic
heterocyclyl. And each R.sup.b independently is H, unsubstituted
C.sub.1-6alkyl, C.sub.1-6alkyl substituted with --N(R.sup.g).sub.2,
carboxyl ester, or 5- or 6-membered nonaromatic heterocyclyl, or
two R.sup.b together with the nitrogen to which they are attached
form a C.sub.3-6nonaromatic heterocyclyl moiety optionally
interrupted with one or two --O-- or --N(R.sup.g), where R.sup.9 is
H or C.sub.1-4alkyl. R may be C.sub.1-6alkyl optionally substituted
with a 5- or 6-membered nonaromatic heterocyclyl, OH,
--OC(O)--R.sup.a, --N(R.sup.b).sub.2, --OC(O)--R.sup.c, carboxyl,
or a combination thereof, where R.sup.a is 5-membered nonaromatic
heterocyclyl, aryl substituted with --CH.sub.2N(R.sup.b).sub.2,
C.sub.3-6cycloalkyl substituted with carboxyl, C.sub.1-6alkoxy,
unsubstituted C.sub.1-6alkyl, or C.sub.1-6alkyl substituted with
one or more of N(R.sup.b).sub.2, carboxyl, carboxyl ester,
--OC.sub.1-6acyl, --NHC(O)(NH.sub.2)C.sub.1-6alkyl, or
--(OCH.sub.2CH.sub.2).sub.1-8N(R.sup.b).sub.2. And,
--OC(O)--R.sup.c is derived from an amino acid where the --OC(O)--
moiety of --OC(O)--R.sup.c corresponds to an acid moiety on the
amino acid and R.sup.c comprises --N(R.sup.b).sub.2 or a
nitrogen-containing nonaromatic heterocyclyl. The amino acid may be
a naturally occurring amino acid, and/or may be selected from
glycine, valine, alanine, leucine, isoleucine, methionine,
phenylalanine, tryptophan, tyrosine, serine, threonine, asparagine,
glutamine, arginine, histidine, lysine, aspartic acid, glutamic
acid, cysteine, or proline.
[0005] Alternatively, R may be C.sub.1-6acyl moiety optionally
substituted with --C(O)O--C.sub.1-4alkyl,
--C(O)O--C.sub.1-4alkyl-N(R.sup.b).sub.2, N(R.sup.b).sub.2,
--NHC(O)C.sub.1-4alkyl, or a combination thereof. In some
embodiments, R is 5- or 6-membered nonaromatic heterocyclyl moiety
optionally substituted with hydroxyl, hydroxymethyl, or a
combination thereof. But in other embodiments, R is
--C(O)O--C.sub.1-6alkyl optionally substituted with
--OC(O)C.sub.1-4alkyl or N(R.sup.b).sub.2, or R is
--C(O)O--C.sub.3-6cycloalkyl optionally substituted with
C.sub.1-4alkyl.
[0006] In certain embodiments, R is hydrogen and the salt is a
hydrochloride, citrate, hemicitrate, hemitartrate, tartrate,
benzene sulfonate, mesylate, sodium, hemisuccinate, or succinate
salt. But in other embodiments, R is not a salt and/or the compound
may be a prodrug of
##STR00003##
[0007] Also disclosed herein are embodiments of a composition
comprising the compound and a pharmaceutically acceptable carrier.
The composition may be a spray-dried composition comprising a
carrier and a compound according to Formula I. However, with
respect to the spray-dried composition, R may be H, aliphatic,
acyl, heterocyclyl, carboxyl ester, amide, alkyl phosphoramidate,
or alkyl phosphate, such as H, alkyl, acyl, carboxyl ester, amide,
nonaromatic heterocyclyl, alkyl phosphoramidate, or alkyl
phosphate. Typically the compound according to Formula I is not in
the form of a salt when spray-dried. For example, suitable
compounds for spray-dried formulations disclosed herein include
compounds of Formula I wherein R is hydrogen, aliphatic, acyl,
heterocyclyl, carboxyl ester or amide.
[0008] The carrier may be a polymer, for example, a cellulose
derivative, vinyl polymer, lactide polymer, sugar, or a combination
thereof. In some embodiments, the cellulose derivative is
hydroxypropylmethylcellulose acetate succinate (HPMCAS),
hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl
methylcellulose (HPMC), or a combination thereof, the vinyl polymer
is poly(vinylpyrrolidone) (PVP), poly(vinylpyrrolidone-co-vinyl
acetate) (PVPVA), or a combination thereof, the lactide polymer is
polylactide (PLA), polylactide-co-glycolide (PLGA), or a
combination thereof, or the sugar is sucrose, trehalose, or a
combination thereof. In certain embodiments, the carrier is
hydroxypropylmethylcellulose acetate succinate, and may be an M
grade and/or fine grade hydroxypropylmethylcellulose acetate
succinate.
[0009] The composition may comprise an effective amount of the
compound according to formula I, such as from 1% to 50% w/w with
respect to the carrier, or from 10% to 35% w/w with respect to the
carrier. Additionally, or alternatively, the spray-dried
composition may further comprise a flavoring, a stabilizer, a
filler, or a combination thereof. And in any embodiments, the
composition is amorphous, and/or may have a glass transition
temperature of from 100.degree. C. to 120.degree. C., such as from
105.degree. C. to 110.degree. C. or from 107.degree. C. to
110.degree. C.
[0010] In certain embodiments, the composition comprises 20% the
disclosed compound(s) and 80% HPMCAS-MF.
[0011] Also disclosed herein are embodiments of a method for making
a spray-dried composition. The method may comprise forming a
mixture of the compound according to formula I, a carrier and a
solvent, and spray-drying the mixture to form a spray dried
formulation comprising the compound and the carrier.
[0012] Embodiments of a method for using the disclosed compounds
and/or compositions comprising the compounds also are disclosed.
The method may comprise administering the compound of a composition
comprising the compound to a subject, such as administering an
effective amount of the compound or the composition to a subject in
need thereof. The method may be a method for treating a disease or
condition for which an IRAK inhibitor is indicated. In some
embodiments, the disease is an auto-immune disease, inflammatory
disorder, cardiovascular disease, neurodegenerative disorder,
allergic disorder, multi-organ failure, kidney disease, platelet
aggregation, cancer, transplantation, sperm motility, erythrocyte
deficiency, graft rejection, lung injury, respiratory disease,
ischemic condition, bacterial infection, viral infection, immune
regulatory disorder or a combination thereof.
[0013] The method may comprise administering a second therapeutic
agent. The second therapeutic agent may be an analgesic, an
antibiotic, an anticoagulant, an antibody, an anti-inflammatory
agent, an immunosuppressant, a guanylate cyclase-C agonist, an
intestinal secretagogue, an antiviral, anticancer, antifungal, or a
combination thereof. In some embodiments, the second therapeutic
agent is administered substantially simultaneously with the
compound or composition. In other embodiments, the second
therapeutic agent is administered sequentially in any order with
the compound or composition, and the compound or composition and
the second therapeutic agent may be administered such that an
effective time period of the compound or composition overlaps with
an effective time period of the second therapeutic agent.
[0014] Additionally, disclosed are embodiments of a method for
inhibiting an IRAK protein, comprising contacting the IRAK protein
with an effective amount of a disclosed compound or a composition
comprising the compound. And in some embodiments, the IRAK protein
is in a subject.
[0015] The foregoing and other objects, features, and advantages of
the invention will become more apparent from the following detailed
description, which proceeds with reference to the accompanying
figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 is a dynamic vapor sorption (DVS) plot of percent
change in mass versus target relative humidity (RH), illustrating
the change in mass of one embodiment of the disclosed spray-dried
formulation at 25.degree. C. under various relative humidity
conditions. The plot provides two isotherms: 1 is the sorption
plot, illustrating the change in mass with increasing relative
humidity steps; and 2 is the desorption plot, illustrating the
change in mass with decreasing relative humidity steps.
[0017] FIG. 2 is a digital image showing a polarized light
microscopy (PLM) image of one embodiment of the disclosed
spray-dried formulation at 400.times. magnification.
[0018] FIG. 3 is a graph of intensity versus scattering angle,
illustrating the X-ray powder diffraction pattern of one embodiment
of the disclosed spray-dried formulation.
[0019] FIG. 4 is a graph of weight and heat flow versus
temperature, providing both the thermogravimetry (TGA) and
differential scanning calorimetry (DSC) plots for one embodiment of
the spray-dried formulation, illustrating the weight change and
heat flow of the dispersion at different temperatures.
[0020] FIG. 5 is a modulated DSC (mDSC) plot of reversing heat flow
versus temperature, illustrating the heat flow for one embodiment
of the spray-dried formulation and showing that the glass
transition temperature (Tg) for that embodiment is 108.3.degree.
C.
[0021] FIG. 6 is a DVS plot of percent change in mass versus target
relative humidity, illustrating the change in mass of one
embodiment of a crystalline sample of compound I-1 at 25.degree. C.
under various relative humidity conditions. The plot provides two
isotherms: 1 is the sorption plot, illustrating the change in mass
with increasing relative humidity steps; and 2 is the desorption
plot, illustrating the change in mass with decreasing relative
humidity steps.
[0022] FIG. 7 is a digital image showing a PLM image of a
crystalline sample of compound I-1 at 400.times. magnification.
[0023] FIG. 8 is a graph of intensity versus scattering angle,
illustrating the X-ray powder diffraction pattern of a crystalline
sample of compound I-1.
[0024] FIG. 9 is a graph of weight and heat flow versus
temperature, providing both the thermogravimetry (TGA) and
differential scanning calorimetry (DSC) plots for a crystalline
sample of compound I-1, illustrating the weight change and heat
flow of the formulation at different temperatures.
[0025] FIG. 10 is an mDSC plot of reversing heat flow versus
temperature, illustrating the heat flow for a crystalline sample of
compound I-1, and showing that the glass transition temperature
(Tg) for the crystalline sample is 106.1.degree. C.
[0026] FIG. 11 is a graph of plasma concentration versus time in
hours, illustrating the individual plasma concentrations and an
average plasma concentration resulting from administering compound
I-1 as a succinate co-crystal (compound I-106) to each of the three
subjects, with the results normalized to a dose of 5 mg/kg of
compound I-1.
[0027] FIG. 12 is a graph of plasma concentration versus time in
hours, illustrating the individual plasma concentrations and an
average plasma concentration resulting from administering compound
I-1 as a phosphate co-crystal (compound I-104) to each of the three
subjects, with the results normalized to a dose of 5 mg/kg of
compound I-1.
[0028] FIG. 13 is a graph of plasma concentration versus time in
hours, illustrating the individual plasma concentrations and an
average plasma concentration resulting from administering compound
I-1 as a gentisate co-crystal (compound I-105) to each of the three
subjects, with the results normalized to a dose of 5 mg/kg of
compound I-1.
[0029] FIG. 14 is a graph of plasma concentration versus time in
hours, illustrating the individual plasma concentrations and an
average plasma concentration resulting from administering compound
I-1 as a tartrate co-crystal (compound I-11) to each of the three
subjects, with the results normalized to a dose of 5 mg/kg of
compound I-1.
[0030] FIG. 15 is a graph of plasma concentration versus time,
illustrating the plasma concentration of compound I-1 from each of
three subjects, and an average plasma concentration, resulting from
administering a dose of one embodiment of the disclosed spray-dried
formulation sufficient to provide of a dose of 5 mg/kg of compound
I-1.
[0031] FIG. 16 is a graph of plasma concentration versus time,
illustrating the plasma concentration of a metabolite of compound
I-1 from each of three subjects, and an average plasma
concentration, resulting from administering a dose of one
embodiment of the disclosed spray-dried formulation sufficient to
provide of a dose of 5 mg/kg of compound I-1.
[0032] FIG. 17 is a graph of plasma concentration versus time,
illustrating the plasma concentration of compound I-1 from each of
three subjects, and an average plasma concentration, resulting from
administering 5 mg/kg of compound I-1 as a stock solution diluted
with orange juice.
[0033] FIG. 18 is a graph of plasma concentration versus time,
illustrating the plasma concentration of a metabolite of compound
I-1 from each of the three subjects, and an average plasma
concentration, resulting from administering 5 mg/kg of compound I-1
as a stock solution diluted with orange juice.
[0034] FIG. 19 is a table of pharmacokinetic data for one
embodiment of the disclosed spray-dried formulation and an organic
solution/organic juice formulation.
[0035] FIG. 20 is a DVS isotherm plot for a potassium salt of
compound I-18.
[0036] FIG. 21 is a DVS isotherm plot for a arginine salt of
compound I-18.
[0037] FIG. 22 is a DVS isotherm plot for a choline salt of
compound I-18.
[0038] FIG. 23 is a DVS isotherm plot for a Tris salt of compound
I-18.
DETAILED DESCRIPTION
I. Definitions
[0039] The following explanations of terms are provided to better
describe the present disclosure and to guide those of ordinary
skill in the art in the practice of the present disclosure. As used
herein, "comprising" means "including" and the singular forms "a"
or "an" or "the" include plural references unless the context
clearly dictates otherwise. The term "or" refers to a single
element of stated alternative elements or a combination of two or
more elements, unless the context clearly indicates otherwise.
[0040] Unless explained otherwise, all technical and scientific
terms used herein have the same meaning as commonly understood to
one of ordinary skill in the art to which this disclosure belongs.
Although methods and materials similar or equivalent to those
described herein can be used in the practice or testing of the
present disclosure, suitable methods and materials are described
below. The materials, methods, and examples are illustrative only
and not intended to be limiting. Other features of the disclosure
are apparent from the following detailed description and the
claims.
[0041] Unless otherwise indicated, all numbers expressing
quantities of components, molecular weights, percentages, and so
forth, as used in the specification or claims are to be understood
as being modified by the term "about." Accordingly, unless
otherwise indicated, implicitly or explicitly, the numerical
parameters set forth are approximations that may depend on the
desired properties sought and/or limits of detection under standard
test conditions/methods. When directly and explicitly
distinguishing embodiments from discussed prior art, the embodiment
numbers are not approximates unless the word "about" is
recited.
[0042] When chemical structures are depicted or described, unless
explicitly stated otherwise, all carbons are assumed to include
hydrogen so that each carbon conforms to a valence of four. For
example, in the structure on the left-hand side of the schematic
below there are nine hydrogen atoms implied. The nine hydrogen
atoms are depicted in the right-hand structure.
##STR00004##
[0043] Sometimes a particular atom in a structure is described in
textual formula as having a hydrogen or hydrogen atoms, for example
--CH.sub.2CH.sub.2--. It will be understood by a person of ordinary
skill in the art that the aforementioned descriptive techniques are
common in the chemical arts to provide brevity and simplicity to
description of organic structures.
[0044] A person of ordinary skill in the art will appreciate that
the definitions may be combined to further describe a particular
compound. For example, hydroxyaliphatic refers to an aliphatic
group substituted with an hydroxy (--OH) group, and haloalkylaryl
refers to an aryl group substituted with an alkyl group, where the
alkyl group too is substituted with a halogen, and where the point
of attachment to the parent structure is via the aryl moiety since
aryl is the base name of the substituent.
[0045] As used herein, the term "substituted" refers to all
subsequent modifiers in a term, for example in the term
"substituted arylC.sub.1-8alkyl," substitution may occur on the
"C.sub.1-8alkyl" portion, the "aryl" portion or both portions of
the arylC.sub.1-8alkyl group. Also by way of example, alkyl
includes substituted cycloalkyl groups.
[0046] "Substituted," when used to modify a specified group or
moiety, means that at least one, and perhaps two or more, hydrogen
atoms of the specified group or moiety is independently replaced
with the same or different substituent groups as defined below. In
a particular embodiment, a group, moiety or substituent may be
substituted or unsubstituted, unless expressly defined as either
"unsubstituted" or "substituted." Accordingly, any of the groups
specified herein may be unsubstituted or substituted. In particular
embodiments, the substituent may or may not be expressly defined as
substituted, but is still contemplated to be optionally
substituted. For example, an "alkyl" substituent may be
unsubstituted or substituted, but an "unsubstituted alkyl" may not
be substituted.
[0047] "Substituents" or "substituent groups" for substituting for
one or more hydrogen atoms on saturated carbon atoms in the
specified group or moiety are, unless otherwise specified,
--R.sup.60, halo, .dbd.O, --OR.sup.70, --SR.sup.70,
--N(R.sup.80).sub.2, haloalkyl, perhaloalkyl, --CN, --NO.sub.2,
.dbd.N.sub.2, --N.sub.3, --SO.sub.2R.sup.70, --SO.sub.3-M.sup.+,
--SO.sub.3R.sup.70, --OSO.sub.2R.sup.70, --OSO.sub.3.sup.-M+,
--OSO.sub.3R.sup.70, --P(O)(O.sup.-).sub.2(M.sup.+).sub.2,
--P(O)(O.sup.-).sub.2M.sup.2+, --P(O)(OR.sup.70)O.sup.-M.sup.+,
--P(O)(OR.sup.70).sub.2, --C(O)R.sup.70, --C(S)R.sup.70,
--C(NR.sup.70)R.sup.70, --CO.sub.2-M.sup.+, --CO.sub.2R.sup.70,
--C(S)OR.sup.70, --C(O)N(R.sup.80).sub.2,
--C(NR.sup.70)(R.sup.80).sub.2, --OC(O)R.sup.70, --OC(S)R.sup.70,
--OCO.sub.2-M.sup.+, --OCO.sub.2R.sup.70, --OC(S)OR.sup.70,
--NR.sup.70C(O)R.sup.70, --NR.sup.70C(S)R.sup.70,
--NR.sup.70CO.sub.2M.sup.+, --NR.sup.70CO.sub.2R.sup.70,
--NR.sup.70C(S)OR.sup.70, --NR.sup.70C(O)N(R.sup.80).sub.2,
--NR.sup.70C(NR.sup.70)R.sup.70 and
--NR.sup.70C(NR.sup.70)N(R.sup.80).sub.2, where R.sup.60 is
C.sub.1-6alkyl optionally substituted with 1, 2, or 3 OH; each
R.sup.70 is independently for each occurrence hydrogen or R.sup.60;
each R.sup.80 is independently for each occurrence R.sup.70 or
alternatively, two R.sup.80 groups, taken together with the
nitrogen atom to which they are bonded, form a 3- to 7-membered
nonaromatic heterocyclyl which optionally includes from 1 to 4 of
the same or different additional heteroatoms selected from O, N and
S, of which N optionally has H or C.sub.1-C.sub.3alkyl
substitution; and each M.sup.+ is a counter ion with a net single
positive charge. Each M.sup.+ is independently for each occurrence,
for example, an alkali metal ion, such as K.sup.+, Na.sup.+,
Li.sup.+; an ammonium ion, such as +NH.sub.4 or +N(R.sup.60).sub.4;
a protonated amino acid ion, such as a naturally occurring amino
acid counter ion, such as a lysine ion (for example, L-lysine ion),
or an arginine ion, such as an L-arginine ion; an amino sugar, such
as meglumine; or an alkaline metal earth ion, such as
[Ca.sup.2+].sub.0.5, [Mg.sup.2+].sub.0.5, or [Ba.sup.2+].sub.0.5 (a
subscript "0.5" means, for example, that one of the counter ions
for such divalent alkali earth ions can be an ionized form of a
compound of the invention and the other a typical counter ion such
as chloride, or two ionized compounds can serve as counter ions for
such divalent alkali earth ions, or a doubly ionized compound can
serve as the counter ion for such divalent alkali earth ions). As
specific examples, --N(R.sup.80).sub.2 includes --NH.sub.2,
--NH-alkyl, --NH-pyrrolidin-3-yl, N-pyrrolidinyl, N-piperazinyl,
4N-methyl-piperazin-1-yl, N-morpholinyl and the like. Any two
hydrogen atoms on a single carbon can be replaced with .dbd.O,
.dbd.NR.sup.70, .dbd.N--OR.sup.70, .dbd.N.sub.2 or .dbd.S.
[0048] Substituent groups for replacing hydrogen atoms on
unsaturated carbon atoms in groups containing unsaturated carbons
are, unless otherwise specified, --R.sup.60, halo,
--O.sup.-M.sup.+, --OR.sup.70, --SR.sup.70, --S.sup.-M.sup.+,
--N(R.sup.80).sub.2, perhaloalkyl, --CN, --OCN, --SCN, --NO,
--NO.sub.2, --N.sub.3, --SO.sub.2R.sup.70, --SO.sub.3.sup.-M.sup.+,
--SO.sub.3R.sup.70, --OSO.sub.2R.sup.70, --OSO.sub.3.sup.-M.sup.+,
--OSO.sub.3R.sup.70, --PO.sub.3.sup.-2(M.sup.+).sub.2,
--PO.sub.3.sup.-2M.sup.2+, --P(O)(OR.sup.70)O.sup.-M.sup.+,
--P(O)(OR.sup.70).sub.2, --C(O)R.sup.70, --C(S)R.sup.70,
--C(NR.sup.70)R.sup.70, --CO.sub.2.sup.-M.sup.+,
--CO.sub.2R.sup.70, --C(S)OR.sup.70, --C(O)NR.sup.80R.sup.80,
--C(NR.sup.70)N(R.sup.80).sub.2, --OC(O)R.sup.70, --OC(S)R.sup.70,
--OCO.sub.2-M.sup.+, --OCO.sub.2R.sup.70, --OC(S)OR.sup.70,
--NR.sup.70C(O)R.sup.70, --NR.sup.70C(S)R.sup.70,
--NR.sup.70CO.sub.2.sup.-M.sup.+, --NR.sup.70CO.sub.2R.sup.70,
--NR.sup.70C(S)OR.sup.70, --NR.sup.70C(O)N(R.sup.80).sub.2,
--NR.sup.70C(NR.sup.70)R.sup.70 and
--NR.sup.70C(NR.sup.70)N(R.sup.80).sub.2, where R.sup.60, R.sup.70,
R.sup.80 and M.sup.+ are as previously defined, provided that in
case of substituted alkene or alkyne, the substituents are not
--O.sup.-M.sup.+, --OR.sup.70, --SR.sup.70, or
--S.sup.-M.sup.+.
[0049] Substituent groups for replacing hydrogen atoms on nitrogen
atoms in groups containing such nitrogen atoms are, unless
otherwise specified, --R.sup.60, --O.sup.-M.sup.+, --OR.sup.70,
--SR.sup.70, --S.sup.-M.sup.+, --N(R.sup.80).sub.2,
perhaloalkyl, --CN, --NO, --NO.sub.2, --S(O).sub.2R.sup.70,
--SO.sub.3.sup.-M.sup.+, --SO.sub.3R.sup.70, --OS(O).sub.2R.sup.70,
--OSO.sub.3.sup.-M.sup.+, --OSO.sub.3R.sup.70,
--PO.sub.3.sup.2-(M.sup.+).sub.2, --PO.sub.3.sup.2-M.sup.2+,
--P(O)(OR.sup.70)O.sup.-M.sup.+, --P(O)(OR.sup.70)(OR.sup.70),
--C(O)R.sup.70, --C(S)R.sup.70, --C(NR.sup.70)R.sup.70,
--CO.sub.2R.sup.70, --C(S)O R.sup.70, --C(O)NR.sup.80R.sup.80,
--C(NR.sup.70)NR.sup.80R.sup.80, --OC(O)R.sup.70, --OC(S)R.sup.70,
--OCO.sub.2R.sup.70, --OC(S)OR.sup.70, --NR.sup.70C(O)R.sup.70,
--NR.sup.70C(S)R.sup.70, --NR.sup.70CO.sub.2R.sup.70,
--NR.sup.70C(S)OR.sup.70, --NR.sup.70C(O)N(R.sup.80).sub.2,
--NR.sup.70C(NR.sup.70)R.sup.70 and
--NR.sup.70C(NR.sup.70)N(R.sup.80).sub.2, where R.sup.60, R.sup.70,
R.sup.80 and M.sup.+ are as previously defined.
[0050] In one embodiment, a group that is substituted has 1
substituent, 2 substituents, substituents, or 4 substituents.
[0051] Additionally, in embodiments where a group or moiety is
substituted with a substituted substituent, the nesting of such
substituted substituents is limited to three, thereby preventing
the formation of polymers. Thus, in a group or moiety comprising a
first group that is a substituent on a second group that is itself
a substituent on a third group, which is attached to the parent
structure, the first (outermost) group can only be substituted with
unsubstituted substituents. For example, in a group comprising
-(aryl-1)-(aryl-2)-(aryl-3), aryl-3 can only be substituted with
substituents that are not themselves substituted.
[0052] "Acyl" refers to the group --C(O)R, where R is H, aliphatic,
heteroaliphatic, heterocyclic or aryl. Exemplary acyl moieties
include, but are not limited to, --C(O)H, --C(O)alkyl,
--C(O)C.sub.1-C.sub.6alkyl,
--C(O)C.sub.1-C.sub.6haloalkyl-C(O)cycloalkyl, --C(O)alkenyl,
--C(O)cycloalkenyl, --C(O)aryl, --C(O)heteroaryl, or
--C(O)heterocyclyl. Specific examples include, --C(O)H, --C(O)Me,
--C(O)Et, or --C(O)cyclopropyl.
[0053] "Aliphatic" refers to a substantially hydrocarbon-based
group or moiety, including alkyl, alkenyl, alkynyl groups, cyclic
versions thereof, such as cycloalkyl, cycloalkenyl or cycloalkynyl,
and further including straight- and branched-chain arrangements,
and all stereo and position isomers as well. Unless expressly
stated otherwise, an aliphatic group contains from one to
twenty-five carbon atoms; for example, from one to fifteen, from
one to ten, from one to six, or from one to four carbon atoms, and
a cyclic aliphatic contains from three to twenty-five carbon atoms;
for example, from three to fifteen, from three to ten, from three
to six, or from three to four carbon atoms.
[0054] "Alkyl" refers to a saturated aliphatic hydrocarbyl group
having from 1 to 25 carbon atoms, typically 1 to 10 carbon atoms
such as 1 to 6 carbon atoms (C.sub.1-6alkyl) or 1 to 4 carbon
atoms, (C.sub.1-4alkyl). An alkyl moiety may be substituted or
unsubstituted. This term includes, by way of example, linear and
branched hydrocarbyl groups such as methyl (CH.sub.3), ethyl
(--CH.sub.2CH.sub.3), n-propyl (--CH.sub.2CH.sub.2CH.sub.3),
isopropyl (--CH(CH.sub.3).sub.2), n-butyl
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.3), isobutyl
(--CH.sub.2CH.sub.2(CH.sub.3).sub.2), sec-butyl
(--CH(CH.sub.3)(CH.sub.2CH.sub.3), t-butyl (--C(CH.sub.3).sub.3),
n-pentyl (--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.3), and
neopentyl (--CH.sub.2C(CH.sub.3).sub.3).
[0055] "Alkoxy" refers to the group --O-alkyl.
[0056] "Amino" refers to the group --NH.sub.2, --NHR, or --NRR,
where each R independently is selected from H, aliphatic, aryl or
heterocyclic, or two R groups together with the nitrogen attached
thereto form a heterocyclic ring. Examples of such heterocyclic
rings include those wherein two R groups together with the nitrogen
to which they are attached form a --(CH.sub.2).sub.2-5-ring
optionally interrupted by one or two heteratom groups, such as
--O-- or --N(R.sup.g) such as in the groups
##STR00005##
and wherein R.sup.g is R.sup.70, --C(O)R.sup.70, --C(O)OR.sup.60 or
--C(O)N(R.sup.80).sub.2.
[0057] "Amide" refers to the group --N(H)acyl, or --C(O)amino.
[0058] "Araliphatic" refers to an aryl group attached to the parent
via an aliphatic moiety. Araliphatic includes aralkyl or arylalkyl
groups such as benzyl and phenylethyl.
[0059] "Aryl" refers to an aromatic group of, unless specified
otherwise, from 5 to 15 ring atoms having a single ring (e.g.,
phenyl) or multiple fused rings in which at least one ring is
aromatic (e.g., naphthyl). For groups having multiple rings, at
least one of which is aromatic and one is not, such groups are
nevertheless referred to as "aryl" provided that the point of
attachment to the remainder of the compound is through an atom of
an aromatic portion of the aryl group. Aryl groups may be
monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise
stated, an aryl group may be substituted or unsubstituted.
[0060] "Carboxyl," "carboxy" or "carboxylate" refers to
--CO.sub.2H, --C(O)O-- or salts thereof.
[0061] Combination: A combination includes two or more components
that are administered such that the effective time period of at
least one component overlaps with the effective time period of at
least one other component. A combination, or a component thereof,
may be a composition. In some embodiments, effective time periods
of all components administered overlap with each other. In an
exemplary embodiment of a combination comprising three components,
the effective time period of the first component administered may
overlap with the effective time periods of the second and third
components, but the effective time periods of the second and third
components independently may or may not overlap with one another.
In another exemplary embodiment of a combination comprising three
components, the effective time period of the first component
administered overlaps with the effective time period of the second
component, but not that of the third component; and the effective
time period of the second component overlaps with those of the
first and third components. A combination may be a composition
comprising the components, a composition comprising one or more
components and another separate component (or components) or
composition(s) comprising the remaining component(s), or the
combination may be two or more individual components. In some
embodiments, the two or more components may comprise the same
component administered at two or more different times, two or more
different components administered substantially simultaneously or
sequentially in any order, or a combination thereof.
[0062] "Carboxyl ester" or "carboxy ester" refers to the group
--C(O)OR, where R is aliphatic, heteroaliphatic, and heterocyclic,
including aryl and heteroaryl.
[0063] "Cycloaliphatic" refers to a cyclic aliphatic group having a
single ring (e.g., cyclohexyl), or multiple rings, such as in a
fused, bridged or spirocyclic system, at least one of which is
aliphatic, provided that the point of attachment is through an atom
of an aliphatic region of the cycloaliphatic group. Cycloaliphatic
includes saturated and unsaturated systems, including cycloalkyl,
cycloalkenyl and cycloalkynyl. Exemplary cycloaliphatic groups
include, but are not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, or
cyclohexenyl.
[0064] "Heteroaliphatic" refers to an aliphatic compound or group
having at least one heteroatom and at least one carbon atom, i.e.,
one or more carbon atoms from an aliphatic compound or group
comprising at least two carbon atoms, has been replaced with an
atom having at least one lone pair of electrons, typically
nitrogen, oxygen, phosphorus, silicon, or sulfur. Heteroaliphatic
compounds or groups may be substituted or unsubstituted, branched
or unbranched, chiral or achiral, and/or acyclic or cyclic, such as
a heterocycloaliphatic group.
[0065] "Heterocyclyl," and "heterocycle" refer to aromatic and
non-aromatic ring systems, and more specifically refer to a stable
three- to fifteen-membered ring moiety comprising carbon atoms and
at least one, such as from one to five heteroatoms. The
heterocyclyl moiety may be a monocyclic moiety, or may comprise
multiple rings, such as in a bicyclic or tricyclic ring system,
provided that at least one of the rings contains a heteroatom. Such
a multiple ring moiety can include fused or bridged ring systems as
well as spirocyclic systems; and the nitrogen, phosphorus, carbon,
silicon or sulfur atoms in the heterocyclyl moiety can be
optionally oxidized to various oxidation states. For convenience,
nitrogens, particularly but not exclusively, those defined as
annular aromatic nitrogens, are meant to include their
corresponding N-oxide form, although not explicitly defined as such
in a particular example. In addition, annular nitrogen atoms can be
optionally quaternized. Heterocycle includes heteroaryl or aromatic
heterocyclyl moieties, and nonaromatic heterocyclyl moieties, which
are heterocyclyl rings which are partially or fully saturated.
Examples of heterocyclyl groups include, but are not limited to,
azetidinyl, oxetanyl, acridinyl, benzodioxolyl, benzodioxanyl,
benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl,
naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl,
phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl,
quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl,
tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl,
pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl,
imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl,
tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl,
isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl,
thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl,
indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl,
octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl,
benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl,
benzoxazolyl, furyl, diazabicycloheptane, diazapane, diazepine,
tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl,
thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl
sulfone, dioxaphospholanyl, and oxadiazolyl.
[0066] "Hydroxyl" refers to the group --OH.
[0067] "Pharmaceutically acceptable excipient" refers to a
substance, other than the active ingredient or prodrug thereof,
that is included in a formulation of the active ingredient. As used
herein, an excipient may be incorporated within particles of a
pharmaceutical composition, or it may be physically mixed with
particles of a pharmaceutical composition. An excipient can be
used, for example, to dilute an active agent and/or to modify
properties of a pharmaceutical composition. Excipients can include,
but are not limited to, antiadherents, binders, coatings, enteric
coatings, disintegrants, flavorings, sweeteners, colorants,
lubricants, glidants, sorbents, preservatives, adjuvants, carriers
or vehicles. Excipients may be starches and modified starches,
cellulose and cellulose derivatives, saccharides and their
derivatives such as disaccharides, polysaccharides and sugar
alcohols, protein, synthetic polymers, crosslinked polymers,
antioxidants, amino acids or preservatives. Exemplary excipients
include, but are not limited to, magnesium stearate, stearic acid,
vegetable stearin, sucrose, lactose, starches, hydroxypropyl
cellulose, hydroxypropyl methylcellulose, xylitol, sorbitol,
maltitol, gelatin, polyvinylpyrrolidone (PVP), polyethyleneglycol
(PEG), tocopheryl polyethylene glycol 1000 succinate (also known as
vitamin E TPGS, or TPGS), carboxy methyl cellulose, dipalmitoyl
phosphatidyl choline (DPPC), vitamin A, vitamin E, vitamin C,
retinyl palmitate, selenium, cysteine, methionine, citric acid,
sodium citrate, methyl paraben, propyl paraben, sugar, silica,
talc, magnesium carbonate, sodium starch glycolate, tartrazine,
aspartame, benzalkonium chloride, sesame oil, propyl gallate,
sodium metabisulphite or lanolin.
[0068] An "adjuvant" is an excipient that modifies the effect of
other agents, typically the active ingredient. Adjuvants are often
pharmacological and/or immunological agents. An adjuvant may modify
the effect of an active ingredient by increasing an immune
response. An adjuvant may also act as a stabilizing agent for a
formulation. Exemplary adjuvants include, but are not limited to,
aluminum hydroxide, alum, aluminum phosphate, killed bacteria,
squalene, detergents, cytokines, paraffin oil, and combination
adjuvants, such as freund's complete adjuvant or freund's
incomplete adjuvant.
[0069] "Pharmaceutically acceptable salt" refers to
pharmaceutically acceptable salts of a compound that are derived
from a variety of organic and inorganic counter ions as will be
known to a person of ordinary skill in the art and include, by way
of example only, sodium, potassium, calcium, magnesium, ammonium,
tetraalkylammonium, tris(hydroxymethyl)aminomethane (tris) and the
like; and when the molecule contains a basic functionality, salts
of organic or inorganic acids, such as hydrochloride, hydrobromide,
tartrate, mesylate, benzene sulfonate, tosylate, succinate,
acetate, maleate, oxalate, and the like. "Pharmaceutically
acceptable acid addition salts" are a subset of "pharmaceutically
acceptable salts" that retain the biological effectiveness of the
free bases while formed by acid partners. In particular, the
disclosed compounds form salts with a variety of pharmaceutically
acceptable acids, including, without limitation, inorganic acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, and the like, as well as organic acids such
as formic acid, acetic acid, trifluoroacetic acid, propionic acid,
glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic
acid, succinic acid, fumaric acid, tartaric acid, citric acid,
benzoic acid, cinnamic acid, mandelic acid, benzene sulfonic acid,
isethionic acid, methanesulfonic acid, ethanesulfonic acid,
p-toluenesulfonic acid, salicylic acid, xinafoic acid, gentisic
acid, and the like. "Pharmaceutically acceptable base addition
salts" are a subset of "pharmaceutically acceptable salts" that are
derived from inorganic bases such as sodium, potassium, lithium,
ammonium, calcium, magnesium, iron, zinc, copper, manganese,
aluminum salts and the like. Exemplary salts are the ammonium,
potassium, sodium, calcium, and magnesium salts. Salts derived from
pharmaceutically acceptable organic bases include, but are not
limited to, salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
isopropylamine, trimethylamine, diethylamine, triethylamine,
tripropylamine, tris(hydroxymethyl)aminomethane (Tris),
ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine (for example, L-lysine), arginine (for
example, L-arginine), histidine, caffeine, procaine, hydrabamine,
choline, betaine, ethylenediamine, glucosamine, meglumine,
methylglucamine, theobromine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins, and the like. Exemplary
organic bases are isopropylamine, diethylamine,
tris(hydroxymethyl)aminomethane (Tris), ethanolamine,
trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for
example, S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm.
Sci., 1977; 66:1-19 which is incorporated herein by reference.) In
particular disclosed embodiments, the compound is in the form of a
benzene sulfonate, hydrochloride, sodium, succinate, tris,
mesylate, or tartrate salt.
[0070] "Phosphate" refers to the group --O--P(O)(OR').sub.2, where
each --OR' independently is --OH, --O-aliphatic, such as --O-alkyl,
--O-aryl, or --O-aralkyl, or --OR' is --O.sup.-M.sup.+, where
M.sup.+ is a counter ion with a single positive charge as disclosed
herein. For example, each M.sup.+ may be an alkali ion, such as
K.sup.+, Na.sup.+, Li.sup.+; an ammonium ion, such as
.sup.+N(R'').sub.4 where each R'' independently is H, aliphatic,
such as alkyl, hydroxyalkyl, or a combination thereof,
heterocyclyl, or aryl; an amino acid, such as arginine or lysine;
an amino sugar, such as meglumine; or an alkaline earth ion, such
as [Ca.sup.2+].sub.0.5, [Mg.sup.2+].sub.0.5, or
[Ba.sup.2+].sub.0.5. Alkyl phosphate refers to the group
-alkyl-phosphate, such as, --CH.sub.2O--P(O)(OR').sub.2 or
--CH.sub.2(CH.sub.3)O--P(O)(OR').sub.2 for example,
--CH.sub.2OP(O)(O-isopropyl).sub.2,
--CH.sub.2OP(O)(OH)(O-tert-butyl),
--CH.sub.2OP(O)(O-tert-butyl).sub.2,
--CH.sub.2OP(O)(OCH.sub.2OCO.sub.2isopropyl).sub.2,
--CH.sub.2OP(O)(OH).sub.2, or a salt thereof, such as
--CH.sub.2OP(O)(O--Na.sup.+).sub.2,
--CH.sub.2OP(O)(O.sup.-).sub.2Mg.sup.2+, or
--CH.sub.2OP(O)(OH)(O.sup.-Na.sup.+)
[0071] "Phosphoramidate" refers to the group
--O--P(O)(OR')(N(R').sub.2), where each R' independently is H,
aliphatic, such as alkyl, aryl, or aralkyl, or --OR' is
--O.sup.-M.sup.+, and where M.sup.+ is a counter ion with a single
positive charge, as disclosed herein. For example, each M.sup.+ may
be an alkali ion, such as K.sup.+, Na.sup.+, Li.sup.+; an ammonium
ion, such as +N(R'').sub.4 where each R'' independently is H,
aliphatic, such as alkyl, hydroxyalkyl, or a combination thereof,
heterocyclyl, or aryl; an amino acid, such as arginine or lysine;
an amino sugar, such as meglumine; or an alkaline earth ion, such
as [Ca.sup.2+].sub.0.5, [Mg.sup.2+].sub.0.5, or
[Ba.sup.2+].sub.0.5. Alkyl phosphoramidate refers to the group
-alkyl-phosphoramidate, such as, for example,
--CH.sub.2O--P(O)(OR')(N(R'.sub.2)) or
--CH.sub.2(CH.sub.3)O--P(O)(OR')(N(R'.sub.2)), such as,
--CH.sub.2OP(O)(0-phenyl)[NHC(CH.sub.3)CO.sub.2isopropyl], or
--CH.sub.2OP(O)(OH)(N(H)alkyl), or a salt thereof, such as
--CH.sub.2OP(O)(O.sup.-Na.sup.+)(N(H)alkyl).
[0072] "Pharmaceutically acceptable carrier" refers to an excipient
that is a carrier or vehicle, such as a suspension aid,
solubilizing aid, or aerosolization aid. Pharmaceutically
acceptable carriers are conventional. Remington: The Science and
Practice of Pharmacy, The University of the Sciences in
Philadelphia, Editor, Lippincott, Williams, & Wilkins,
Philadelphia, Pa., 21.sup.st Edition (2005), describes compositions
and formulations suitable for pharmaceutical delivery of one or
more therapeutic compositions and additional pharmaceutical
agents.
[0073] In general, the nature of the carrier will depend on the
particular mode of administration being employed. For instance,
parenteral formulations usually comprise injectable fluids that
include pharmaceutically and physiologically acceptable fluids such
as water, physiological saline, balanced salt solutions, aqueous
dextrose, glycerol or the like as a vehicle. In some examples, the
pharmaceutically acceptable carrier may be sterile to be suitable
for administration to a subject (for example, by parenteral,
intramuscular, or subcutaneous injection). In addition to
biologically-neutral carriers, pharmaceutical compositions to be
administered can contain minor amounts of non-toxic auxiliary
substances, such as wetting or emulsifying agents, preservatives,
and pH buffering agents and the like, for example sodium acetate or
sorbitan monolaurate.
[0074] "Effective amount" with respect to a compound or composition
refer to an amount of the compound or composition sufficient to
achieve a particular desired result, such as to inhibit a protein
or enzyme, particularly an interleukin-1 receptor-associated
kinase; to elicit a desired biological or medical response in a
tissue, system, subject or patient; to treat a specified disorder
or disease; to ameliorate or eradicate one or more of its symptoms;
and/or to prevent the occurrence of the disease or disorder. The
amount of a compound which constitutes an "effective amount" may
vary depending on the compound, the desired result, the disease
state and its severity, the age of the patient to be treated, and
the like.
[0075] "Prodrug" refers to compounds that are transformed in vivo
to yield a biologically active compound, particularly the parent
compound, for example, by hydrolysis in the gut or enzymatic
conversion. Typically, a prodrug compound of a compound has less
activity against a desired biological target that the parent
compound. A prodrug negligible or less activity with respect to a
desired target until it is metabolized to the active form. Common
examples of prodrug moieties include, but are not limited to,
ester, amide, carbamate, and urea forms of a compound having an
active form bearing a carboxylic acid moiety. Examples of
pharmaceutically acceptable esters of the compounds of this
invention include, but are not limited to, esters of phosphate
groups and carboxylic acids, such as aliphatic esters, particularly
alkyl esters (for example C.sub.1-6alkyl esters). Other prodrug
moieties include phosphate esters, such as
--(CH.sub.2).sub.n--O--P(O)(OR').sub.2, wherein n is 1 or 2 and R'
is H or C.sub.1-6alkyl, such as --CH.sub.2--O--P(O)(OR').sub.2
wherein each R' is independently H or C.sub.1-6alkyl, when at least
one R' is H, the phosphate moiety can be in the form of a salt,
such as a mono or dianion salt with an organic or inorganic
cationic counter ion. Acceptable esters also include cycloalkyl
esters and arylalkyl esters such as, but not limited to benzyl.
Examples of pharmaceutically acceptable amides of the compounds of
this invention include, but are not limited to, primary amides, and
secondary and tertiary alkyl amides (for example with between one
and six carbons). Amides and esters of disclosed exemplary
embodiments of compounds according to the present invention can be
prepared according to conventional methods. A thorough discussion
of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as
Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and
in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987, both
of which are incorporated herein by reference for all purposes.
[0076] "Spray-dried dispersion" refers to a single-phase dispersion
of a compound or compounds in a polymer matrix. Typically, the
compound or compounds are amorphous.
[0077] "Subject" refers to humans and non-human subjects.
[0078] "Solvate" refers to a complex formed by combination of
solvent molecules with molecules or ions of the solute. The solvent
can be an organic compound, an inorganic compound, or a mixture of
both. Some examples of solvents include, but are not limited to,
methanol, N,N-dimethylformamide, tetrahydrofuran,
dimethylsulfoxide, and water. The compounds described herein can
exist in un-solvated as well as solvated forms when combined with
solvents, pharmaceutically acceptable or not, such as water,
ethanol, and the like. Solvated forms of the presently disclosed
compounds are within the scope of the embodiments disclosed
herein.
[0079] The above definitions and the following general formulas are
not intended to include impermissible substitution patterns (e.g.,
methyl substituted with 5 fluoro groups). Such impermissible
substitution patterns are easily recognized by a person having
ordinary skill in the art.
[0080] Any of the groups referred to herein may be optionally
substituted by at least one, possibly two or more, substituents as
defined herein. That is, a substituted group has at least one,
possible two or more, substitutable hydrogens replaced by a
substituent or substituents as defined herein, unless the context
indicates otherwise or a particular structural formula precludes
substitution.
[0081] A person of ordinary skill in the art will appreciate that
compounds may exhibit the phenomena of tautomerism, conformational
isomerism, geometric isomerism, and/or optical isomerism. For
example, certain disclosed compounds can include one or more chiral
centers and/or double bonds and as a consequence can exist as
stereoisomers, such as double-bond isomers (i.e., geometric
isomers), enantiomers, diastereomers, and mixtures thereof, such as
racemic mixtures. As another example, certain disclosed compounds
can exist in several tautomeric forms, including the enol form, the
keto form, and mixtures thereof. As the various compound names,
formulae and compound drawings within the specification and claims
can represent only one of the possible tautomeric, conformational
isomeric, optical isomeric, or geometric isomeric forms, it would
be understood that the disclosed compounds encompass any
tautomeric, conformational isomeric, optical isomeric, and/or
geometric isomeric forms of the compounds described herein, as well
as mixtures of these various different isomeric forms. In cases of
limited rotation, e.g. around the amide bond or between two
directly attached rings such as the pyrazole and pyridinyl rings,
atropisomers are also possible and are also specifically included
in the compounds of the invention.
[0082] Particular examples of the presently disclosed compounds
include one or more asymmetric centers; thus these compounds can
exist in different stereoisomeric forms. Accordingly, compounds and
compositions may be provided as individual pure enantiomers or
diastereomers, or as stereoisomeric mixtures, including racemic
mixtures. In certain embodiments the compounds disclosed herein are
synthesized in or are purified to be in substantially enantiopure
form, such as in at least 90% enantiomeric excess, 95% enantiomeric
excess, 97% enantiomeric excess, 98% enantiomeric excess, 99%
enantiomeric excess, 99.5% enantiomeric excess, or greater than
99.5% enantiomeric excess, such as in enantiopure form.
[0083] In any embodiments, any or all hydrogens present in the
compound, or in a particular group or moiety within the compound,
may be replaced by a deuterium or a tritium. Thus, a recitation of
alkyl includes deuterated alkyl, where from one to the maximum
number of hydrogens present may be replaced by deuterium. For
example, ethyl may be C.sub.2H.sub.5 or C.sub.2H.sub.5 where from 1
to 5 hydrogens are replaced by deuterium.
II. Compounds
[0084] Disclosed herein are pyrazole compounds, methods of making
the compounds, and methods of using the compounds. In one
embodiment, the disclosed compounds are tyrosine kinase inhibitors
and/or may be useful in blocking one or more cytokine signaling
pathways, such as the IL-17 signaling pathway. For certain
embodiments, the pyrazole compounds are useful for treating
conditions in which inhibition of an interleukin-1
receptor-associated kinase (IRAK) pathway is therapeutically
useful. In some embodiments, the compounds inhibit an IRAK protein,
such as IRAK1, IRAK2, IRAK3 or IRAK4. In other embodiments, the
compounds are useful for delivering an IRAK inhibitor compound,
and/or may be a prodrug of an IRAK inhibitor. In certain
embodiments, the pyrazole compound is a prodrug of
##STR00006##
[0085] In some embodiments, the pyrazole compound has a general
formula I
##STR00007##
With respect to formula I, R is H, aliphatic, acyl, heterocyclyl,
carboxyl ester, amide, alkyl phosphoramidate, or alkyl phosphate. A
person of ordinary skill in the art understands that Formula I also
includes solvates, co-crystals, salts, and/or N-oxides of the
compounds, as well as free base compounds. In some embodiments, R
is not H, or alternatively, R is hydrogen. When R is hydrogen the
compound may be a free base or in the form of a salt. In other
embodiments, R is alkyl, acyl, carboxyl ester, amide, nonaromatic
heterocyclyl, alkyl phosphoramidate, or alkyl phosphate. A person
of ordinary skill in the art understands that compounds where R is
not H may act a prodrug of the compound where R is H, for example,
when administered to a subject.
[0086] In one aspect, the compound of Formula I is in the form of a
co-crystal. Examples of co-crystals include, but are not limited
to, a succinate co-crystal, a phosphate co-crystal, a gentisate
co-crystal, or a tartrate co-crystal.
[0087] In some embodiments, R is H, C.sub.1-4alkyl phosphate,
C.sub.1-4alkyl phosphoramidate, C.sub.1-6alkyl, C.sub.1-6acyl,
--C(O)O--C.sub.1-6aliphatic, --C(O)N(R.sup.b).sub.2, or 5- or
6-membered nonaromatic heterocyclyl, but in certain embodiments, R
is not H, or R is H and the compound is a salt.
[0088] With respect to the R moiety, the C.sub.1-6alkyl moiety may
be unsubstituted, or it may be substituted, such as with a 5- or
6-membered nonaromatic heterocyclyl, OH, --OC(O)--R.sup.a,
--N(R.sup.b).sub.2, --OC(O)--R.sup.c, carboxyl, or a combination
thereof;
[0089] the C.sub.1-6acyl moiety may be unsubstituted or it may be
substituted with --C(O)O--C.sub.1-4alkyl,
--C(O)O--C.sub.1-4alkyl-N(R.sup.b).sub.2, N(R.sup.b).sub.2,
--NHC(O)C.sub.1-4alkyl, or a combination thereof;
[0090] the 5- or 6-membered heterocyclyl moiety may be a 5- or
6-membered oxygen-containing heterocyclyl, and/or may be
substituted with hydroxyl, hydroxymethyl, or a combination thereof,
or
[0091] the --C(O)O--C.sub.1-6aliphatic may be
--C(O)O--C.sub.1-6alkyl optionally substituted with
--OC(O)C.sub.1-4alkyl, or N(R.sup.b).sub.2, or the
--C(O)O--C.sub.1-6aliphatic may be --C(O)O--C.sub.3-6cycloalkyl
optionally substituted with C.sub.1-4alkyl.
[0092] In any embodiments, each R.sup.a independently is 5-membered
nonaromatic heterocyclyl, aryl substituted with
--CH.sub.2N(R.sup.b).sub.2, C.sub.3-6cycloalkyl substituted with
carboxyl, C.sub.1-6alkoxy, unsubstituted C.sub.1-6alkyl, or
C.sub.1-6alkyl substituted with one or more, such as 1, 2 or 3, of
N(R.sup.b).sub.2, carboxyl, carboxyl ester, --OC.sub.1-6acyl,
--NHC(O)(NH.sub.2)C.sub.1-6alkyl, or
--(OCH.sub.2CH.sub.2).sub.1-8N(R.sup.b).sub.2;
[0093] each R.sup.b independently is H, unsubstituted
C.sub.1-6alkyl, C.sub.1-6alkyl substituted with --N(R.sup.g).sub.2,
carboxyl ester, or 5- or 6-membered nonaromatic heterocyclyl, or
two R.sup.b together with the nitrogen to which they are attached
form a C.sub.3-6nonaromatic heterocyclyl moiety optionally
interrupted with one or two --O-- or --N(R.sup.g), where R.sup.9 is
H or C.sub.1-4alkyl; and
[0094] --OC(O)--R.sup.c is derived from an amino acid where the
--OC(O)-- moiety of --OC(O)--R.sup.c corresponds to an acid moiety
on the amino acid, and R.sup.c comprises --N(R.sup.b).sub.2 or a
nitrogen-containing nonaromatic heterocyclyl, such as a 5- or
6-membered unsaturated nitrogen-containing heterocyclyl, for
example, pyrrolidinyl. The amino acid can be any amino acid, such
as a naturally occurring amino acid, and may be an amino acid
selected from glycine, valine, alanine, leucine, isoleucine,
methionine, phenylalanine, tryptophan, tyrosine, serine, threonine,
asparagine, glutamine, arginine, histidine, lysine, aspartic acid,
glutamic acid, cysteine, or proline. A person of ordinary skill in
the art will understand that where the amino acid comprises one or
more chiral center, all enantiomers, diastereomers and/or mixtures
thereof are contemplated. For example, the amino acid may be the
L-amino acid, the D-amino acid or a mixture thereof. In some
embodiments, the amino acid is the L-amino acid. And in certain
embodiments, --OC(O)--R.sup.c is --OC(O)CH(NH.sub.2)R.sup.d,
##STR00008##
or --OC(O)--(CH.sub.2).sub.1-2C(NH.sub.2)CO.sub.2H, where R.sup.6
is an amino acid side chain, and/or may be H, --CH.sub.3,
isopropyl, --CH.sub.2CH(CH.sub.3).sub.2, --CH(CH.sub.3)Et,
--CH.sub.2CH.sub.2SCH.sub.3,
##STR00009##
--CH.sub.2OH, --CH(OH)CH.sub.3, --CH.sub.2C(O)NH.sub.2,
--CH.sub.2CH.sub.2C(O)NH.sub.2, --CH.sub.2SH,
--CH.sub.2CH.sub.2CH.sub.2NHC(O)(NH)NH.sub.2,
##STR00010##
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2NH.sub.2, --CH.sub.2CO.sub.2H, or
CH.sub.2CH.sub.2CO.sub.2H.
[0095] In any embodiments, the compound may be a salt, such as a
pharmaceutically acceptable salt as defined herein, and in some
embodiments, the salt is a hydrochloride, citrate, hemicitrate,
hemitartrate, tartrate, benzene sulfonate, mesylate, sodium,
hemisuccinate, or succinate salt.
[0096] Some exemplary compounds according to formula I include:
##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015##
##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020##
##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025##
##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030##
##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035##
##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041## ##STR00042## ##STR00043## ##STR00044## ##STR00045##
##STR00046## ##STR00047## ##STR00048## ##STR00049##
[0097] Exemplary compounds according to formula I include: [0098]
I-1:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide; [0099] I-2:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
dihydrogen phosphate; [0100] I-3: di-tert-butyl
((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
phosphate; [0101] I-4:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl phosphate
disodium salt; [0102] I-5:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-methyl-1H-pyrazol-4-yl)thiazole-4-carboxamide; [0103]
I-6:
2-(1-(acetyl-L-leucyl)-1H-pyrazol-4-yl)-N-(3-(3,6-difluoropyridin-2-yl)-1-
-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide;
[0104] I-7: 1-methylcyclopropyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate; [0105]
I-8: 1-(isobutyryloxy)ethyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate; [0106]
I-9:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1H-pyrazol-4-yl)thiaz-
ole-4-carboxamide; [0107] I-10: 2-morpholinoethyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate; [0108]
I-11:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide hemi-tartrate
salt; [0109] I-12:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(morpholine-4-carbonyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide-
; [0110] I-13:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-((3-morpholinopropyl)carbamoyl)-1H-pyrazol-4-yl)thiazole-4-car-
boxamide; [0111] I-14:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-((3-(dimethylamino)propyl)carbamoyl)-1H-pyrazol-4-yl)thiazole--
4-carboxamide; [0112] I-15: 3-morpholinopropyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate; [0113]
I-16:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate hydrochloride; [0114] I-17:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-prolinate hydrochloride; [0115] I-18:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate; [0116] I-19:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl glycinate
hydrochloride; [0117] I-20:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
phosphate disodium salt; [0118] I-21:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate hydrochloride; [0119] I-22:
2-(1-acetyl-1H-pyrazol-4-yl)-N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-
-ethoxycyclohexyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide; [0120]
I-23:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-amino-2-methylpropanoate hydrochloride; [0121] I-24:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-4-oxobutano-
ic acid; [0122] I-25: methyl
4-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-oxobutanoate;
[0123] I-26:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(2-morpholinoacetyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide;
[0124] I-27:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(2-hydroxy-3-morpholinopropyl)-1H-pyrazol-4-yl)thiazole-4-carb-
oxamide; [0125] I-28:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-morpholinoacetate; [0126] I-29:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate; [0127] I-30:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate benzene sulfonate; [0128] I-31:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate mesylate; [0129] I-32: 2-(4-methylpiperazin-1-yl)ethyl
4-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-oxobutanoate;
[0130] I-33:
1-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
4-methyl L-aspartate hydrochloride; [0131] I-34: methyl
N-(2-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-2-oxoethyl)-N-met-
hylglycinate; [0132] I-35:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate; [0133] I-36:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate benzene sulfonate; [0134] I-37:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-(morpholinomethyl)benzoate; [0135] I-38:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
1-methyl L-aspartate hydrochloride; [0136] I-39:
(1R,2R)-2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclo-
hexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)car-
bonyl)cyclohexane-1-carboxylic acid; [0137] I-40:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate mesylate; [0138] I-41:
(S)-2-amino-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycy-
clohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-
-4-oxobutanoic acid hydrochloride; [0139] I-42:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4S)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-((2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
-2H-pyran-2-yl)-1H-pyrazol-4-yl)thiazole-4-carboxamide; [0140]
I-43:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4R)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
-2H-pyran-2-yl)-1H-pyrazol-4-yl)thiazole-4-carboxamide; [0141]
I-44: tert-butyl
(1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl)
hydrogen phosphate sodium acetate salt; [0142] I-45:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl isopropyl
carbonate; [0143] I-46:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
di(((isopropoxycarbonyl)oxy)methyl) phosphate; [0144] I-47:
1-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
4-methyl L-aspartate; [0145] I-48:
1-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
4-methyl L-aspartate benzene sulfonate; [0146] I-49:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate tris salt; [0147] I-50:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl glycinate
benzene sulfonate; [0148] I-51: 2-(4-methylpiperazin-1-yl)ethyl
4-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-oxobutanoate
benzene sulfonate; [0149] I-52: 2-(4-methylpiperazin-1-yl)ethyl
4-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-oxobutanoate
succinate salt; [0150] I-53:
(2R,3R)-2,3-diacetoxy-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)--
4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-y-
l)methoxy)-4-oxobutanoic acid; [0151] I-54:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl acetate;
[0152] I-55:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohex-
yl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
1-methyl L-aspartate benzene sulfonate; [0153] I-56:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-4-oxobutano-
ic acid tris salt; [0154] I-57:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-amino-3-methylbutanamido)butanoate hydrochloride; [0155]
I-58:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide;
[0156] I-59:
2-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)acetic acid;
[0157] I-60:
((((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohex-
yl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(hydro-
xy)phosphoryl)oxy)methyl isopropyl carbonate; [0158] I-61:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
1-amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate hydrochloride;
[0159] I-62: isopropyl
(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)-L-alaninate; [0160] I-63:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
dihydrogen phosphate tris salt; [0161] I-64:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide hydrochloride;
[0162] I-65:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide benzene
sulfonate; [0163] I-66:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide tartrate; [0164]
I-67:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide sodium salt;
[0165] I-68:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide hemicitrate;
[0166] I-69:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
dihydrogen phosphate ditris salt; [0167] I-70: benzyl
((S)-1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl-
)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-methyl-1-oxop-
entan-2-yl)carbamate; [0168] I-71:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-prolinate; [0169] I-72:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
glycinate; [0170] I-73:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(R)-2-amino-3,3-dimethylbutanoate; [0171] I-74:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-amino-2-methylpropanoate; [0172] I-75:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
1-methyl L-aspartate; [0173] I-76:
(S)-2-amino-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycy-
clohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-
-4-oxobutanoic acid; [0174] I-77:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-amino-3-methylbutanamido)butanoate; [0175] I-78:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
1-amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate; [0176] I-79:
2-(1-(acetyl-D-leucyl)-1H-pyrazol-4-yl)-N-(3-(3,6-difluoropyridin-2-yl)-1-
-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide;
[0177] I-80:
2-(1-(acetylleucyl)-1H-pyrazol-4-yl)-N-(3-(3,6-difluoropyridin-2-yl)-1-((-
1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide;
[0178] I-81:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-
-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
D-valinate; [0179] I-82:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl valinate;
[0180] I-83:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-
-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
D-prolinate; [0181] I-84:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
prolinate; [0182] I-85:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-amino-3,3-dimethylbutanoate; [0183] I-86:
(1S,2S)-2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclo-
hexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)car-
bonyl)cyclohexane-1-carboxylic acid; [0184] I-87:
(1R,2S)-2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclo-
hexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)car-
bonyl)cyclohexane-1-carboxylic acid;
[0185] I-88:
(1S,2R)-2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclo-
hexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)car-
bonyl)cyclohexane-1-carboxylic acid; [0186] I-89:
2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1-
H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)carbonyl)cy-
clohexane-1-carboxylic acid; [0187] I-90:
(R)-2-amino-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycy-
clohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-
-4-oxobutanoic acid; [0188] I-91:
2-amino-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycycloh-
exyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-4-o-
xobutanoic acid; [0189] I-92:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
1-methyl D-aspartate; [0190] I-93:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
1-methyl aspartate; [0191] I-94:
1-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
4-methyl D-aspartate; [0192] I-95:
1-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl)
4-methyl aspartate; [0193] I-96:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((R)-2-amino-3-methylbutanamido)butanoate; [0194] I-97:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-(2-amino-3-methylbutanamido)butanoate; [0195] I-98: isopropyl
(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)-D-alaninate; [0196] I-99: isopropyl
(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)alaninate; [0197] I-100:
(2R,3S)-2,3-diacetoxy-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)--
4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-y-
l)methoxy)-4-oxobutanoic acid; [0198] I-101:
(2S,3R)-2,3-diacetoxy-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)--
4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-y-
l)methoxy)-4-oxobutanoic acid; [0199] I-102:
(2S,3S)-2,3-diacetoxy-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)--
4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-y-
l)methoxy)-4-oxobutanoic acid; [0200] I-103:
2,3-diacetoxy-4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxy-
cyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methox-
y)-4-oxobutanoic acid; [0201] I-104:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide phosphate; [0202]
I-105:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide gentisate; [0203]
I-106:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide succinate; [0204]
I-107: sodium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohex-
yl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
hydrogen phosphate; [0205] I-108: potassium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate; [0206] I-109: potassium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
phosphate; [0207] I-110:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate arginine salt; [0208] I-111:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate choline salt; [0209] I-112: ammonium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate; [0210] I-113:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate lysine salt; [0211] I-114:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate meglumine salt; [0212] I-115: magnesium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
phosphate; or [0213] I-116: Calcium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
phosphate.
III. Compositions and/or Combinations Comprising Pyrazole
Compounds
[0214] A. Combinations with Other Therapeutic Agents
[0215] The pyrazole compounds of the present invention may be used
alone, in combination with one another, or as an adjunct to, or in
combination with, other established therapies. In another aspect,
the compounds of the present invention may be used in combination
with other therapeutic agents useful for the disorder or condition
being treated. These compounds may be administered simultaneously,
sequentially in any order, by the same route of administration, or
by a different route.
[0216] In some embodiments, the second therapeutic agent is an
analgesic, an antibiotic, an anticoagulant, an antibody, an
anti-inflammatory agent, an immunosuppressant, a guanylate
cyclase-C agonist, an intestinal secretagogue, an antiviral,
anticancer, antifungal, a cell therapy, or a combination thereof.
The anti-inflammatory agent may be a steroid or a nonsteroidal
anti-inflammatory agent. In certain embodiments, the nonsteroidal
anti-inflammatory agent is selected from aminosalicylates,
cyclooxygenase inhibitors, diclofenac, etodolac, famotidine,
fenoprofen, flurbiprofen, ketoprofen, ketorolac, ibuprofen,
indomethacin, meclofenamate, mefenamic acid, meloxicam,
nambumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac,
tolmetin, or a combination thereof. In some embodiments, the
immunosuppressant is mercaptopurine, a corticosteroid, an
alkylating agent, a calcineurin inhibitor, an inosine monophosphate
dehydrogenase inhibitor, antilymphocyte globulin, antithymocyte
globulin, an anti-T-cell antibody, or a combination thereof. In one
embodiment, the antibody is infliximab.
[0217] In some embodiments, the present compounds may be used with
anti-cancer or cytotoxic agents. Various classes of anti-cancer and
anti-neoplastic compounds include, but are not limited to,
alkylating agents, antimetabolites, BCL-2 inhibitors, vinca
alkyloids, taxanes, antibiotics, enzymes, cytokines, platinum
coordination complexes, proteasome inhibitors, substituted ureas,
kinase inhibitors, hormones and hormone antagonists, and
hypomethylating agents, for example DNMT inhibitors, such as
azacitidine and decitabine. Exemplary alkylating agents include,
without limitation, mechlorothamine, cyclophosphamide, ifosfamide,
melphalan, chlorambucil, ethyleneimines, methylmelamines, alkyl
sulfonates (e.g., busulfan), and carmustine. Exemplary
antimetabolites include, by way of example and not limitation,
folic acid analog methotrexate; pyrimidine analog fluorouracil,
cytosine arbinoside; purine analogs mercaptopurine, thioguanine,
and azathioprine. Exemplary vinca alkyloids include, by way of
example and not limitation, vinblastine, vincristine, paclitaxel,
and colchicine. Exemplary antibiotics include, by way of example
and not limitation, actinomycin D, daunorubicin, and bleomycin. An
exemplary enzyme effective as an anti-neoplastic agent includes
L-asparaginase. Exemplary coordination compounds include, by way of
example and not limitation, cisplatin and carboplatin. Exemplary
hormones and hormone related compounds include, by way of example
and not limitation, adrenocorticosteroids prednisone and
dexamethasone; aromatase inhibitors amino glutethimide, formestane,
and anastrozole; progestin compounds hydroxyprogesterone caproate,
medroxyprogesterone; and anti-estrogen compound tamoxifen.
[0218] These and other useful anti-cancer compounds are described
in Merck Index, 13th Ed. (O'Neil M. J. et al., ed.) Merck
Publishing Group (2001) and Goodman and Gilman's The
Pharmacological Basis of Therapeutics, 12th Edition, Brunton L. L.
ed., Chapters 60-63, McGraw Hill, (2011), both of which are
incorporated by reference herein.
[0219] Among the CTLA 4 antibodies that can be used in combination
with the presently disclosed inhibitors is ipilimumab, marketed as
YERVOY.RTM. by Bristol-Myers Squibb.
[0220] Other chemotherapeutic agents for combination include
immunooncology agents, such as checkpoint pathway inhibitors, for
example, PD-1 inhibitors, such as nivolumab and lambrolizumab, and
PD-L1 inhibitors, such as pembrolizumab, MEDI-4736 and
MPDL3280A/RG7446. Additional checkpoint inhibitors for combination
with the compounds disclosed herein include, Anti-LAG-3 agents,
such as BMS-986016 (MDX-1408).
[0221] Further chemotherapeutic agents for combination with the
presently disclosed inhibitors include Anti-SLAMF7 agents, such as
the humanized monoclonal antibody elotuzumab (BMS-901608), anti-KIR
agents, such as the anti-KIR monoclonal antibody lirilumab
(BMS-986015), and anti-CD137 agents, such as the fully human
monoclonal antibody urelumab (BMS-663513).
[0222] Additional anti-proliferative compounds useful in
combination with the compounds of the present invention include, by
way of example and not limitation, antibodies directed against
growth factor receptors (e.g., anti-Her2); and cytokines such as
interferon-.alpha. and interferon-.gamma., interleukin-2, and
GM-CSF.
[0223] Additional chemotherapeutic agents useful in combination
with the present pyrazole compounds include proteasome inhibitors,
such as bortezomib, carfilzomib, marizomib and the like.
[0224] Examples of cell therapies include, but are not limited to,
cells expressing chimeric antigen receptors (CARs) and/or T cell
receptors (TCRs). YESCARTA and KYMRIAH are two commercially
available examples.
[0225] Examples of kinase inhibitors that are useful in combination
with the presently disclosed compounds, particularly in treating
malignancies, include Btk inhibitors, such as ibrutinib, CDK
inhibitors, such as palbociclib, EGFR inhibitors, such as afatinib,
erlotinib, gefitinib, lapatinib, osimertinib and vandetinib, Mek
inhibitors, such as trametinib, Raf inhibitors, such as dabrafenib,
sorafenib and vemurafenib, VEGFR inhibitors, such as axitinib,
lenvatinib, nintedanib, pazopanib, BCR-Abl inhibitors, such as
bosutinib, dasatinib, imatinib and nilotinib, Syk inhibitors, such
as fostamatinib, and JAK inhibitors, such as ruxolitinib, In other
embodiments, the second therapeutic agent may be selected from any
of the following:
[0226] analgesics--morphine, fentanyl, hydromorphone, oxycodone,
codeine, acetaminophen, hydrocodone, buprenorphine, tramadol,
venlafaxine, flupirtine, meperidine, pentazocine, dextromoramide,
dipipanone;
[0227] antibiotics--aminoglycosides (e.g., amikacin, gentamicin,
kanamycin, neomycin, netilmicin, tobramycin, and paromycin),
carbapenems (e.g., ertapenem, doripenem, imipenem, cilastatin, and
meropenem), cephalosporins (e.g., cefadroxil, cefazolin, cefalotin,
cephalexin, cefaclor, cefamandole, cefoxitin, cefprozil,
cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone,
cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime,
ceftriaxone, cefepime, and cefobiprole), glycopeptides (e.g.,
teicoplanin, vancomycin, and telavancin), lincosamides (e.g.,
clindamycin and incomysin), lipopeptides (e.g., daptomycin),
macrolides (e.g., azithromycin, clarithromycin, dirithromycin,
erythromycin, roxithromycin, troleandomycin, telithromycin, and
spectinomycin), monobactams (e.g., aztreonam), nitrofurans (e.g.,
furazolidone and nitrofurantoin), penicilllins (e.g., amoxicillin,
ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin,
flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin,
penicillin G, penicillin V, piperacillin, temocillin, and
ticarcillin), penicillin combinations (e.g.,
amoxicillin/clavulanate, ampicillin/sulbactam,
piperacillin/tazobactam, and ticarcillin/clavulanate), polypeptides
(e.g., bacitracin, colistin, and polymyxin B), quinolones (e.g.,
ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin,
moxifloxacin, nalidixic acid, norfloxacin, ofloxacin,
trovafloxacin, grepafloxacin, sparfloxacin, and temafloxacin),
sulfonamides (e.g., mafenide, sulfonamidochrysoidine,
sulfacetamide, sulfadiazine, silver sulfadiazine, sulfamethizole,
sulfamethoxazole, sulfanilimide, sulfasalazine, sulfisoxazole,
trimethoprim, and trimethoprim-sulfamethoxaxzole), tetracyclines
(e.g., demeclocycline, doxycycline, minocycline, oxytetracycline,
and tetracycline), antimycobacterial compounds (e.g., clofazimine,
dapsone, capreomycin, cycloserine, ethambutol, ethionamide,
isoniazid, pyrazinamide, rifampicin (rifampin), rifabutin,
rifapentine, and streptomycin), and others, such as arsphenamine,
chloramphenicol, fosfomycin, fusidic acid, linezolid,
metronidazole, mupirocin, platensimycin, quinuprisin/dalfopristin,
rifaximin, thiamphenicol, tigecycline, and timidazole;
[0228] antibodies--anti-TNF-.alpha. antibodies, e.g., infliximab
(Remicade.TM.), adalimumab, golimumab, certolizumab; anti-B cell
antibodies, e.g., rituximab; anti-IL-6 antibodies, e.g.,
tocilizumab; anti-IL-1 antibodies, e.g., anakinra; anti PD-1 and/or
anti-PD-L1 antibodies, e.g. nivolumab, pembrolizumab, pidilizumab,
BMS-936559, MPDL3280A, AMP-224, MEDI4736; ixekizumab, brodalumab,
ofatumumab, sirukumab, clenoliximab, clazakiumab, fezakinumab,
fletikumab, mavrilimumab, ocrelizumab, sarilumab, secukinumab,
toralizumab, zanolimumab;
[0229] anticoagulants--warfarin (Coumadin.TM.), acenocoumarol,
phenprocoumon, atromentin, phenindione, heparin, fondaparinux,
idraparinux, rivaroxaban, apixaban, hirudin, lepirudin,
bivalirudin, argatrobam, dabigatran, ximelagatran, batroxobin,
hementin;
[0230] anti-inflammatory agents--steroids, e.g., budesonide,
nonsteroidal anti-inflammatory agents, e.g., aminosalicylates
(e.g., sulfasalazine, mesalamine, olsalazine, and balsalazide),
cyclooxygenase inhibitors (COX-2 inhibitors, such as rofecoxib,
celecoxib), diclofenac, etodolac, famotidine, fenoprofen,
flurbiprofen, ketoprofen, ketorolac, ibuprofen, indomethacin,
meclofenamate, mefenamic acid, meloxicam, nambumetone, naproxen,
oxaprozin, piroxicam, salsalate, sulindac, tolmetin;
[0231] immunosuppressants--mercaptopurine, corticosteroids such as
dexamethasone, hydrocortisone, prednisone, methylprednisolone and
prednisolone, alkylating agents such as cyclophosphamide,
calcineurin inhibitors such as cyclosporine, sirolimus and
tacrolimus, inhibitors of inosine monophosphate dehydrogenase
(IMPDH) such as mycophenolate, mycophenolate mofetil and
azathioprine, and agents designed to suppress cellular immunity
while leaving the recipient's humoral immunologic response intact,
including various antibodies (for example, antilymphocyte globulin
(ALG), antithymocyte globulin (ATG), monoclonal anti-T-cell
antibodies (OKT3)) and irradiation. Azathioprine is currently
available from Salix Pharmaceuticals, Inc. under the brand name
Azasan; mercaptopurine is currently available from Gate
Pharmaceuticals, Inc. under the brand name Purinethol; prednisone
and prednisolone are currently available from Roxane Laboratories,
Inc.; Methyl prednisolone is currently available from Pfizer;
sirolimus (rapamycin) is currently available from Wyeth-Ayerst
under the brand name Rapamune; tacrolimus is currently available
from Fujisawa under the brand name Prograf; cyclosporine is current
available from Novartis under the brand name Sandimmune and Abbott
under the brand name Gengraf; IMPDH inhibitors such as
mycophenolate mofetil and mycophenolic acid are currently available
from Roche under the brand name Cellcept and Novartis under the
brand name Myfortic; azathioprine is currently available from Glaxo
Smith Kline under the brand name Imuran; and antibodies are
currently available from Ortho Biotech under the brand name
Orthoclone, Novartis under the brand name Simulect (basiliximab)
and Roche under the brand name Zenapax (daclizumab); and
[0232] Guanylate cyclase-C receptor agonists or intestinal
secretagogues--for example linaclotide, sold under the name
Linzess.
[0233] These various agents can be used in accordance with their
standard or common dosages, as specified in the prescribing
information accompanying commercially available forms of the drugs
(see also, the prescribing information in the 2006 Edition of The
Physician's Desk Reference), the disclosures of which are
incorporated herein by reference.
[0234] B. Compositions Comprising Pyrazole Compounds
[0235] The disclosed pyrazole compounds may be used alone, in any
combination, and in combination with, or adjunctive to, at least
one second therapeutic agent, and further the pyrazole compounds,
and the at least one second therapeutic if present, may be used in
combination with any suitable additive useful for forming
compositions for administration to a subject. Additives can be
included in pharmaceutical compositions for a variety of purposes,
such as to dilute a composition for delivery to a subject, to
facilitate processing of the formulation, to provide advantageous
material properties to the formulation, to facilitate dispersion
from a delivery device, to stabilize the formulation (e.g.,
antioxidants or buffers), to provide a pleasant or palatable taste
or consistency to the formulation, or the like. Typical additives
include, by way of example and without limitation: pharmaceutically
acceptable excipients; pharmaceutically acceptable carriers; and/or
adjuvants, such as mono-, di-, and polysaccharides, sugar alcohols
and other polyols, such as, lactose, glucose, raffinose,
melezitose, lactitol, maltitol, trehalose, sucrose, mannitol,
starch, or combinations thereof, surfactants, such as sorbitols,
diphosphatidyl choline, and lecithin; bulking agents; buffers, such
as phosphate and citrate buffers; anti-adherents, such as magnesium
stearate; binders, such as saccharides (including disaccharides,
such as sucrose and lactose), polysaccharides (such as starches,
cellulose, microcrystalline cellulose, cellulose ethers (such as
hydroxypropyl cellulose), gelatin, synthetic polymers (such as
polyvinylpyrrolidone, polyalkylene gylcols); coatings (such as
cellulose ethers, including hydroxypropylmethyl cellulose, shellac,
corn protein zein, and gelatin); release aids (such as enteric
coatings); disintegrants (such as crospovidone, crosslinked sodium
carboxymethyl cellulose, and sodium starch glycolate); fillers
(such as dibasic calcium phosphate, vegetable fats and oils,
lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate,
and magnesium stearate); flavors and sweeteners (such as mint,
cherry, anise, peach, apricot or licorice, raspberry, and vanilla;
lubricants (such as minerals, exemplified by talc or silica, fats,
exemplified by vegetable stearin, magnesium stearate or stearic
acid); preservatives (such as antioxidants exemplified by vitamin
A, vitamin E, vitamin C, retinyl palmitate, and selenium, amino
acids, exemplified by cysteine and methionine, citric acid and
sodium citrate, parabens, exemplified by methyl paraben and propyl
paraben); colorants; compression aids; emulsifying agents;
encapsulation agents; gums; granulation agents; and combinations
thereof.
IV. Method of Use
[0236] The present disclosure provides pyrazole compounds and
combinations and/or compositions thereof, that may be useful to
ameliorate, treat and/or prevent a variety of diseases and/or
disorders. Certain disclosed compounds, referred to herein as
active compounds, have activity as IRAK inhibitors and/or may be
used to ameliorate, treat or prevent a disease and/or disorder when
administered at a dose that provides a desired benefit to the
subject but does not cause significant unwanted and/or harmful side
effects to the subject. In some embodiments, the disease and/or
disorder is one for which an IRAK inhibitor is indicated. The
present disclosure also addresses the problem of administering
and/or providing a biologically effective amount of such an active
compound to a subject, such as a subject in need of an IRAK
inhibitor. Certain embodiments concern pyrazole compounds that are
useful to provide and/or deliver a biologically effective amount of
an active compound to the subject. Such compounds may be a prodrug
of the active compound, a salt of the active compound, or a
combination thereof. Also disclosed are embodiments of a
formulation comprising one or more of the pyrazole compounds that
are useful for delivering the active compound, a prodrug and/or
salt of the active compound, or a combination thereof. Certain
embodiments of the composition concern a spray-dried
formulation.
[0237] A. Diseases/Disorders
[0238] The disclosed pyrazole compounds, as well as combinations
and/or compositions thereof, may be useful to ameliorate, treat
and/or prevent a variety of diseases and/or disorders. In
particular embodiments, the pyrazole compound, combinations of
pyrazole compounds, and/or compositions thereof, may be useful for
treating or preventing auto-immune diseases, inflammatory
disorders, cardiovascular diseases, nerve disorders,
neurodegenerative disorders, allergic disorders, asthma,
pancreatitis, multi-organ failure, kidney diseases, platelet
aggregation, cancer, transplantation, sperm motility, erythrocyte
deficiency, graft rejection, lung injuries, respiratory diseases,
ischemic conditions, cytokine release syndrome (CRS), and bacterial
and viral infections.
[0239] In some embodiments, the pyrazole compound, combinations of
pyrazole compounds, and/or compositions thereof, may be useful or
treating or preventing allergic diseases, amyotrophic lateral
sclerosis (ALS), systemic lupus erythematosus, rheumatoid
arthritis, type I diabetes mellitus, inflammatory bowel disease,
biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease,
ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis,
autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves
ophthalmopathy or asthma.
[0240] The pyrazole compound, combinations of pyrazole compounds,
and/or compositions thereof, may also be useful for ameliorating,
treating or preventing immune regulatory disorders related to bone
marrow or organ transplant rejection or graft-versus-host disease.
Examples of inflammatory and immune regulatory disorders that can
be treated with the present compounds include, but are not limited
to, transplantation of organs or tissue, graft-versus-host diseases
brought about by transplantation, autoimmune syndromes including
rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's
thyroiditis, multiple sclerosis, systemic sclerosis, myasthenia
gravis, type I diabetes, uveitis, posterior uveitis, allergic
encephalomyelitis, glomerulonephritis, postinfectious autoimmune
diseases including rheumatic fever and post-infectious
glomerulonephritis, inflammatory and hyperproliferative skin
diseases, psoriasis, atopic dermatitis, contact dermatitis,
eczematous dermatitis, seborrhoeic dermatitis, lichen planus,
pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria,
angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus
erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal
conjunctivitis, uveitis associated with Behcet's disease,
keratitis, herpetic keratitis, conical cornea, dystrophia
epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's
ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada
syndrome, sarcoidosis, pollen allergies, reversible obstructive
airway disease, bronchial asthma, allergic asthma, intrinsic
asthma, extrinsic asthma, dust asthma, chronic or inveterate
asthma, late asthma and airway hyper-responsiveness, bronchitis,
gastric ulcers, vascular damage caused by ischemic diseases and
thrombosis, ischemic bowel diseases, inflammatory bowel diseases,
necrotizing enterocolitis, intestinal lesions associated with
thermal burns, celiac diseases, proctitis, eosinophilic
gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis,
migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's
syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple
myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis,
multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism,
Basedow's disease, pure red cell aplasia, aplastic anemia,
hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune
hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic
anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung,
idiopathic interstitial pneumonia, dermatomyositis, leukoderma
vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous
T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis,
atherosclerosis, aortitis syndrome, polyarteritis nodosa,
myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome,
adiposis, eosinophilic fascitis, lesions of gingiva, periodontium,
alveolar bone, substantia ossea dentis, glomerulonephritis, male
pattern alopecia or alopecia senilis by preventing epilation or
providing hair germination and/or promoting hair generation and
hair growth, muscular dystrophy, pyoderma and Sezary's syndrome,
Addison's disease, ischemia-reperfusion injury of organs which
occurs upon preservation, transplantation or ischemic disease,
endotoxin-shock, pseudomembranous colitis, colitis caused by drug
or radiation, ischemic acute renal insufficiency, chronic renal
insufficiency, toxinosis caused by lung-oxygen or drugs, lung
cancer, pulmonary emphysema, cataracta, siderosis, retinitis
pigmentosa, senile macular degeneration, vitreal scarring, comeal
alkali burn, dermatitis erythema multiforme, linear IgA ballous
dermatitis and cement dermatitis, gingivitis, periodontitis,
sepsis, pancreatitis, diseases caused by environmental pollution,
aging, carcinogenesis, metastasis of carcinoma and hypobaropathy,
disease caused by histamine or leukotriene-C4 release, Behcet's
disease, autoimmune hepatitis, primary biliary cirrhosis,
sclerosing cholangitis, partial liver resection, acute liver
necrosis, necrosis caused by toxin, viral hepatitis, shock, or
anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis,
alcoholic liver disease, including alcoholic cirrhosis,
non-alcoholic steatohepatitis (NASH), hepatic failure, fulminant
hepatic failure, late-onset hepatic failure, "acute-on-chronic"
liver failure, augmentation of chemotherapeutic effect,
cytomegalovirus infection, HCMV infection, AIDS, cancer, senile
dementia, Parkinson's disease, trauma, or chronic bacterial
infection.
[0241] In certain embodiments, the present compounds are useful for
treating nerve pain, including neuropathic pain and inflammation
induced pain.
[0242] In certain embodiments, the pyrazole compound, combinations
of pyrazole compounds, and/or compositions thereof, are useful for
treating and/or preventing rheumatoid arthritis, psoriatic
arthritis, osteoarthritis, systemic lupus erythematosus, lupus
nephritis, ankylosing spondylitis, osteoporosis, systemic
sclerosis, multiple sclerosis, psoriasis, in particular pustular
psoriasis, type I diabetes, type II diabetes, inflammatory bowel
disease (Crohn's disease and ulcerative colitis),
hyperimmunoglobulinemia d and periodic fever syndrome,
cryopyrin-associated periodic syndromes, Schnitzler's syndrome,
systemic juvenile idiopathic arthritis, adult's onset Still's
disease, gout, gout flares, pseudogout, sapho syndrome, Castleman's
disease, sepsis, stroke, atherosclerosis, celiac disease, DIRA
(deficiency of Il-1 receptor antagonist), Alzheimer's disease, or
Parkinson's disease.
[0243] Proliferative diseases that may be treated by the pyrazole
compound, combinations of pyrazole compounds, and/or compositions
thereof, include benign or malignant tumors, solid tumor, carcinoma
of the brain, kidney, liver, adrenal gland, bladder, breast,
stomach, gastric tumors, ovaries, colon, rectum, prostate,
pancreas, lung, vagina, cervix, testis, genitourinary tract,
esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas,
neuroblastomas, multiple myeloma, gastrointestinal cancer,
especially colon carcinoma or colorectal adenoma, a tumor of the
neck and head, an epidermal hyperproliferation, psoriasis, prostate
hyperplasia, a neoplasia, a neoplasia of epithelial character,
adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma,
large cell carcinoma, non-small-cell lung carcinoma, lymphomas,
Hodgkins and Non-Hodgkins, a mammary carcinoma, follicular
carcinoma, undifferentiated carcinoma, papillary carcinoma,
seminoma, melanoma, IL-1 driven disorders, a MyD88 driven disorder
(such as ABC diffuse large B-cell lymphoma (DLBCL), Waldenstrom's
macroglobulinemia, Hodgkin's lymphoma, primary cutaneous T-cell
lymphoma or chronic lymphocytic leukemia), smoldering or indolent
multiple myeloma, or hematological malignancies (including
leukemia, acute myeloid leukemia (AML), DLBCL, ABC DLBCL, chronic
lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary
effusion lymphoma, Burkitt lymphoma/leukemia, acute lymphocytic
leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic
lymphoma, myelodysplastic syndromes (MDS), myelofibrosis,
polycythemia vera, Kaposi's sarcoma, Waldenstrom's
macroglobulinemia (WM), splenic marginal zone lymphoma, multiple
myeloma, plasmacytoma, or intravascular large B-cell lymphoma). In
particular, the presently disclosed compounds are useful for
treating drug resistant malignancies, such as those resistant to
JAK inhibitors, ibrutinib resistant malignancies, including
ibrutinib resistant hematological malignancies, such as ibrutinib
resistant CLL and ibrutinib resistant Waldenstrom's
macroglobulinemia.
[0244] Examples of allergic disorders that may be treated using the
pyrazole compound, combinations of pyrazole compounds, and/or
compositions thereof, include, but are not limited to, asthma (e.g.
atopic asthma, allergic asthma, atopic bronchial IgE-mediated
asthma, non-atopic asthma, bronchial asthma, non-allergic asthma,
essential asthma, true asthma, intrinsic asthma caused by
pathophysiologic disturbances, essential asthma of unknown or
unapparent cause, emphysematous asthma, exercise-induced asthma,
emotion-induced asthma, extrinsic asthma caused by environmental
factors, cold air induced asthma, occupational asthma, infective
asthma caused by or associated with bacterial, fungal, protozoal,
or viral infection, incipient asthma, wheezy infant syndrome,
bronchiolitis, cough variant asthma or drug-induced asthma),
allergic bronchopulmonary aspergillosis (ABPA), allergic rhinitis,
perennial allergic rhinitis, perennial rhinitis, vasomotor
rhinitis, post-nasal drip, purulent or non-purulent sinusitis,
acute or chronic sinusitis, and ethmoid, frontal, maxillary, or
sphenoid sinusitis.
[0245] As another example, rheumatoid arthritis (RA) typically
results in swelling, pain, loss of motion and tenderness of target
joints throughout the body. RA is characterized by chronically
inflamed synovium that is densely crowded with lymphocytes. The
synovial membrane, which is typically one cell layer thick, becomes
intensely cellular and assumes a form similar to lymphoid tissue,
including dendritic cells, T-, B- and NK cells, macrophages and
clusters of plasma cells. This process, as well as a plethora of
immunopathological mechanisms including the formation of
antigen-immunoglobulin complexes, eventually result in destruction
of the integrity of the joint, resulting in deformity, permanent
loss of function and/or bone erosion at or near the joint. The
pyrazole compound, combinations of pyrazole compounds, or
compositions thereof, may be used to treat, ameliorate or prevent
any one, several or all of these symptoms of RA. Thus, in the
context of RA, the compounds are considered to provide therapeutic
benefit when a reduction or amelioration of any of the symptoms
commonly associated with RA is achieved, regardless of whether the
treatment results in a concomitant treatment of the underlying RA
and/or a reduction in the amount of circulating rheumatoid factor
("RF").
[0246] The American College of Rheumatology (ACR) has developed
criteria for defining improvement and clinical remission in RA.
Once such parameter, the ACR20 (ACR criteria for 20% clinical
improvement), requires a 20% improvement in the tender and swollen
joint count, as well as a 20% improvement in 3 of the following 5
parameters: patient's global assessment, physician's global
assessment, patient's assessment of pain, degree of disability, and
level of acute phase reactant. These criteria have been expanded
for 50% and 70% improvement in ACR50 and ACR70, respectively. Other
criteria include Paulu's criteria and radiographic progression
(e.g. Sharp score).
[0247] In some embodiments, therapeutic benefit in patients
suffering from RA is achieved when the patient exhibits an ACR20.
In specific embodiments, ACR improvements of ACRC50 or even ACR70
may be achieved.
[0248] B. Formulations and Administration
[0249] Pharmaceutical compositions comprising the active compounds
of the invention (or prodrugs thereof) may be manufactured by means
of conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or
lyophilization processes. The compositions may be formulated in
conventional manner using one or more physiologically acceptable
excipients, diluents, carriers, adjuvants or auxiliaries to provide
preparations which can be used pharmaceutically.
[0250] The active compound or a prodrug thereof may be formulated
in the pharmaceutical compositions per se, or in the form of a
hydrate, solvate, N-oxide, co-crystal, or pharmaceutically
acceptable salt. Typically, such salts are more soluble in aqueous
solutions than the corresponding free acids and bases, but salts
having lower solubility than the corresponding free acids and bases
may also be formed.
[0251] Pharmaceutical compositions of the invention may take a form
suitable for virtually any mode of administration, including, for
example, topical, ocular, oral, buccal, systemic, nasal, injection,
such as i.v. or i.p., transdermal, rectal, vaginal, etc., or a form
suitable for administration by inhalation or insufflation.
[0252] For topical administration, the active compound(s), hydrate,
solvate, N-oxide, co-crystal, or pharmaceutically acceptable salt
and/or prodrug(s) may be formulated as solutions, gels, ointments,
creams, suspensions, etc. as are well-known in the art.
[0253] Systemic formulations include those designed for
administration by injection, e.g., subcutaneous, intravenous,
intramuscular, intrathecal or intraperitoneal injection, as well as
those designed for transdermal, transmucosal oral or pulmonary
administration.
[0254] Useful injectable preparations include sterile suspensions,
solutions or emulsions of the active compound(s) in aqueous or oily
vehicles. The compositions may also contain formulating agents,
such as suspending, stabilizing and/or dispersing agent. The
formulations for injection may be presented in unit dosage form,
e.g., in ampules or in multidose containers, and may contain added
preservatives.
[0255] Alternatively, the injectable formulation may be provided in
powder form for reconstitution with a suitable vehicle, including
but not limited to sterile, pyrogen-free water, buffer, dextrose
solution, etc., before use. To this end, the pyrazole compound(s)
maybe dried by any art-known technique, such as lyophilization, and
reconstituted prior to use.
[0256] For transmucosal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are known in the art.
[0257] For oral administration, the pharmaceutical compositions may
take the form of, for example, lozenges, tablets or capsules
prepared by conventional means with pharmaceutically acceptable
excipients, such as: binding agents (e.g., pregelatinised maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or
silica); disintegrants (e.g., potato starch or sodium starch
glycolate); and/or wetting agents (e.g., sodium lauryl sulfate).
The tablets may be coated by methods well known in the art with,
for example, sugars, films or enteric coatings.
[0258] Liquid preparations for oral administration may take the
form of, for example, elixirs, solutions, syrups or suspensions, or
they may be presented as a dry product for constitution with water
or other suitable vehicle before use. Such liquid preparations may
be prepared by conventional means with pharmaceutically acceptable
additives such as: suspending agents (e.g., sorbitol syrup,
cellulose derivatives or hydrogenated edible fats); emulsifying
agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g.,
almond oil, oily esters, ethyl alcohol, Cremophore.TM. or
fractionated vegetable oils); and preservatives (e.g., methyl or
propyl-p-hydroxybenzoates or sorbic acid). The preparations may
also contain buffer salts, preservatives, flavoring, coloring and
sweetening agents as appropriate.
[0259] Preparations for oral administration may be suitably
formulated to give controlled release of the active compound or
prodrug, as is well known.
[0260] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0261] For rectal and vaginal routes of administration, the
pyrazole compound(s) may be formulated as solutions (for retention
enemas) suppositories or ointments containing conventional
suppository bases, such as cocoa butter or other glycerides.
[0262] For nasal administration or administration by inhalation or
insufflation, the active compound(s), hydrate, solvate, N-oxide,
co-crystal, pharmaceutically acceptable salt and/or prodrug(s) can
be conveniently delivered in the form of an aerosol spray from
pressurized packs or a nebulizer with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, fluorocarbons, carbon dioxide or other
suitable gas. In the case of a pressurized aerosol, the dosage unit
may be determined by providing a valve to deliver a metered amount.
Capsules and cartridges for use in an inhaler or insufflator (for
example capsules and cartridges comprised of gelatin) may be
formulated containing a powder mix of the compound and a suitable
powder base such as lactose or starch.
[0263] A specific example of an aqueous suspension formulation
suitable for nasal administration using commercially-available
nasal spray devices includes the following ingredients: active
compound or prodrug (0.5 to 20 mg/ml); benzalkonium chloride (0.1
to 0.2 mg/mL); polysorbate 80 (TWEEN.RTM. 80; 0.5 to 5 mg/ml);
carboxymethylcellulose sodium or microcrystalline cellulose (1 to
15 mg/ml); phenylethanol (1 4 mg/ml); and dextrose (20 to 50
mg/ml). The pH of the final suspension can be adjusted to range
from about pH 5 to pH 7, with a pH of about pH 5.5 being
typical.
[0264] Another specific example of an aqueous suspension suitable
for administration of the compounds via inhalation contains 20
mg/mL Compound or prodrug, 1% (v/v) Polysorbate 80 (TWEEN.RTM. 80),
50 mM citrate and/or 0.9% sodium chloride.
[0265] For ocular administration, the active compound(s) or
prodrug(s) may be formulated as a solution, emulsion, suspension,
etc. suitable for administration to the eye. A variety of vehicles
suitable for administering compounds to the eye are known in the
art. Specific non-limiting examples are described in U.S. Pat. Nos.
6,261,547; 6,197,934; 6,056,950; 5,800,807; 5,776,445; 5,698,219;
5,521,222; 5,403,841; 5,077,033; 4,882,150; and 4,738,851, which
are incorporated herein by reference.
[0266] For prolonged delivery, the pyrazole compound(s) can be
formulated as a depot preparation for administration by
implantation or intramuscular injection. The pyrazole compound
maybe formulated with suitable polymeric or hydrophobic materials
(e.g., as an emulsion in an acceptable oil) or ion exchange resins,
or as sparingly soluble derivatives, e.g., as a sparingly soluble
salt. Alternatively, transdermal delivery systems manufactured as
an adhesive disc or patch which slowly releases the active
compound(s) for percutaneous absorption may be used. To this end,
permeation enhancers may be used to facilitate transdermal
penetration of the active compound(s). Suitable transdermal patches
are described in for example, U.S. Pat. Nos. 5,407,713; 5,352,456;
5,332,213; 5,336,168; 5,290,561; 5,254,346; 5,164,189; 5,163,899;
5,088,977; 5,087,240; 5,008,110; and 4,921,475, which are
incorporated herein by reference.
[0267] Alternatively, other pharmaceutical delivery systems may be
employed. Liposomes and emulsions are well-known examples of
delivery vehicles that may be used to deliver the pyrazole
compound(s). Certain organic solvents, such as dimethylsulfoxide
(DMSO), may also be employed, although usually at the cost of
greater toxicity.
[0268] The pharmaceutical compositions may, if desired, be
presented in a pack or dispenser device which may contain one or
more unit dosage forms containing the active compound(s). The pack
may, for example, comprise metal or plastic foil, such as a blister
pack. The pack or dispenser device may be accompanied by
instructions for administration.
[0269] I. Spray-Dried Formulation
[0270] Disclosed herein are embodiments of a spray-dried
formulation comprising one or more compounds according to formula
I. The spray-dried formulation may be a dispersion, such as a
spray-dried dispersion of the compound(s) according to formula I in
a carrier or matrix, such as a polymer matrix. Typically, the
spray-dried formulation comprises a single phase, amorphous
dispersion of the disclosed compound(s) in the carrier, such as a
polymer matrix.
[0271] Embodiments of the spray-dried formulation comprise, consist
essentially of, or consist of, an effective amount of one or more
compounds according to formula I and an amount of the carrier
sufficient to form the spray-dried formulation. A person of
ordinary skill in the art will appreciate that an effective amount
of the compound(s) may vary, but typically the effective amount is
from 0.1% to 50% (w/w with respect to the carrier) or more, such as
from 1% to 50%, from 5% to 40%, from 10% to 35%, from 15% to 30%,
or from 15% to 25%. In particular embodiments, the spray-dried
formulation comprises, consists essentially of, or consists of, 20%
w/w of the disclosed compound(s) and 80% w/w carrier, such as a
polymer matrix.
[0272] In some embodiments, the carrier is a polymer, such as a
polymer that is suitable to form a spray-dried formulation with the
disclosed compound(s). Suitable polymers include, but are not
limited to, cellulose derivatives, such as
hydroxypropylmethylcellulose acetate succinate (hypromellose
acetate succinate; HPMCAS), hydroxypropyl methylcellulose phthalate
(hypromellose phthalate; HPMCP) or hydroxypropyl methylcellulose
(HPMC); vinyl polymers, such as poly(vinylpyrrolidone) (PVP), or
poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA); lactide polymers,
such as polylactide (PLA) or polylactide-co-glycolide (PLGA);
sugars, such as sucrose or trehalose; or any combination thereof.
In certain embodiments, the carrier is HPMCAS. The polymer, such as
HPMCAS, may be of any grade suitable to form the spray-dried
formulation, such as grade L, grade M, or grade H. In particular
embodiments, grade M is used. Additionally, the HPMCAS may be a
fine grade (F) or a granular grade (G), and in certain embodiments,
fine grade is used. And in certain working embodiments, the carrier
is HPMCAS-MF.
[0273] In some embodiments, the spray-dried formulation has a
suitable glass transition temperature. The glass transition
temperature may be from 100.degree. C. or less to 120.degree. C. or
more, such as from 105.degree. C. to 110.degree. C. or 107.degree.
C. to 110.degree. C. In certain working embodiments, the glass
transition temperature is from 108.degree. C. to 109.degree. C.
[0274] In some embodiments, the formulation may comprise additional
components. Additional components can be included in pharmaceutical
compositions for a variety of purposes, such as to dilute a
composition for delivery to a subject, to facilitate processing of
the formulation, to provide advantageous material properties to the
formulation, to facilitate dispersion from a delivery device, to
stabilize the formulation (e.g., antioxidants or buffers), to
provide a pleasant or palatable taste or consistency to the
formulation, or the like. Typical additional components include, by
way of example and without limitation: pharmaceutically acceptable
excipients; pharmaceutically acceptable carriers; and/or adjuvants,
such as mono-, di-, and polysaccharides, sugar alcohols and other
polyols, such as, lactose, glucose, raffinose, melezitose,
lactitol, maltitol, trehalose, sucrose, mannitol, starch, or
combinations thereof, surfactants, such as sorbitols,
diphosphatidyl choline, and lecithin; bulking agents; buffers, such
as phosphate and citrate buffers; anti-adherents, such as magnesium
stearate; binders, such as saccharides (including disaccharides,
such as sucrose and lactose), polysaccharides (such as starches,
cellulose, microcrystalline cellulose, cellulose ethers (such as
hydroxypropyl cellulose), gelatin, synthetic polymers (such as
polyvinylpyrrolidone, polyalkylene gylcols); coatings (such as
cellulose ethers, including hydroxypropylmethyl cellulose, shellac,
corn protein zein, and gelatin); release aids (such as enteric
coatings); disintegrants (such as crospovidone, crosslinked sodium
carboxymethyl cellulose, and sodium starch glycolate); fillers
(such as dibasic calcium phosphate, vegetable fats and oils,
lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate,
and magnesium stearate); flavors and sweeteners (such as mint,
cherry, anise, peach, apricot or licorice, raspberry, and vanilla;
lubricants (such as minerals, exemplified by talc or silica, fats,
exemplified by vegetable stearin, magnesium stearate or stearic
acid); preservatives (such as antioxidants exemplified by vitamin
A, vitamin E, vitamin C, retinyl palmitate, and selenium, amino
acids, exemplified by cysteine and methionine, citric acid and
sodium citrate, parabens, exemplified by methyl paraben and propyl
paraben); colorants; compression aids; emulsifying agents;
encapsulation agents; gums; granulation agents; and combinations
thereof.
[0275] II. Method of Making a Spray-Dried Formulation
[0276] Embodiments of a method for making the spray-dried
formulation are also disclosed herein. In some embodiments, one or
more compounds according to formula I and the polymer are dissolved
in a suitable solvent or mixture of solvents, and then spray-dried.
Suitable solvent(s) include any solvent or mixture of solvents that
dissolves the disclosed compound(s) and the carrier and is suitable
for a spray-drying process. Exemplary solvents include, but are not
limited to, alcohol, such as methanol, ethanol, isopropanol,
n-propanol, and the like; chlorinated solvents, such as
dichloromethane, chloroform. In some embodiments, the disclosed
compound(s) is dissolved in the solvent or mixture of solvents, and
the polymer is added to the mixture. However, in other embodiments,
the polymer is dissolved first and the compound(s) is subsequently
added, or the compound(s) and the polymer are mixed substantially
simultaneously with the solvent or solvent mixture. Regardless of
the order of addition, the mixture typically is mixed until the
disclosed compound(s) and the polymer are dissolved, and/or the
mixture has a uniform appearance. In some embodiments, the
resulting mixture is stored at a reduced temperature, such as below
25.degree. C., or from less than 25.degree. C. to 0.degree. C.,
from 15.degree. C. to 0.degree. C., from 10.degree. C. to 0.degree.
C., or from 7.degree. C. to 3.degree. C., typically at about
5.degree. C. The solution also may be protected from light, i.e.
stored in a dark environment.
[0277] The solution is then spray-dried using a spray drying
apparatus. Suitable spray-drying apparatuses are known to persons
of ordinary skill in the art. In some embodiments, the parameters
of the spray drying apparatus, such as feed temperature, inlet
temperature, target outlet temperature and aspiration are set to
values suitable for the disclosed compound(s) and the polymer, as
understood by a person of ordinary skill in the art. In certain
embodiments, the feed temperature is from 15.degree. C. or less to
35.degree. C. or more, such as from 20.degree. C. to 25.degree. C.
The inlet temperature may be from 40.degree. C. or less to
60.degree. C. or more, such as from 45.degree. C. to 55.degree. C.
The target outlet temperature may be from 30.degree. C. or less to
45.degree. C. or more, such as from 32.degree. C. to 42.degree. C.
or from 34.degree. C. to 40.degree. C. And/or the aspirator may be
from 50% or more to 100%, such as from 70% to 100% or from 80% to
100%.
[0278] The resulting spray-dried solid may be further dried at a
temperature suitable to remove at least some, and may be
substantially all, of any remaining solvent without substantially
degrading the disclosed compound(s) and/or the carrier. In some
embodiments, the solid is dried at a temperature of from 25.degree.
C. to 100.degree. C. or more, such as from 30.degree. C. to
75.degree. C., or from 35.degree. C. to 50.degree. C. The
dispersion may be dried until substantially all the remaining
solvent has been removed, and/or until no further weight loss is
achieved. The drying may continue for from 1 hour to 48 hours or
more, such as from 6 hours to 36 hours, from 12 hours to 32 hours,
or from 18 hours to 24 hours. The resulting solid formulation may
be stored at a reduced temperature, such as such as below
25.degree. C., or from less than 25.degree. C. to 0.degree. C.,
from 15.degree. C. to 0.degree. C., from 10.degree. C. to 0.degree.
C., or from 7.degree. C. to 3.degree. C., typically at about
5.degree. C. The solution also may be protected from light, i.e.
stored in a dark environment, and/or stored under dry conditions,
such as in the presence of a desiccant and/or under a dry
atmosphere.
[0279] C. Dosages
[0280] The pyrazole compound or combinations of pyrazole compounds
will generally be used in an amount effective to achieve an
intended result, for example, in an amount effective to treat
and/or prevent a particular disease or disorder. The pyrazole
compound(s), or compositions thereof, can be administered
therapeutically to achieve therapeutic benefit or prophylactically
to achieve prophylactic benefit. Therapeutic benefit means
eradication or amelioration of the underlying disorder being
treated and/or eradication or amelioration of one or more of the
symptoms associated with the underlying disorder such that the
patient reports an improvement in feeling or condition,
notwithstanding that the patient may still be afflicted with the
underlying disorder. For example, administration of a compound to a
patient suffering from an allergy provides therapeutic benefit not
only when the underlying allergic response is eradicated or
ameliorated, but also when the patient reports a decrease in the
severity or duration of the symptoms associated with the allergy
following exposure to the allergen. As another example, therapeutic
benefit in the context of asthma includes an improvement in
respiration following the onset of an asthmatic attack or a
reduction in the frequency or severity of asthmatic episodes.
Therapeutic benefit also includes halting or slowing the
progression of the disease, regardless of whether improvement is
realized.
[0281] As known by those of ordinary skill in the art, the
preferred dosage of pyrazole compounds will also depend on various
factors, including the age, weight, general health, and severity of
the condition of the patient or subject being treated. Dosage may
also need to be tailored to the sex of the individual and/or the
lung capacity of the individual, when administered by inhalation.
Dosage may also be tailored to individuals suffering from more than
one condition or those individuals who have additional conditions
that affect lung capacity and the ability to breathe normally, for
example, emphysema, bronchitis, pneumonia, and respiratory
infections. Dosage, and frequency of administration of the
disclosed pyrazole compound(s) or compositions thereof, will also
depend on whether the pyrazole compound(s) are formulated for
treatment of acute episodes of a condition or for the prophylactic
treatment of a disorder. A person or ordinary skill in the art will
be able to determine the optimal dose for a particular
individual.
[0282] For prophylactic administration, the pyrazole compound,
combinations of pyrazole compounds, or compositions thereof, can be
administered to a patient or subject at risk of developing one of
the previously described conditions. For example, if it is unknown
whether a patient or subject is allergic to a particular drug, the
pyrazole compound, combinations of pyrazole compounds, or
compositions thereof, can be administered prior to administration
of the drug to avoid or ameliorate an allergic response to the
drug. Alternatively, prophylactic administration can be used to
avoid or ameliorate the onset of symptoms in a patient diagnosed
with the underlying disorder. For example, a pyrazole compound(s),
or composition thereof, can be administered to an allergy sufferer
prior to expected exposure to the allergen. A pyrazole compound,
combinations of pyrazole compounds, or compositions thereof, can
also be administered prophylactically to healthy individuals who
are repeatedly exposed to agents known to one of the
above-described maladies to prevent the onset of the disorder. For
example, a pyrazole compound, combinations of pyrazole compounds,
or compositions thereof, can be administered to a healthy
individual who is repeatedly exposed to an allergen known to induce
allergies, such as latex, in an effort to prevent the individual
from developing an allergy. Alternatively, a pyrazole compound,
combinations of pyrazole compounds, or compositions thereof, can be
administered to a patient suffering from asthma prior to partaking
in activities which trigger asthma attacks to lessen the severity
of, or avoid altogether, an asthmatic episode.
[0283] Effective dosages can be estimated initially from in vitro
assays. For example, an initial dosage for use in subjects can be
formulated to achieve a circulating blood or serum concentration of
active compound that is at or above an IC.sub.50 or EC.sub.50 of
the particular compound as measured in an in vitro assay. Dosages
can be calculated to achieve such circulating blood or serum
concentrations taking into account the bioavailability of the
particular compound. Fingl & Woodbury, "General Principles,"
In: Goodman and Gilman's The Pharmaceutical Basis of Therapeutics,
Chapter 1, pages 1-46, Pergamon Press, and the references cited
therein, provide additional guidance concerning effective
dosages.
[0284] In some embodiments, the disclosed compounds have an
EC.sub.50 from greater than 0 to 20 .mu.M, such as from greater
than 0 to 10 .mu.M, from greater than 0 to 5 .mu.M, from greater
than 0 to 1 .mu.M, from greater than 0 to 0.5 .mu.M, or from
greater than 0 to 0.1 .mu.M.
[0285] Initial dosages can also be estimated from in vivo data,
such as animal models. Animal models useful for testing the
efficacy of compounds to treat or prevent the various diseases
described above are well-known in the art. Suitable animal models
of hypersensitivity or allergic reactions are described in Foster,
(1995) Allergy 50(21 Suppl):6-9, discussion 34-38 and Tumas et al.,
(2001), J. Allergy Clin. Immunol. 107(6):1025-1033. Suitable animal
models of allergic rhinitis are described in Szelenyi et al.,
(2000), Arzneimittelforschung 50(11):1037-42; Kawaguchi et al.,
(1994), Clin. Exp. Allergy 24(3):238-244 and Sugimoto et al.,
(2000), Immunopharmacology 48(1):1-7. Persons of ordinary skill in
the art can adapt such information to determine dosages suitable
for human administration.
[0286] Dosage amounts of disclosed pyrazole compounds will
typically be in the range of from greater than 0 mg/kg/day, such as
0.0001 mg/kg/day or 0.001 mg/kg/day or 0.01 mg/kg/day, up to at
least 100 mg/kg/day. More typically, the dosage (or effective
amount) may range from 0.0025 mg/kg to 1 mg/kg administered at
least once per day, such as from 0.01 mg/kg to 0.5 mg/kg or from
0.05 mg/kg to 0.15 mg/kg. The total daily dosage typically ranges
from 0.1 mg/kg to 5 mg/kg or to 20 mg/kg per day, such as from 0.5
mg/kg to 10 mg/kg per day or from 0.7 mg/kg per day to 2.5
mg/kg/day. Dosage amounts can be higher or lower depending upon,
among other factors, the activity of the pyrazole compound, its
bioavailability, the mode of administration, and various factors
discussed above.
[0287] Dosage amount and dosage interval can be adjusted for
individuals to provide plasma levels of the pyrazole compound that
are sufficient to maintain therapeutic or prophylactic effect. For
example, the compounds can be administered once per day, multiple
times per day, once per week, multiple times per week (e.g., every
other day), one per month, multiple times per month, or once per
year, depending upon, amongst other things, the mode of
administration, the specific indication being treated, and the
judgment of the prescribing physician. Persons of ordinary skill in
the art will be able to optimize effective local dosages without
undue experimentation.
[0288] Compositions comprising one or more of the disclosed
pyrazole compounds typically comprise from greater than 0 up to 99%
of the pyrazole compound, or compounds, and/or other therapeutic
agent by total weight percent. More typically, compositions
comprising one or more of the disclosed pyrazole compounds comprise
from 1 to 20 total weight percent of the pyrazole compound and
other therapeutic agent, and from 80 to 99 weight percent of a
pharmaceutically acceptable additive.
[0289] Preferably, the pyrazole compound, combinations of pyrazole
compounds, and/or compositions thereof, will provide therapeutic or
prophylactic benefit without causing substantial toxicity. Toxicity
of the pyrazole compound can be determined using standard
pharmaceutical procedures. The dose ratio between toxic and
therapeutic (or prophylactic) effect is the therapeutic index.
Pyrazole compounds that exhibit high therapeutic indices are
preferred.
IV. Working Examples
Example 1
[0290] Compound I-1 (8 g, 20% w/w) was slowly added to a mixture of
methylene chloride (360 g) and methanol (40 g) while mixing, and
the mixing was continued until compound I-1 dissolved. HPMCAS-MF
(32 g) was then slowly added to the mixture while mixing, and
resultant mixture was mixed until the HPMCAS-MF dissolved, and the
solution was visually uniform. The solution was stored at 5.degree.
C. and protected from light.
[0291] A spray drier apparatus (Buchi B290) was prepared with a
feed temperature of 25.degree. C., an inlet temperature of
50.degree. C., and a target outlet temperature of 38.degree. C.
During the spray drying, the outlet temperature varied from 34 to
40.degree. C., the inlet temperature varied from 45 to 51.degree.
C. and the aspirator varied from 80 to 100%. The yield was 32 g,
90%.
[0292] The resulting solid dispersion was collected and further
dried in an oven set at 40.degree. C. for 24 hours. The resulting
powder was stored at 5.degree. C. in the presence of a desiccant.
The yield after the secondary drying was 27 g, 67.5%. Table 1
provides stability data for the solid dispersion.
TABLE-US-00001 TABLE 1 Stability data LOD, at Moisture uptake
Storage Storage Storage Tg 150.degree. C. at 80% RH Crystallinity
Temp Config Time (.degree. C.) (% w/w) (% w/w) by XRPD 25.degree.
C. Sealed T = 0 108.3 1.1 5.8 Amorphous T = 1 m 108.3 1.0 5.8
Amorphous T = 3 m 108.7 1.1 5.8 Amorphous 40.degree. C. Sealed T =
0 108.3 1.1 5.8 Amorphous T = 1 m -- 2.0 -- Amorphous T = 3 m 107.5
1.2 -- Amorphous Open T = 0 108.3 1.1 5.8 Amorphous T = 1 m 108.4
2.7 4.9 Amorphous T = 3 m 108.0 1.3 -- Amorphous
[0293] FIGS. 1-10 provide structural and stability data concerning
the spray-dried formulation (FIGS. 1-5) and a crystalline sample of
compound I-1 (FIGS. 6-10). FIGS. 1 and 6 provide DVS isotherm plots
for the spray-dried formulation and crystalline compound,
respectively. FIGS. 1 and 6 clearly show that the crystalline
compound has a substantially smaller change in mass when exposed to
higher relative humidity than the dispersion. FIGS. 2 and 3
demonstrate that the dispersion does not have a substantially
crystalline structure, whereas FIGS. 7 and 8 clearly show that the
compound I-1 has a crystalline structure.
Example 2
[0294] Two groups of male cynomolgus monkeys (n=3/group) were
administered test articles in a 3-way crossover design as indicated
in Table 2. The washout period between doses was 3-4 days. Test
article capsules were prepared such that each capsule contained an
equivalent of 25 mg of free base compound I-1. The organic stock
solution of compound I-1 was prepared at a concentration of 5 mg/ml
using TPGS/PEG400/PG, and was diluted with apple juice within 1
hour of dosing (PO) at 1 part stock solution to 3 parts apple
juice.
TABLE-US-00002 TABLE 2 Study design Dose, Corrected dose, mg of mg
compound Test Test article compound I-1/kg, Group Phase Article
Description I-1 Average/(range) 1 I Capsule Phosphate 25 5.99
co-crystal II Capsule Gentisate 25 5.96 co-crystal III Capsule
Spray-dried 25 5.90 Dispersion (SDD) 2 I Capsule Succinate 25 5
co-crystal II Capsule Tartrate 25 5.06 co-crystal III Liquid
Organic stock -- 5 in apple juice
FIGS. 11-14 provide graphs of the plasma concentrations obtained
from administering the co-crystal formulations of compound I-1 to
monkeys. And Table 3 provides pharmacokinetic (PK) data for the
co-crystal formulations, including the average area under the curve
(AUC) and percent bioavailability.
TABLE-US-00003 TABLE 3 AUC and percent bioavailability (% F) Test
Average AUC.sub.0-24 h .+-. SD Article (5 mg/kg basis) % F
Phosphate 921 .+-. 446 7.9 co-crystal Succinate 1470 .+-. 1000 12.7
co-crystal Gentisate 1140 .+-. 811 9.8 cocystal Tartrate 2860 .+-.
1120 24.7 co-crystal
[0295] FIG. 19 provides PK data for one embodiment of the disclosed
spray-dried formulation, and the organic/juice formulation. FIG. 19
demonstrates that administration of the spray-dried formulation
resulted in 88% bioavailability of compound I-1.
Example 3
[0296] Rats were administered either compound I-1 or a potential
prodrug form of compound I-1. Area under the curve (AUC) and
percent bioavailability (% F) data concerning compound I-1
resulting from the prodrug administration were determined by
standard techniques known to a person of ordinary skill in the art
(Table 4).
TABLE-US-00004 TABLE 4 AUC and percent bioavailability (% F) of
compound I-1 after administration of potential prodrugs of I-1
Compound Dose I-1 Rat Code Prodrug Type Form equiv. AUC.sub.last %
F I-1 parent iv 1 mg/kg 1051 I-18 alpha-methyl, 1050 30
methylene-Phosphate I-20 alpha-methyl, Disodium salt 3.73 mg/kg
3790 >100 methylene-Phosphate of I-18 I-45 319 10 I-46 Phosphate
4510 >100 I-62 Phosphate 694 25 I-21 HCl salt of I-35, 3.68
mg/kg 1850 56.6 partially crystalline I-61 Pegylated Ester 2530 103
I-32 N-acetyl Free base, 3.44 mg/kg 2310 75 methylpiperazine
crystalline
Example 4
Formation of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide Benzenesulfonic
Acid Salt (I-65)
##STR00050##
[0298]
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (0.050 g,
0.100 mmol, 1.0 eq) was dissolved in chloroform (1.0 eq) to obtain
a clear colorless solution. Benzenesulfonic acid (0.019 g, 0.120
mmol, 1.2 eq) was added and a precipitate formed over the next 15
minutes. The reaction was stirred at room temperature for 1 hour
and the precipitate was isolated by filtration to obtain the title
compound (0.038 g) as a white solid; .sup.1H nmr (400 MHz,
D.sub.6-DMSO) .delta. 8.53 (1H, s, thiazoleH-5 or pyrazoleH-5),
8.30 (1H, s, 1H of thiazoleH-5 or pyrazoleH-5, pyrazoleH-3, H-5),
8.29 (1H, s, 1H of thiazoleH-5 or pyrazoleH-5, pyrazoleH-3, H-5),
8.28 (1H, s, 1H of thiazoleH-5 or pyrazoleH-5, pyrazoleH-3, H-5),
8.08 (1H, dt, J 9.0, 6.5 Hz, pyridineH-4 or H-5), 7.59-7.56 (2H, m,
2H of C.sub.6H.sub.5SO.sub.3H), 7.32-7.27 (4H, m, pyridineH-4 or
H-5, 3H of C.sub.6H.sub.5SO.sub.3H), 4.33 (1H, tt, J 11.5, 3.5 Hz,
cyclohexaneH-1 or H-4), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.34 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1 or H-4), 2.08 (4H, m,
4H of cyclohexaneH-2, H-3, H-5, H-6), 1.85 (2H, m, cyclohexaneH-2,
H-3, H-5, H-6), 1.35 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.10 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -73.0 (dd, 24.5, 2.5 Hz), -124.2 (ddd, J
26.0, 9.5, 1.5 Hz); m/z: 500 [M+H].sup.+.
Example 5
Formation of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide Sodium Salt
(I-67)
##STR00051##
[0300]
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (0.062 g,
0.124 mmol, 1.0 eq) was dissolved in chloroform (2.0 mL) to obtain
a clear solution. Sodium hydroxide (0.05 mL of a 3M aqueous
solution, 0.149 mmol, 1.2 eq) was added and the reaction was
stirred at room temperature for 3 days. No precipitate was formed.
The reaction was concentrated and further concentrated from
acetonitrile (5 mL) to obtain the title compound as a white solid;
.sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 8.53 (1H, s,
thiazoleH-5 or pyrazoleH-5), 8.13 (3H, br s, thiazoleH-5 or
pyrazoleH-5, pyrazoleH-3, H-5), 8.08 (1H, dt, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.28 (1H, ddd, J 9.0, 3.0, 2.5 Hz, pyridineH-4
or H-5), 4.33 (1H, tt, J 11.5, 3.0 Hz, cyclohexaneH-1 or H-4), 3.47
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.35 (1H, tt, J 11.0, 3.5 Hz,
cyclohexaneH-1 or H-4), 2.08 (4H, m, 4H of cyclohexaneH-2, H-3,
H-5, H-6), 1.85 (2H, m, cyclohexaneH-2, H-3, H-5, H-6), 1.35 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); m/z: 500 [M+H].sup.+.
Example 6
Formation of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide tartaric Acid
Cocrystal (I-66)
##STR00052##
[0302] L-Tartaric acid (0.017 g, 0.110 mmol, 1.1 eq) was added to a
solution of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (0.050 g 0.100
mmol, 1.0 eq) in chloroform (1.0 eq). A white solid slowly
precipitated. The reaction was stirred at room temperature for 18
hours and the precipitate isolated by filtration to obtain the
title compound (0.055 g, 85%) as a white solid; .sup.1H nmr (400
MHz, D.sub.6-DMSO) .delta. 8.53 (1H, s, thiazoleH-5 or
pyrazoleH-5), 8.29 (3H, br s, thiazoleH-5 or pyrazoleH-5,
pyrazoleH-3, H-5), 8.08 (1H, dt, J 9.5, 6.5 Hz, pyridineH-4 or
H-5), 7.28 (1H, dt, J 9.0, 3.0 Hz, pyridineH-4 or H-5), 5.05 (2H,
br s, 2.times.OH), 4.33 (1H, tt, J 11.5, 3.5 Hz, cyclohexaneH-1 or
H-4), 4.29 (2H, s, COCH(OH)CH(OH)CO), 3.47 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.34 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1 or
H-4), 2.08 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.85 (2H,
m, cyclohexaneH-2, H-3, H-5, H-6), 1.35 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.09 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz, D.sub.6-DMSO) .delta.
173.5, 161.7, 157.7, 157.6 (d, J 236.0 Hz), 153.5 (dd, J 259.0, 4.0
Hz), 149.2, 138.2 (t, J 15.0 Hz), 132.6 (d, J 9.0 Hz), 131.9 (dd, J
22.5, 9.0 Hz), 123.5, 121.5, 120.2, 116.2, 109.2 (dd, J 43.0, 8.5
Hz), 76.0, 72.6, 63.0, 60.8, 30.9, 30.9, 16.1; .sup.19F nmr (380
MHz, D.sub.6-DMSO) .delta.-73.0, -124.2; m/z: 500 [M+H].sup.+.
Example 7
Formation of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide
hemi((2R,3R)-2,3-dihydroxysuccinate) (I-11)
##STR00053##
[0304] A MeOH (1.3 mL) solution of (L)-Tartaric Acid (750.5 mg, 5
mmol) was added dropwise to a CH.sub.2Cl.sub.2-MeOH (60 mL-5 mL)
solution of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (5.0 g, 10 mmol) at
35.degree. C., additional MeOH (5 mL) and CH.sub.2Cl.sub.2 (100 mL)
were added after 15 minutes. The mixture was stirred at 35.degree.
C. for another 20 hours, and then cooled to room temperature. Solid
was collected by filtration, washed with CH.sub.2Cl.sub.2, and was
further dried in vacuo. The title compound was obtained as a white
solid: 3.48 g (60.7% yield); .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 13.32 (br s, 1H), 12.74 (br s, 1H), 11.45 (s, 1H), 8.51 (s,
1H), 8.27 (s, 1H), 8.43-8.14 (m, 2H), 8.07 (ddd, J=9.8, 8.8, 6.3
Hz, 1H), 7.27 (ddd, J=8.8, 2.9, 2.9 Hz, 1H), 5.07 (br s, 1H), 4.31
(tt, partially overlapped, J=11.7, 3.2 Hz, 1H), 4.27 (s, 1H), 3.45
(q, J=7.0 Hz, 2H), 3.33 (tt, partially overlapped with H.sub.2O,
J=10.7, 3.6 Hz, 1H), 2.08-2.03 (m, 4H), 1.88-1.78 (m, 2H),
1.38-1.28 (m, 2H), 1.08 (t, J=7.0 Hz, 3H); .sup.19F NMR (376 MHz,
DMSO-d.sub.6) .delta. -72.97 (ddd, J=28.1, 6.8, 3.8 Hz), -124.18
(ddd, J=28.1, 10.3, 3.2 Hz); LRMS (M+H) m/z 500.2.
A second crop (1.58 g, combined yield: 88%) of the same compound
was obtained from the filtrate, after removal of the solvent in
vacuo, and resuspended the solid in CH.sub.2Cl.sub.2-MeOH (25 mL-2
mL) at 35.degree. C. overnight.
Example 8
Preparation of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (I-1)--Method 1
##STR00054##
[0305] I. Preparation of
2-bromo-N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)thiazole-4-carboxamide C-3 from C2.HCl
##STR00055##
[0307] Diisopropylethylamine (8.5 mL, 48.95 mmol, 3.5 eq) was added
to a mixture of the aminopyrazole C-2.HCl (5.00 g, 13.99 mmol, 1.0
eq) and bromothiazolecarboxylic acid (3.20 g, 15.38 mmol, 1.1 eq)
in dichloromethane (50 mL) at 0.degree. C. HATU (5.85 g, 15.38
mmol, 1.1 eq) added. The reaction was stirred at 0.degree. C. for
10 minutes and then at room temperature for 4 hours. The reaction
was diluted with CH.sub.2Cl.sub.2 (100 mL). The organics were
washed with NaHCO.sub.3 (150 mL), NH.sub.4Cl (150 mL) and brine
(100 mL), dried (Na.sub.2SO.sub.4) and concentrated under reduced
pressure. The residue was suspended in EtOAc-hexane (1:1, 50 mL)
and the resulting solid was isolated by filtration. The solid was
suspended in NaHCO.sub.3 (50 mL) for 1 hour to remove residual
coupling agent before isolating by filtration and drying under
vacuum to obtain C-3 (5.3 g, 74%) as an off-white solid; IR
.nu..sub.max (film) 3290, 3121, 2942, 2865, 1671, 1615, 1552, 1485,
1431, 1377, 1237, 1154, 1104, 1056, 1011, 819, 787, 731 cm.sup.-1;
.sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.42 (1H, d, J 0.5 Hz,
thiazoleH-5 or pyrazoleH-5), 8.09 (1H, s, thiazoleH-5 or
pyrazoleH-5), 7.63 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or H-5),
6.85 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 4.26 (1H,
tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.55 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.36 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.28 (2H, br d, J 13.0 Hz, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.21 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.91, 1.84
(2H, 2dd AB system, J 13.0, 3.5 Hz, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.46 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H,
t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz, CDCl.sub.3)
.delta. 157.6 (d, J 238.0 Hz), 156.9, 153.3 (dd, J 260.0, 8.5 Hz),
150.0, 138.6 (t, J 14.0 Hz), 136.1, 133.1 (d, J 8.5 Hz), 129.8 (dd,
J 23.0, 8.5 Hz), 126.7, 121.7, 119.2, 107.8 (dd, J 39.5, 5.5 Hz),
76.4, 63.6, 61.5, 31.1, 30.9, 15.7; .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.3, -124.9; m/z: 536, 534 [M+Na].sup.+, 514,
512 [M+H].sup.+. The filtrate from the initial trituration was
purified by column chromatography (20.fwdarw.80% EtOAc-hexane) to
obtain further C-3 (0.8 g, 9%) as a pink foam.
II. Preparation of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (I-1)
##STR00056##
[0309] Dioxane (400 mL) was added to a mixture of the bromothiazole
C-3 (25.0 g, 48.8 mmol, 1.0 eq) and pyrazole-4-boronic acid (8.2 g,
73.2 mmol, 1.5 eq) followed by aqueous solution of sodium carbonate
(73.3 mL of a 2M solution, 146.5 mmol, 3.0 eq). The reaction
mixture was degassed by bubbling argon through for five
minutes.
Tetrakis(triphenylphosphine)palladium (1.4 g, 1.2 mmol, 0.025 eq)
was added and the reaction further degassed before heating to
105.degree. C. for 6 hours. The reaction was filtered through
Celite.RTM. while hot, eluting with EtOAc (200 mL). The filtrate
was concentrated to approximately 150 mL, upon which a precipitate
formed. The precipitate was isolated by filtration. The filtrate
was concentrated to remove the remaining organics, filtered to
remove more precipitate, diluted with water-brine (1:2, 300 mL) and
extracted with EtOAc (3.times.200 mL). The combined organics were
combined, dried (Na.sub.2SO.sub.4) and concentrated under reduced
pressure. The combined precipitates and extracts were loaded onto
silica. Column chromatography (silica, 0.fwdarw.10%
MeOH--CH.sub.2Cl.sub.2) yielded the title compound (16.5 g, 68%) as
a white solid; IR .nu..sub.max(film) 3229, 2938, 2861, 1663, 1615,
1589, 1549, 1482, 1425, 1377, 1237, 1104, 1055, 972, 930, 903, 875,
820, 786, 715, 664 cm.sup.-1; .sup.1H nmr (400 MHz, CDCl.sub.3)
.delta. 8.52 (1H, s, thiazoleH-5 or pyrazoleH-5), 8.24 (2H, s,
NHpyrazoleH-3, H-5), 8.07 (1H, s, thiazoleH-5 or pyrazoleH-5), 7.41
(1H, td, J 9.0, 6.0 Hz, pyridineH-4 or H-5), 6.86 (1H, ddd, J 9.0,
3.5, 2.5 Hz, pyridineH-4 or H-5), 4.28 (1H, tt, J 11.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 3.57 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.37 (1H, tt, J 11.0, 4.0 Hz, cyclohexaneH-1 or H-4), 2.26 (4H, m,
4H of cyclohexaneH-2, H-3, H-5, H-6), 1.92, 1.86 (2H, 2dd AB
system, J 13.0, 3.5 Hz, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.50,
1.44 (2H, 2dd AB system, J 13.0, 3.5 Hz, 2H of cyclohexaneH-2, H-3,
H-5, H-6), 1.23 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.13C nmr
(100 MHz, CDCl.sub.3) .delta. 160.6, 158.6, 158.3, 156.3, 154.8,
152.2, 150.2, 138.9, 133.0 (d, J 9.0 Hz), 129.9 (dd, J 23.5, 9.0
Hz), 122.0, 121.6, 119.4, 117.2, 107.5 (dd, J 40.5, 5.0 Hz), 76.4,
63.7, 61.5, 31.1, 30.9, 15.7; .sup.19F nmr (380 MHz, CDCl.sub.3)
.delta. -72.7 (dddd, J 27.0, 9.5, 5.5, 4.0 Hz), -124.3 (ddd, J
27.5, 9.5, 3.0 Hz); m/z: 500 [M+H].sup.+ (found [M+H].sup.+,
500.1687, C.sub.23H.sub.23F.sub.2N.sub.7O.sub.2S requires
[M+H].sup.+ 500.1675).
Example 9
Preparation of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (I-1)--Method 2
##STR00057##
[0310] I. Formation of 2-(1H-pyrazol-4-yl)thiazole-4-carboxylic
Acid
##STR00058##
[0312] A 1,4-Dioxane-H.sub.2O (32 mL-8 mL) solution of
2-bromothiazole-4-carboxylic acid (2.08 g, 10 mmol, 1.0 eq),
(1H-pyrazol-4-yl)boronic acid (3.36 g, 30 mmol, 3.0 eq),
tetrakis(triphenylphosphine)palladium (0.23 g, 0.2 mmol, 0.02 eq)
and sodium carbonate (3.18 g, 30 mmol, 3.0 eq) was degassed,
backed-filled with nitrogen gas, three times. The cloudy solution
was stirred at 60.degree. C. for 2 hours (by LC-MS, starting
material: product.apprxeq.1:1), then at 100.degree. C. for a
further 3 hours, until the reaction went to completion as monitored
by LC-MS. After removal of organic solvent under reduced pressure,
the crude mixture was diluted with water (100 mL) and mixed well.
The aqueous solution was passed through a Celite.RTM. pad, and
washed with water. While stirring, the filtrate with acidified with
6M HCl aq. solution (about 11 mL) until pH=1-2. The precipitate was
collected by filtration, washed with water and further dried in
vacuo to obtain the title compound (1.79 g 92% yield) as a light
tan color solid; .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 13.11
(2H, br s, NH, OH), 8.28 (1H, s, thiazoleH-4), 8.17 (2H, br s,
pyrazoleH-3, H-5); m/z: 196 [M+H].sup.+.
II. Preparation of
N-(3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyrazol-4-
-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (I-1)
##STR00059##
[0314] A mixture of the C2.HCl aminopyrazole hydrochloride (1.00 g,
2.80 mmol, 1.0 eq) and 2-(1H-pyrazol-4-yl)thiazole-4-carboxylic
acid (0.65 g, 3.36 mmol, 1.2 eq) in dimethylformamide (14 mL) was
cooled to 0.degree. C. and diisopropylethylamine (1.22 mL, 6.99
mmol, 2.5 eq) added. A solution resulted to which was added HATU
(1.17 g, 3.08 mmol, 1.1 eq). The solution was stirred at 0.degree.
C. for 15 minutes and room temperature for 1 hour, before adding
the reaction to water (75 mL). A solid formed that collapsed to a
gum. The liquid was decanted isolating any solid by filtration. The
gum and solid were dissolved in EtOAc-MeOH (4:1, 100 mL), combined
and concentrated under reduced pressure. The resulting solid was
triturated from 10% EtOH-EtOAc (4 mL) to obtain the title compound
I-1 as an off-white solid (0.76 g, 55%). The filtrate was
concentrated and loaded onto silica. Column chromatography
(0.fwdarw.10% MeOH--CH.sub.2Cl.sub.2) yielded a pale yellow solid,
which was stirred with NaHCO.sub.3 (15 mL). The liquid was decanted
and the residue triturated with 10% EtOH-EtOAc (4 mL) to obtain
further product as an off-white solid (0.226 g, 16%). Total yield
0.99 g, 71%; data agreed with that stated above.
Example 10
Exemplary Synthesis of Alkyl Phosphate Compounds
##STR00060##
[0315] I. Preparation of di-tert-butyl
((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl) phosphate
(I-3)
##STR00061##
[0317] Potassium carbonate (0.41 g, 3.01 mmol, 1.5 eq) was added to
a suspension of I-1 (1.00 g, 2.00 mmol, 1.0 eq) in
dimethylformamide (14 mL). The reaction was stirred at room
temperature for 30 minutes before adding a solution of chloromethyl
di-tert-butyl phosphate (1.04 g, 4.01 mmol, 2.0 eq) in
dimethylformamide (2 mL). The reaction was stirred at room
temperature for 14 hours. Further chloromethyl di-tert-butyl
phosphate (0.52 g, 2.00 mmol, 1.0 eq) and potassium carbonate (0.21
g, 1.50 mmol, 0.75 eq) was added and the reaction stirred for a
further 24 hours. The reaction was cooled to 0.degree. C. and water
(25 mL) added dropwise over 45 minutes. A sticky solid resulted
which was isolated by decanting the liquid. The liquid was added to
water (40 mL) and stirred to obtain more solid, which was isolated
by filtration. The solid was dried under vacuum and used without
further purification (1.76 g, quantitative-theoretical yield 1.44
g); IR .nu..sub.max (film) 3308, 2979, 2978, 2864, 1668, 1615,
1592, 1549, 1482, 1374, 1266, 1234, 1104, 998, 965, 822, 787, 714,
666 cm.sup.-1; .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.50 (1H,
s, pyrazoleH-5, thiazoleH-5), 8.34 (1H, s, 1H of pyrazoleH-3, H-5),
8.21 (1H, s, 1H of pyrazoleH-3, H-5), 8.06 (1H, s 1H of
pyrazoleH-5, thiazoleH-5), 7.65 (1H, td, J 9.0, 6.0 Hz, pyridineH-4
or H-5), 6.88 (1H, ddd, J 9.0, 3.0, 2.5 Hz, pyridineH-4 or H-5),
5.93 (2H, d, J 12.5 Hz, NCH.sub.2OP), 4.27 (1H, tt, J 12.0, 4.0 Hz,
cyclohexaneH-1 or H-4), 3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.37 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or H-4), 2.29 (2H, br
d, J 12.5 Hz, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.22 (2H, br d,
J 11.0 Hz, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.89 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.50 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.45 (18H, s, 2.times.OC(CH.sub.3).sub.3), 1.22
(3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz,
CDCl.sub.3) .delta. 160.0, 158.2, 157.5 (d, J 236.5 Hz), 153.5 (dd,
J 260.0, 5.0 Hz), 150.2, 139.5 (d, J 6.0 Hz), 138.9 (t, J 15.0 Hz),
133.0 (d, J 9.0 Hz), 130.0 (d, J 4.5 Hz), 129.8 (d, J 9.0 Hz),
122.0, 121.8, 119.4, 118.6, 107.6 (dd, J 40.5, 5.0 Hz), 83.9, 83.8,
77.2, 76.4, 63.6, 61.5, 31.1, 30.9, 29.8, 29.7, 15.7; .sup.31P nmr
(162 MHz, CDCl.sub.3) .delta. -11.1; .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.4 (dt, J 27.0, 5.5 Hz), -124.5 (dd, J 27.5,
9.5 Hz); m/z: 744 [M+Na].sup.+.
II. Preparation of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyra-
zol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl dihydrogen
phosphate (I-2)
##STR00062##
[0319] To a solution of I-3 (1.58 g crude mass, 1.80 mmol, 1.0 eq)
in dichloromethane (8.0 mL) was added trifluoroacetic acid (0.99
mL, 12.80 mmol, 7.1 eq). The reaction was stirred at room
temperature for 20 hours, during which time a precipitate formed.
After 20 hours the precipitate was isolated by filtration. The
solid was washed with CH.sub.2Cl.sub.2 (2.times.8 mL) to obtain a
white solid. The solid was stirred with dioxane-water (10:1, 11 mL)
for 5 hours and filtered, washing with dioxane-water (10:1, 11 mL)
to obtain I-2 (0.60 g, 55% over two steps) as a white solid. The
filtrate was concentrated and stirred in dioxane-water (10:1, 11
mL) for 18 hours before isolating by filtration. The solid was
washed with dioxane-water (10:1, 2.times.5.5 mL) to obtain further
product (0.12 g, total 0.72 g, 66%) as a white solid; .sup.1H nmr
(400 MHz, D.sub.6-DMSO) .delta. 8.59 (1H, s, 1H of pyrazoleH-3,
H-5), 8.52 (1H, s, 1H of pyrazoleH-3, H-5), 8.34 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5), 8.19 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5), 8.08 (1H, td, J 9.5, 6.5 Hz, pyridineH-4 or H-5),
6.88 (1H, ddd, J 9.0, 3.0, 2.5 Hz, pyridineH-4 or H-5), 5.83 (2H,
d, J 12.5 Hz, NCH.sub.2OP), 4.33 (1H, tt, J 12.0, 3.0 Hz,
cyclohexaneH-1 or H-4), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.35 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1 or H-4), 2.29 (4H, br
d, J 11.0 Hz, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.85 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.35 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz, CDCl.sub.3) .delta.
160.6, 157.6, 157.6 (d, J 234.5 Hz), 154.3 (dd, J 259.5, 4.0 Hz),
149.4, 137.7 (d, J 7.0 Hz), 138.2, 132.6 (d, J 9.0 Hz), 131.9 (dd,
J 22.0, 9.0 Hz), 131.4, 124.1, 121.4, 120.2, 117.7, 109.2 (d, 38.0
Hz), 76.0, 75.2, 63.0, 60.8, 30.9 (2C), 16.1; .sup.31P nmr (162
MHz, D.sub.6-DMSO) .delta. -2.7; .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -72.8, -124.2 (ddd, J 27.0, 9.5, 3.0 Hz);
m/z: 610 [M+H].sup.+ (found [M+H].sup.+, 610.1451,
C.sub.24H.sub.26F.sub.2N.sub.7O.sub.6PS requires [M+H].sup.+
610.1444).
[0320] Other phosphate compounds were made by similar methods
Example 11
Exemplary Synthesis of Carbamates and Ureas as Potential IRAK
ProDrugs
I. Formation of 2-morpholinoethyl (4-nitrophenyl) carbonate
##STR00063##
[0322] A solution of 4-nitrophenol chloroformate (0.500 g, 2.48
mmol, 1.0 eq) in dichloromethane (20 mL) was cooled to -78.degree.
C. Diisopropylethylamine (0.65 mL, 3.72 mmol, 1.5 eq) was added
followed by 4-(2-hydroxyethyl)morpholine (0.30 mL, 2.48 mmol, 1.0
eq) and the reaction was stirred between -78.degree. C. and room
temperature over 16 hours. The reaction was diluted with
dichloromethane (40 mL) and washed with NaHCO.sub.3 (60 mL) and
brine (60 mL), dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure to obtain the title compound as an orange oil;
.sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.27 (2H, d, J 9.5 Hz, 2H
of C.sub.6H.sub.4NO.sub.2), 7.37 (2H, d, J 9.0 Hz, 2H of
C.sub.6H.sub.4NO.sub.2), 4.39 (2H, t, J 5.5 Hz, 2H of
COOCH.sub.2CH.sub.2N), 3.72, 3.71 (4H, 2d AB system, J 4.5 Hz, 4H
of morpholine), 2.72 (2H, t, J 5.5 Hz, 2H of COCH.sub.2CH.sub.2N),
2.54, 2.53 (4H, 2d AB system, J 4.5 Hz, 4H of morpholine).
II. Formation of 3-morpholinopropyl (4-nitrophenyl) carbonate
##STR00064##
[0324] Diisopropylethylamine (0.65 mL, 3.72 mmol, 1.5 eq) was added
to a solution of 4-nitrophenyl chloroformate (0.500 g, 2.48 mmol,
1.0 eq) in dichloromethane (20 mL) at -78.degree. C.
3-(Hydroxypropyl)morpholine (0.34 mL, 2.48 mmol, 1.0 eq) was added
dropwise and the reaction stirred at -78.degree. C. for 30 minutes.
The reaction froze and was warmed to 0.degree. C. After stirred at
0.degree. C. for 5 hours the reaction was allowed to warm to room
temperature over 16 hours. The reaction was diluted with
dichloromethane (20 mL) and washed with NaHCO.sub.3 (3.times.40
mL). The organics were dried (Na.sub.2SO.sub.4) and concentrated
under reduced pressure to obtain the title compound as a pale
yellow oil; .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.26 (2H, d,
J 9.5 Hz, 2H of C.sub.6H.sub.4NO.sub.2), 7.36 (2H, d, J 9.0 Hz, 2H
of C.sub.6H.sub.4NO.sub.2), 4.36 (2H, t, J 6.5 Hz,
OCH.sub.2CH.sub.2CH.sub.2N), 3.70 3.69 (4H, 2d AB system, J 4.5 Hz,
4H of morpholine), 2.49-2.43 (6H, m, 4H of morpholine,
OCH.sub.2CH.sub.2CH.sub.2N), 1.93 (pentet, J 6.5 Hz,
OCH.sub.2CH.sub.2CH.sub.2N).
III. Formation of 2-morpholinoethyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
(I-10)
##STR00065##
[0326] To the nitrophenyl carbonate (0.050 g, 0.169 mmol, 1.5 eq)
in dichloromethane (1.0 mL) at 0.degree. C. was added
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (0.056 g, 0.113
mmol, 1.0 eq) and dimethylaminopyridine (0.001 g, 0.011 mmol, 0.1
eq). Triethylamine (0.023 mL, 0.169 mmol, 1.5 eq) was added and the
reaction stirred at 0.degree. C. for 30 minutes and room
temperature for 1 hour. The reaction was partitioned between
CH.sub.2Cl.sub.2 (30 mL) and NaHCO.sub.3 (30 mL). The aqueous phase
was extracted with CH.sub.2Cl.sub.2 (2.times.30 mL). The combined
organics were dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure. MPLC (20.fwdarw.80% acetone-hexane, 0.1%
triethylamine) yielded the title compound as a white solid; .sup.1H
nmr (400 MHz, CDCl.sub.3) .delta. 8.75 (1H, s, 1H of thiazoleH-5,
pyrazoleH-5, pyrazoleH-3, H-5), 8.49 (1H, s, 1H of thiazoleH-5,
pyrazoleH-5, pyrazoleH-3, H-5), 8.35 (1H, s, 1H of thiazoleH-5,
pyrazoleH-5, pyrazoleH-3, H-5), 8.13 (1H, s, 1H of thiazoleH-5,
pyrazoleH-5, pyrazoleH-3, H-5), 7.64 (1H, td, J 9.0, 6.0 Hz,
pyridineH-4 or H-5), 6.86 (1H, dt, J 8.5, 3.5, 2.5 Hz, pyridineH-4
or H-5), 4.63 (2H, t, J 6.0 Hz, COOCH.sub.2CH.sub.2N), 4.26 (1H,
tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.70, 3.68 (4H, 2d AB
system, J 4.5 Hz, 4H of morpholine), 3.55 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.36 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.84 (2H, t, J 6.0 Hz, COOCH.sub.2CH.sub.2N), 2.58, 2.57 (4H,
2d AB system, J 4.5 Hz, 4H of morpholine), 2.28 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 2.20 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.88 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.45 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.21 (3H, t, J
7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3)
.delta. -72.7 (ddd, J 27.0, 5.5, 4.0 Hz), -124.3 (ddd, 27.0, 11.0,
9.5 Hz); m/z: 657 [M+H].sup.+.
IV. Formation of 3-morpholinopropyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
(I-15)
##STR00066##
[0328] To a mixture of the nitrophenyl carbonate (0.068 g, 0.220
mmol, 1.1 eq) and
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (0.100 g,
0.200 mmol, 1.0 eq) in dichloromethane (2.0 mL) at 0.degree. C. was
added triethylamine (0.031 mL, 0.220 mmol, 1.1 eq) and
dimethylaminopyridine (0.002 g, 0.020 mmol, 0.1 eq). The reaction
stirred at 0.degree. C. for 1 hour and then at room temperature for
3 hours, resulting an almost clear solution. The reaction was
partitioned between CH.sub.2Cl.sub.2 (30 mL) and NaHCO.sub.3 (30
mL). The aqueous phase was extracted with CH.sub.2Cl.sub.2
(2.times.30 mL). The combined organics were dried
(Na.sub.2SO.sub.4) and concentrated under reduced pressure. MPLC
(40.fwdarw.100% acetone-hexane, 0.1% triethylamine) yielded the
title compound (0.077 g, 57%) as a white solid; .sup.1H nmr (400
MHz, CDCl.sub.3) .delta. 8.75 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.49 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.34 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.12 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 7.64 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or
H-5), 6.87 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 4.61
(2H, 6.5 Hz, 2H of OCH.sub.2CH.sub.2CH.sub.2N), 4.26 (1H, tt, J
11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.66, 3.65 (4H, 2d AB system,
J 4.5 Hz, 4H of morpholine), 3.55 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.35 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.52 (2H, J 7.0 Hz, 2H of OCH.sub.2CH.sub.2CH.sub.2N), 2.44
(4H, m, 4H of morpholine), 2.30-2.24 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.24-2.17 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.05 (2H, pentet, J 6.5 Hz, OCH.sub.2CH.sub.2CH.sub.2N),
1.93-1.83 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.51-1.41
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.21 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.7 (ddd, J 28.5, 5.5, 4.0 Hz), -124.3 (ddd, J 28.0, 9.5, 2.5
Hz); m/z: 671 [M+H].sup.+ (found [M+H].sup.+, 671.2560,
C.sub.31H.sub.36F.sub.2N.sub.8O.sub.5S requires [M+H].sup.+
671.2570).
[0329] A person of ordinary skill in the art will understand that
the above methods also can be used to make the corresponding urea
compounds, such as I-13 and I-14, by using an amine in place of the
starting hydroxy compound. An exemplary scheme to synthesis urea
compound I-13 is provided below.
##STR00067##
Example 12
Exemplary Synthesis of Amino Acid Esters
Synthesis of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyra-
zol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl L-valinate
hydrochloride (I-16)
##STR00068##
[0330] I. Preparation of chloromethyl
(tert-butoxycarbonyl)-L-valinate
##STR00069##
[0332] To a solution of N-Boc-valine (5.00 g, 23.0 mmol, 1.0 eq) in
dichloromethane (100 mL) was added sodium bicarbonate (7.74 g, 92.2
mmol, 4.0 eq) and tetrabutylammonium hydrogen sulfate (0.78 g, 2.3
mmol, 0.1 eq) followed by water (100 mL). The mixture was stirred
for 10 minutes to allow for dissolution before cooling to 0.degree.
C. and adding a solution of chloromethyl chlorosulfate (3.0 mL,
29.0 mmol, 1.3 eq) in dichloromethane (20 mL) dropwise over 20
minutes. The reaction was stirred at 0.degree. C. for 1 hour and
then at room temperature for 18 hours. The reaction was partitioned
and the aqueous phase was extracted with CH.sub.2Cl.sub.2 (20 mL).
The combined organic phases were washed with water (3.times.100 mL)
and brine (100 mL), dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure to obtain the title compound (6.10 g,
quantitative) as a colourless oil; .sup.1H nmr (400 MHz,
CDCl.sub.3) .delta. 5.87 (1H, d, J 6.0 Hz, 1H of OCH.sub.2Cl), 5.61
(1H, d, J 6.0 Hz, 1H of OCH.sub.2Cl), 4.97 (1H, br d, J 7.0 Hz,
NH), 4.27 (1H, dd, J 9.0, 4.5 Hz, COCHNH), 2.22-2.17 (1H, m,
CHCH(CH.sub.3).sub.2), 1.44 (9H, s, C(CH.sub.3).sub.3), 0.99 (3H,
d, J 6.5 Hz, 1.times.CH.sub.3 of CH(CH.sub.3).sub.2), 0.92 (3H, d,
J 7.0 Hz, 1.times.CH.sub.3 of CH(CH.sub.3).sub.2).
II. Preparation of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyra-
zol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(tert-butoxycarbonyl)-L-valinate
##STR00070##
[0334] To a mixture of I-1 (5.00 g, 10.0 mmol, 1.0 eq) and
N-Boc-valine chloromethyl ester (2.93 g, 11.0 mmol, 1.1 eq) was
added dimethylformamide (50 mL). Caesium carbonate (3.92 g, 12.0
mmol, 1.2 eq) was added and the reaction stirred at room
temperature for 16 hours. The reaction was partitioned between
EtOAc (150 mL) and water (150 mL). The organics were washed with
brine (100 mL). The combined organics were back-extracted with
EtOAc (75 mL). The combined organics were washed with water (200
mL) and brine (150 mL), dried (Na.sub.2SO.sub.4) and concentrated
under reduced pressure. MPLC (50.fwdarw.100% EtOAc-hexane) yielded
the title compound (6.51 g, 89%) as a white solid; .sup.1H nmr (400
MHz, CDCl.sub.3) .delta. 8.48 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.29 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.14 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.04 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 7.63 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or
H-5), 6.87 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 6.21,
6.02 (2H, 2d AB system, J 10.5 Hz, NCH.sub.2O), 4.94 (1H, d, J 9.0
Hz, NHBoc), 4.28-4.21 (2H, m, cyclohexaneH-1 or H-4, COCHNH), 3.54
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.43 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.30-2.24 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.23-2.16 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.13-2.04 (1H, m, CHCH(CH.sub.3).sub.2), 1.92-1.82 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.49-1.40 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.40 (9H, s, C(CH.sub.3).sub.3),
1.20 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 0.86 (3H, d, J 6.5 Hz,
1.times.CH.sub.3 of CH(CH.sub.3).sub.2), 0.77 (3H, d, J 6.5 Hz,
1.times.CH.sub.3 of CH(CH.sub.3).sub.2); .sup.13C nmr (100 MHz,
CDCl.sub.3) .delta. 171.9, 159.7, 158.2, 15.times. (d, J 236.5 Hz),
155.6, 153..times. (dd, J 260.5, 4.5 Hz), 150.2, 139.8 (d, J 5.0
Hz), 138.9 (t, J 14.5 Hz), 133.0 (d, J 8.5 Hz), 130.5 (d, J 5.0
Hz), 129.9 (dd, J 22.5, 9.0 Hz), 122.0, 121.8, 119.4, 118.6, 107.6
(dd, J 40.5, 5.5 Hz), 80.1, 77.2, 76.4, 72.6, 63.6, 61.5, 58.4,
31.1, 31.0, 30.9, 28.3, 18.8, 17.4, 15.7; .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.6, -124.4; m/z: 751 [M+H].sup.+, 673
[M+H--C.sub.4H.sub.8]+, 629
[M+H--C.sub.4H.sub.8--CO.sub.2].sup.+.
III. Preparation of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-pyra-
zol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl L-valinate
hydrochloride, I-16
##STR00071##
[0336] To a solution/suspension of the Boc-protected valine
methylene ester (1.73 g, 2.38 mmol, 1.0 eq) in ethyl acetate (25
mL) was added hydrogen chloride 5.94 mL of a 4M solution in
dioxane, 23.76 mmol, 10.0 eq). The reaction was stirred at room
temperature for 18 hours. Further hydrogen chloride 3.0 mL of a 4M
solution in dioxane, 11.88 mmol, 5.0 eq) was added and the reaction
stirred for a further 8 hours before concentrating under reduced
pressure. The residue was concentrated from EtOAc (2.times.30 ml)
and dried under vacuum to yield the title compound (1.50 g,
quantitative) as a white solid; .sup.1H nmr (400 MHz, D.sub.6-DMSO)
.delta. 8.66 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.51 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.35
(1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.22 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.07 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 7.25 (1H, ddd, J 8.5, 3.0, 2.5 Hz,
pyridineH-4 or H-5), 6.2.times., 6.2.times. (2d, AB system, J Hz,
NCH.sub.2OCO), 4.32 (1H, tt, J 11.5, 3.0 Hz, cyclohexaneH-1 or
H-4), 3.90 (1H, d, J 4.0 Hz, COCHNH.sub.2), 3.45 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.30 (1H, tt, J 11.0, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.12-2.00 (5H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6,
CH(CH.sub.3).sub.2), 1.88-1.80 (2H, m, 2H of cyclohexaneH-2, H-3,
H-5, H-6), 1.38-1.29 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.08 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 0.87 (3H, d, J 7.0 Hz,
3H of CH(CH.sub.3).sub.2), 0.83 (3H, d, J 7.0 Hz, 3H of
CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-73.0 (d, J 28.5 Hz), -124.1 (dd, J 27.0, 9.5 Hz); m/z: 629
[M+H].sup.+ (found [M+H].sup.+, 629.2477,
C.sub.29H.sub.34F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
629.2465).
[0337] A person of ordinary skill in the art will understand that
this method is generally applicable to any amino acid, particularly
a naturally occurring amino acid, as disclosed herein.
Example 13
Synthesis of
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen
phosphate (I-18)
##STR00072##
[0338] I. Preparation of chloroethyl chlorosulfate
##STR00073##
[0340] Chlorosulfonic acid (4.90 mL, 73.7 mmol, 1.46 eq) was added
dropwise to chloroethyl chloroformate (5.44 mL, 50.4 mmol, 1.0 eq)
at 0.degree. C. over 20 minutes. The reaction was stirred at
0.degree. C. for 2 hours and then at room temperature for 10
minutes (during which time the solution temperature rose to
5.degree. C.). Dichloromethane (50 mL) was added followed carefully
by ice (2 g), and the mixture stirred rapidly to ensure mixing.
Some bubbling was observed and the yellow solution became
green-black. The mixture was washed with NaHCO.sub.3 (2.times.40
mL) to ensure the organics are not acidic. The organics were washed
with brine (40 mL), dried (Na.sub.2SO.sub.4) to obtain a clear
solution, which was concentrated under reduced pressure to obtain
the title compound (4.72 g, 52%) as a black-brown oil; .sup.1H nmr
(400 MHz, CDCl.sub.3) .delta. 6.46 (1H, q, J 6.0 Hz,
ClCH(CH.sub.3)O), 1.97 (3H, d, J 5.5 Hz, CHCH.sub.3).
II. Synthesis of 1-chloroethyl di-tert-butyl phosphate
##STR00074##
[0342] Potassium di-tert-butyl phosphate (5.44 g, 21.97 mmol, 1.0
eq was dissolved in dichloromethane-water (200 mL, 1:1) and cooled
to 0.degree. C. Sodium bicarbonate (7.37 g, 87.74 mmol, 4.0 eq) and
tetrabutylammonium hydrogen phosphate (0.74 g, 2.19 mmol, 0.1 eq)
were added and the reaction was stirred at 0.degree. C. for 10
minutes. Chloroethyl chlorosulfate (4.72 g as a solution in 20 mL
of dichloromethane, 26.37 mmol, 1.2 eq) was then added dropwise
over 30 minutes at 0.degree. C. The resulting mixture was stirred
rapidly at room temperature for 18 hours and partitioned. The
organics were washed with water (3.times.100 mL) and brine (100
mL), dried (Na.sub.2SO.sub.4) and concentrated under reduced
pressure to obtain the title compound (2.35 g, 39%) as a pale brown
oil; .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 6.19 (1H, dq, J 8.5,
5.5 Hz, ClCH(CH.sub.3)O), 1.79 (3H, dd, J 5.5, 1.0 Hz, CHCH.sub.3),
1.49 (9H, s, 1.times.OC(CH.sub.3).sub.3), 1.48 (9H, s,
1.times.OC(CH.sub.3).sub.3); .sup.32P nmr (380 MHz, CDCl.sub.3)
.delta. -13.0.
III. Preparation of di-tert-butyl
(1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl)
phosphate
##STR00075##
[0344] To a suspension of I-1 (2.00 g, 4.01 mmol, 1.0 eq) in
degassed dimethylformamide (15 mL) was added potassium iodide (0.07
g, 0.40 mmol, 0.1 eq) and potassium hydroxide (0.90 g, 16.03 mmol,
4.0 eq) as small flakes. Chloroethyl di-tert-butyl phosphate (1.64
g as a solution in 5 mL of dimethylformamide, 6.01 mmol, 1.5 eq)
was added dropwise over 10 minutes. The resulting mixture was
heated to 50.degree. C. for 14 hours before cooling and diluting
with EtOAc (50 mL). The reaction was partitioned between EtOAc (100
mL) and water (150 mL). The organics were washed with brine (100
mL), water (150 mL) and brine (100 mL), dried (Na.sub.2SO.sub.4)
and concentrated under reduced pressure. Column chromatography
(silica, 50.fwdarw.100% EtOAc-hexane) yielded the title compound as
a white solid; .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 11.73 (1H,
s, NH), 8.51 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.33 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.16
(1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.05 (1H, s
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.65 (1H, td, J 9.0,
6.5 Hz, pyridineH-4 or H-5), 6.88 (1H, ddd, J 8.0, 3.0, 2.5 Hz,
pyridineH-4 or H-5), 6.39 (1H, dq, J 7.5, 6.5 Hz, NCH(CH.sub.3)O),
4.27 (1H, tt, J 11.5, 3.5 Hz, cyclohexaneH-1 or H-4), 3.56 (2H, q,
J 7.0 Hz, OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.5 Hz,
cyclohexaneH-1 or H-4), 2.32-2.26 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.26-1.90 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.94 (3H, d, J 6.5 Hz, NCH(CH.sub.3)O), 1.93-1.84 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.42 (11H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6, 1.times.C(CH.sub.3).sub.3), 1.37
(9H, s, 1.times.C(CH.sub.3).sub.3), 1.23 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.3, -124.5; .sup.32P nmr (380 MHz, CDCl.sub.3) .delta. -11.9;
m/z: 758 [M+Na].sup.+.
[0345] Alternative synthesis of di-tert-butyl
(1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-p-
yrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl)
phosphate
[0346] To a mixture of I-1 (7.00 g, 14.0 mmol, 1.0 eq) and
potassium iodide (0.23 g, 1.4 mmol, 0.1 eq) was added dioxane (48
mL) followed by cesium carbonate (9.15 g, 28.1 mmol, 2.0 eq).
[0347] The resulting suspension was stirred at room temperature and
chloroethyl di-tert-butyl phosphate (4.20 g as a solution in 8 mL
of dioxane, 15.4 mmol, 1.1 eq) was added. The reaction was heated
to 70.degree. C. for 30 hours before cooling and partitioning
between EtOAc (100 mL) and NH.sub.4Cl-water (1:1, 100 mL). The
organics were dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure. On standing in the fridge a solid formed along
with some liquid thought to be water. The liquid did not contain
any product and was decanted. EtOAc (7.5 mL) was added and the
solid isolated by filtration, washing with EtOAc (7.5 mL and 5 mL).
The solid was dried under vacuum to obtain the title compound (5.20
g, 50%) as an off white solid; .sup.1H nmr (400 MHz, CDCl.sub.3)
.delta. 11.73 (1H, s, NH), 8.51 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.33 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.16 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.05 (1H, s pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 7.65 (1H, td, J 9.0, 6.5 Hz, pyridineH-4 or
H-5), 6.88 (1H, ddd, J 8.0, 3.0, 2.5 Hz, pyridineH-4 or H-5), 6.39
(1H, dq, J 7.5, 6.5 Hz, NCH(CH.sub.3)O), 4.27 (1H, tt, J 11.5, 3.5
Hz, cyclohexaneH-1 or H-4), 3.56 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.5 Hz, cyclohexaneH-1 or
H-4), 2.32-2.26 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
2.26-1.90 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.94 (3H,
d, J 6.5 Hz, NCH(CH.sub.3)O), 1.93-1.84 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.42 (11H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6, 1.times.C(CH.sub.3).sub.3), 1.37
(9H, s, 1.times.C(CH.sub.3).sub.3), 1.23 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.3, -124.5; .sup.32P nmr (162 MHz, CDCl.sub.3) .delta. -11.9;
m/z: 758 [M+Na].sup.+. The filtrate contains further product.
IV. Preparation of
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl dihydrogen
phosphate
##STR00076##
[0349] A solution of the di-tert-butyl phosphate (0.202 g, 0.275
mmol) in dichloromethane (3 mL) was cooled to 0.degree. C. and
phosphoric acid (85%, 9 mL) was added. The reaction was stirred at
room temperature for 3 minutes before adding to water (60 mL). The
organics were extracted with EtOAc (3.times.40 mL). The combined
organics were dried (Na.sub.2SO.sub.4) and concentrated under
reduced pressure to approximately 7 mL. A precipitate formed, which
was isolated by filtration to obtain the title compound (0.082 g,
48%) as a pink solid; .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta.
11.45 (1H, s, NH), 8.55 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.50 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.30 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.13 (1H, s pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.06 (1H, td, J 9.5, 6.5 Hz, pyridineH-4 or
H-5), 7.24 (1H, dt, J 9.0, 2.5 Hz, pyridineH-4 or H-5), 6.28-6.21
(1H, m, NCH(CH.sub.3)O), 4.31 (1H, brt, J 11.5 Hz, cyclohexaneH-1
or H-4), 3.46 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.30 (1H, brt,
J 10.5 Hz, cyclohexaneH-1 or H-4), 2.10-2.03 (4H, m, 4H of
cyclohexaneH-2, H-3, H-5, H-6), 1.88-1.78 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.77 (3H, d, J 6.0 Hz,
NCH(CH.sub.3)O), 1.38-1.29 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.08 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380
MHz, D.sub.6-DMSO) .delta. -72.8, -124.2; .sup.32P nmr (380 MHz,
D.sub.6-DMSO) .delta. -3.3; m/z: 624 [M+H].sup.+ (found
[M+H].sup.+, 624.1610, C.sub.25H.sub.28F.sub.2N.sub.7O.sub.6PS
requires [M+H].sup.+ 624.1600).
[0350] To a suspension of the di-tert-butyl phosphate (0.100 g,
0.136 mmol, 1.0 eq) in tetrahydrofuran (0.8 mL) water (0.8 mL,
distilled, deionized, 18M.OMEGA.) was added sodium acetate (0.008
g, 0.010 mmol, 0.75 eq). The reaction was sealed and stirred at
70.degree. C. for 5.5 hours before cooling and adding acetone (20
mL). A precipitate resulted, which was isolated by filtration to
obtain the title compound (0.055 g, 65%) as a white solid; data
agrees with that stated above.
V. Preparation of sodium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate
(I-20)
##STR00077##
[0352] A suspension of the phosphate (I-18) (2.34 g, 3.75 mmol, 1.0
eq) in acetonitrile (15 mL) and water (20 mL) was cooled to
0.degree. C. and sodium hydroxide (0.27 g in 5 mL of water, 6.76
mmol, 1.8 eq) was added dropwise over 30 minutes (approximately 4
mL of solution added, reaction mixture pH about 9). The reaction
was stirred at 0.degree. C. for a further 15 minutes before water
(10 mL) was added. The mixture was stirred for 15 minutes at
0.degree. C. and filtered (filter paper). The filtrate was frozen
and dried by lyophilisation to obtain the title compound (2.40 g,
96%) as a white powder; .sup.1H nmr (400 MHz, D.sub.2O) .delta.
8.05 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.86
(1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.55 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.52 (1H, s
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.37 (1H, m,
pyridineH-4 or H-5), 6.59 (1H, m, pyridineH-4 or H-5), 6.00 (1H, t,
J 7.5 Hz, NCH(CH.sub.3)O), 3.94 (1H, m, cyclohexaneH-1 or H-4),
3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.43 (1H, m,
cyclohexaneH-1 or H-4), 2.16-2.08 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.07-2.00 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.69 (3H, d, J 6.0 Hz, NCH(CH.sub.3)O), 1.68-1.60 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.36-1.25 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz, D.sub.2O) .delta. 160.4,
157.9, 156.8 (d, J 237 Hz), 152.4 (d, J 256.5 Hz), 147.5, 137.2 (d,
J 10.5 Hz), 135.9 (t, J 14.5 Hz), 132.0 (d, J 9.0 Hz), 130.2 (dd, J
25.0, 8.5 Hz), 128.0, 122.7, 120.4, 119.2, 116.0, 108.6 (d, J 41.0
Hz), 82.1, 76.7, 63.8, 60.7, 30.5, 30.2, 22.1, 14.5; .sup.19F nmr
(380 MHz, D.sub.2O) .delta. -72.8, -124.8; .sup.32P nmr (162 MHz,
D.sub.2O) .delta. 1.2; m/z: 624 [M+H].sup.+.
VI. Preparation of sodium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate (I-107)
##STR00078##
[0354] To a suspension of the di-tert-butyl phosphate (1.81 g, 2.47
mmol, 1.0 eq) in tetrahydrofuran (14.5 mL) was added sodium acetate
(0.15 g, 1.85 mmol, 0.75 eq). Water (14.5 mL, distilled, deionized,
18M.OMEGA.) was added and the reaction stirred at 70.degree. C. for
8 hours. The reaction was analyzed at hourly intervals from 4 hours
and heating continued until the profile showed approximately 10% of
the monophosphate and 70% product (prolonged heating may result in
product decomposition). The reaction was cooled and added to
acetone (75 mL) resulting in a precipitate, which was isolated by
filtration to obtain the title compound (1.04 g, 67%) as a white
solid; IR .nu..sub.max (film) 3427, 2935, 2869, 1660, 1593, 1556,
1490, 1372, 1333, 1229, 1103, 1092, 1022, 963, 823, 784, 713, 665,
647 cm.sup.-1; .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.43
(1H, s, NH), 8.42 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3, H-5), 8.47 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3, H-5), 8.23 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3, H-5), 8.04 (1H, dt, J 9.5, 6.5 Hz, pyridineH-4 or
H-5), 8.03 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 7.27 (1H, dt, J 8.5, 2.5 Hz, 1H of pyridineH-4 or H-5), 6.11
(1H, dq, J 3.5, 6.0 Hz, NCH(CH.sub.3)O), 4.31 (1H, tt, J 11.5, 3.5
Hz, cyclohexaneH-1 or H-4), 3.47 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.35 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1 or
H-4), 2.12-2.05 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6),
1.90-1.80 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.63 (3H,
d, J 6.0 Hz, CHCH.sub.3), 1.41-1.30 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); m/z: 624
[M+H].sup.+.
VII. Preparation of potassium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate
##STR00079##
[0356] A similar procedure was used to the procedure provided above
for the sodium salt but using potassium acetate instead of sodium
acetate, and the reaction may take longer to reach completion.
.sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.43 (1H, s, NH), 8.47
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.46
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.22
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.07-8.00 (1H, m, pyridineH-4 or H-5), 8.02 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.25 (1H, d, J 8.5 Hz,
1H of pyridineH-4 or H-5), 6.10 (1H, dq, J 9.0, 6.0 Hz,
NCH(CH.sub.3)O), 4.30 (1H, br t, J 11.5 Hz, cyclohexaneH-1 or H-4),
3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.34 (1H, br t, J 10.5
Hz, cyclohexaneH-1 or H-4), 2.12-2.03 (4H, m, 4H of cyclohexaneH-2,
H-3, H-5, H-6), 2.00-1.78 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.63 (3H, d, J 6.0 Hz, CHCH.sub.3), 1.39-1.29 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.09 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.32P nmr (162 MHz, D.sub.6-DMSO) .delta.
-2.0; .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta. -72.5 (d, J 27.5
Hz), -124.4 (dd, J 30.5, 11.0 Hz); m/z: 624 [M+H].sup.+.
VIII. Preparation of 2-amino-2-(hydroxymethyl)propane-1,3-diol
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-(trans-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen
phosphate (I-49)
##STR00080##
[0358] A similar procedure was used to the procedure provided above
for the sodium salt but using tris(hydroxymethyl)aminomethane.
.sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.45 (1H, s, NH), 8.49
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.47
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.25
(1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.08-8.02 (1H, m Hz, pyridineH-4 or H-5), 8.05 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.27 (1H, br d, J 8.5
Hz, 1H of pyridineH-4 or H-5), 6.11 (1H, dq, J 9.0, 6.0 Hz,
NCH(CH.sub.3)O), 4.31 (1H, br t, J 11.5 Hz, cyclohexaneH-1 or H-4),
3.46 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.40 (6H, s,
NH.sub.2C(CH.sub.2OH).sub.3), 3.34 (1H, br t, J 10.0 Hz,
cyclohexaneH-1 or H-4), 2.12-2.04 (4H, m, 4H of cyclohexaneH-2,
H-3, H-5, H-6), 1.89-1.79 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.65 (3H, d, J 6.0 Hz, CHCH.sub.3), 1.39-1.29 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.09 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.32P nmr (162 MHz, D.sub.6-DMSO) .delta.
-1.7; .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta. -72.5 (d, J 27.5
Hz), -124.4 (dd, J 30.5, 11.0 Hz); m/z: 624 [M+H].sup.+.
Example 14
Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl Isopropyl
Carbonate (I-45)
##STR00081##
[0360] To a solution of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide (50 mg, 0.1 mmol)
and chloromethyl isopropyl carbonate (20 mg, 0.13 mmol) in
anhydrous DMF (1 mL) was added cesium carbonate (40 mg, 0.12 mmol).
The resulting reaction mixture was then allowed to stir at ambient
temperature overnight and then diluted with water (50 mL) to
provide upon filtration and drying
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl isopropyl
carbonate as a white solid, wt. 49 mg (80%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 11.73 (s, 1H), 8.55-8.47 (m, 2H), 8.26-8.15 (m,
2H), 7.88 (ddd, J=9.7, 8.8, 6.2 Hz, 1H), 7.14-7.06 (m, 1H), 6.11
(d, J=4.3 Hz, 2H), 4.96-4.88 (m, 1H), 4.36-4.25 (m, 1H), 3.60 (qd,
J=7.0, 1.4 Hz, 2H), 3.52-3.42 (m, 1H), 2.31-2.18 (m, 4H), 1.97 (q,
J=11.5 Hz, 2H), 1.54-1.41 (m, 2H), 1.29 (d, J=6.3 Hz, 6H), 1.21 (t,
J=7.0 Hz, 3H). MS m/e: Calculated 615.21; Found 616.2
(M+H).sup.+.
Example 15
Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-amino-3-methylbutanamido)butanoate Hydrochloride
(I-57)
##STR00082##
[0361] I. Synthesis of Methyl
(S)-4-(2-((tert-Butoxycarbonyl)amino)-3-methylbutanamido)butanoate
(3)
[0362] To a solution of methyl 4-aminobutanoate hydrogen chloride
salt 1 (306 mg, 2.0 mmol) and (tert-butoxycarbonyl)-L-valine 2 (433
mg, 2.0 mmol) in anhydrous DMF (5 mL) was added
diisopropylethylamine (568 mg, 0.76 mL, 4.4 mmol). The mixture was
then cooled down to 0.degree. C. and HATU (835 mg, 2.2 mmol) was
added and the resulting solution was allowed to warm up to ambient
temperature and stirred for 17 hours. Water (50 mL) and ethyl
acetate (100 mL) were then added and the organic layer was
separated, washed with water (3.times.30 mL), brine (30 mL), dried
over anhydrous magnesium sulfate, filtered and concentrated under
reduced pressure. The residue obtained was purified by
chromatography using 0 to 100% ethyl acetate in hexane gradient to
afford methyl
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
3 (591 mg, 94%) as a pale sticky oil. MS m/e: Calculated 316.20;
Found 261.1 [M-.sup.tBu+H].sup.+.
II. Synthesis of
(S)-4-(2-((tert-Butoxycarbonyl)amino)-3-methylbutanamido)butanoic
Acid (4)
[0363] To a solution of methyl
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
3 (583 mg, 1.85 mmol) in a mixture of THF (4 mL) and MeOH (1 mL)
was added NaOH aqueous solution (1 mL, 4N, 4 mmol). The resulting
solution was stirred at ambient temperature for 15 hours. Most of
the solvent mixture was removed under reduced pressure and water
(50 mL) was added to the obtained residue. The aqueous layer was
then washed with ethyl ether (50 mL), acidified with aqueous HCl (5
mL, 1N) to pH 4 and extracted with ethyl acetate (3.times.40 mL).
Combined organic layer was washed with brine (20 mL), dried over
anhydrous magnesium sulfate, filtered and concentrated under
reduced pressure to afford
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoic
acid 4 (480 mg, 86%) as a white solid. MS m/e: Calculated 302.18;
Found 247.2 [M-.sup.tBu+H].sup.+.
III. Synthesis of Chloromethyl
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
(6)
[0364] To a solution of
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoic
acid 4 (370 mg, 1.23 mmol) in a mixture of dichloromethane (7 mL)
and water (7 mL), were added sodium bicarbonate (412 mg, 4.90 mmol)
and tetrabutylammonium bisulfate (42 mg, 0.123 mmol), followed by
chloromethyl chlorosulfate 5 (233 mg, 143 .mu.L, 1.41 mmol). The
resulting solution was stirred at ambient temperature for 2 days
and dichloromethane (80 mL) and water (30 mL) were added. The
organic layer was separated, and the aqueous layer was extracted
with dichloromethane (30 mL). The combined organic layers were
dried over anhydrous magnesium sulfate, filtered and concentrated
under reduced pressure to afford crude product which was further
purified by chromatography using 0 to 100% ethyl acetate in hexane
gradient to afford chloromethyl
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
6 (369 mg, 86%) as a colorless oil. MS m/e: Calculated 350.16;
Found 251.1 [M-Boc+H].sup.+.
IV. Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
(8)
[0365] To a solution of chloromethyl
(S)-4-(2-((tert-butoxycarbonyl)amino)-3-methylbutanamido) butanoate
6 (45 mg, 0.128 mmol) in anhydrous DMF (1 mL) was added
diisopropylethylamine (33.2 mg, 45 .mu.L, 0.128 mmol) followed by
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide 7 (64 mg, 0.128
mmol). The resulting solution was stirred at ambient temperature
for 2 days, then water (20 mL) was added and the aqueous solution
was extracted with ethyl acetate (2.times.40 mL). The combined
organic layers were then washed with brine (20 mL), dried over
anhydrous magnesium sulfate, filtered and concentrated under
reduced pressure. The resulting crude product was purified by
reverse phase HPLC (40 to 100% acetonitrile in water buffered with
0.1% formic acid). Desired fractions were combined and lyophilized
to afford
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
8 (26 mg, 25%) as a white foam. MS m/e: Calculated 813.34; Found
814.3 [M+H].sup.+.
V. Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-amino-3-methylbutanamido)butanoate Hydrochloride
(I-57)
[0366] To a suspension of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanamido)butanoate
8 (26 mg, 0.032 mmol) in ethyl acetate was added HCl (0.31 mL, 4M
in dioxane). The resulting solution was stirred at ambient
temperature for 19 hours. A cloudy solution was obtained, filtered
and the resulting solid was washed with ethyl acetate and hexanes
and dried under high vacuum to afford
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-((S)-2-amino-3-methylbutanamido)butanoate hydrogen chloride (21.4
mg, 89%) as a white solid. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.51-8.48 (m, 2H), 8.22 (d, J=0.7 Hz, 1H), 8.20 (s, 1H),
7.89 (td, J=9.2, 6.2 Hz, 1H), 7.09 (ddd, J=8.8, 3.4, 2.6 Hz, 1H),
6.15 (s, 2H), 4.31 (ddd, J=11.7, 8.4, 3.7 Hz, 1H), 3.61 (q, J=7.0
Hz, 2H), 3.53 (d, J=5.9 Hz, 1H), 3.50-3.40 (m, 1H), 3.27 (dt,
J=6.9, 3.4 Hz, 2H), 2.48 (t, J=7.4 Hz, 2H), 2.30-2.17 (m, 4H), 2.11
(dq, J=13.4, 6.4 Hz, 1H), 2.05-1.91 (m, 2H), 1.86 (p, J=7.2 Hz,
2H), 1.47 (q, J=11.8 Hz, 2H), 1.21 (t, J=7.0 Hz, 3H), 1.01 (dd,
J=6.9, 5.4 Hz, 6H). MS m/e: Calculated 713.29; Found 714.3
[M+H].sup.+
Example 16
Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate Hydrochloride
(I-61)
##STR00083##
[0367] I. Synthesis of Chloromethyl
2,2-Dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
(11)
[0368] To a solution of
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oic
acid (250 mg, 0.551 mmol) 10 in the mixture of dichloromethane (5.2
mL) and water (5.2 mL) were added sodium bicarbonate (185 mg, 2.21
mmol) and tetrabutylammonium bisulfate (18.7 mg, 0.0551 mmol).
Chloromethyl chlorosulfate 5 (105 mg, 64 .mu.L, 0.634 mmol) was
then added and the resulting solution was stirred at ambient
temperature for 18 hours. Water (10 mL) was then added, and the
resulting aqueous solution was extracted with dichloromethane
(3.times.30 mL). The combined organic layers were washed with brine
(20 mL), dried over anhydrous magnesium sulfate, filtered and
concentrated under reduced pressure to afford crude product of
chloromethyl
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
11 (303 mg, 100%) with 910% purity. The crude product was directly
used in next step without further purification. MS m/e: Calculated
501.23; Found 402.1 [M-Boc+H].sup.+.
II. Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
(12)
[0369] To a solution of chloromethyl
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
11 (51.8 mg, 0.103 mmol) and
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide 7 (51.5 mg, 0.103
mmol) in anhydrous DMF (1 mL) was added anhydrous cesium carbonate
(37 mg, 0.113 mmol). The resulting reaction mixture was stirred at
ambient temperature for 16 hours. Water (20 mL) and ethyl acetate
(100 mL) were then added, and the organic layer was separated,
washed with brine, dried over anhydrous magnesium sulfate, filtered
and concentrated under reduced pressure. The residue obtained was
purified by reverse phase HPLC (30 to 100% acetonitrile in water
buffered with 0.1% formic acid). The desired fractions were
combined, lyophilized to afford
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
12 (57.4 mg, 58%) as a colorless sticky oil. MS m/e: Calculated
964.42; Found 865.3[M-Boc+H].sup.+.
III. Synthesis of
(4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
1-Amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate Hydrochloride
(I-61)
[0370] To a solution of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2,2-dimethyl-4-oxo-3,8,11,14,17,20,23-heptaoxa-5-azahexacosan-26-oate
12 (57.4 mg, 0.0595 mmol) in ethyl acetate (5 mL) was added HCl
(2.4 mL, 1M in ethyl ether, 2.4 mmol). The resulting solution was
stirred at ambient temperature for 2 days. All solvents were
removed under reduced pressure and the residue obtained was
purified by reverse phase HPLC (0 to 70% acetonitrile in water
buffered with 0.1% formic acid). The desired fractions were
combined and HCl solution (65 .mu.L, 1N) was added and lyophilized
to afford
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
1-amino-3,6,9,12,15,18-hexaoxahenicosan-21-oate hydrochloride (19
mg, 35%) as a sticky pale yellow solid. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 11.71 (s, 1H), 8.50 (s, 2H), 8.28-8.16 (m, 2H),
7.90 (td, J=9.2, 6.1 Hz, 1H), 7.21-7.00 (m, 1H), 6.17 (s, 2H), 4.31
(ddd, J=11.8, 8.3, 3.7 Hz, 1H), 3.76 (t, J=5.9 Hz, 2H), 3.72-3.48
(m, 24H), 3.06 (t, J=5.1 Hz, 2H), 2.70 (t, J=5.9 Hz, 2H), 2.66 (s,
1H), 2.30-2.17 (m, 4H), 1.97 (dt, J=13.7, 11.2 Hz, 2H), 1.56-1.41
(m, 2H), 1.29 (s, 3H), 1.21 (t, J=7.0 Hz, 3H). MS m/e: Calculated
864.37; Found 865.3 [M+H].sup.+.
Example 17
Synthesis of Isopropyl
(((4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)-L-alaninate (I-62)
##STR00084##
[0371] I. Synthesis of
N-(3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(hydroxymethyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
(14)
[0372] To a solution of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide 7 (501 mg, 1 mmol)
in absolute ethanol (3 mL) was added formaldehyde aqueous solution
(162 mg, 0.15 mL, 37% wt., 2 mmol). The resulting solution was
heated at 50.degree. C. for 18 hours, and the resulting cloudy
reaction mixture was filtered, washed with absolute ethanol and
hexanes. The white solid obtained was placed under high vacuum to
afford
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(hydroxymethyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
14 (385 mg, 73%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.47
(s, 1H), 8.52 (d, J=8.5 Hz, 2H), 8.31 (s, 1H), 8.10 (d, J=15.2 Hz,
2H), 7.28 (s, 1H), 6.99 (s, 1H), 5.43 (d, J=7.7 Hz, 2H), 4.33 (s,
1H), 3.47 (d, J=7.4 Hz, 2H), 2.08 (d, J=11.9 Hz, 4H), 1.86 (d,
J=13.4 Hz, 2H), 1.35 (d, J=12.3 Hz, 2H), 1.10 (t, J=7.0 Hz, 3H). MS
m/e: Calculated 529.17; Found 530.1[M+H].sup.+.
II. Synthesis of Isopropyl
(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)-L-alaninate (I-62)
[0373] To a solution of
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-
-4-yl)-2-(1-(hydroxymethyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
14 (57.3 mg, 0.108 mmol) in anhydrous dichloromethane (2 mL),
diisopropylethylamine (28 mg, 38 .mu.L, 0.217 mmol) was added
followed by isopropyl (chloro(phenoxy)phosphoryl)-L-alaninate 15
(36.4 mg, 30 .mu.L, 0.119 mmol). The resulting solution was stirred
at ambient temperature for 2 days and then concentrated under
reduced pressure. The residue obtained was purified by reverse
phase HPLC (50 to 100% acetonitrile in water buffered with 0.1%
formic acid) and the desired fractions were combined and
lyophilized to afford isopropyl
(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(phenoxy)phos-
phoryl)-L-alaninate (16 mg, 19%) as a white solid. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.51 (s, 1H), 8.48 (d, J=14.4 Hz, 1H),
8.24 (d, J=4.5 Hz, 1H), 8.22 (s, 1H), 7.87 (ddd, J=9.7, 8.8, 6.2
Hz, 1H), 7.33-7.25 (m, 2H), 7.21-7.01 (m, 4H), 6.11 (d, J=11.8 Hz,
1H), 6.06 (dd, J=11.6, 2.3 Hz, 1H), 4.95 (pd, J=6.3, 5.3 Hz, 1H),
4.38-4.25 (m, 1H), 3.99-3.81 (m, 1H), 3.60 (q, J=7.0 Hz, 2H),
3.51-3.39 (m, 1H), 2.32-2.14 (m, 4H), 1.98 (q, J=12.1, 11.6 Hz,
2H), 1.47 (q, J=12.1 Hz, 2H), 1.32 (ddd, J=8.8, 7.2, 1.2 Hz, 3H),
1.26-1.09 (m, 9H). MS m/e: Calculated 798.25; Found 799.2
[M+H].sup.+
Example 18
Synthesis of
((((4-(4-((3-(3,6-Difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-
-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)(hydroxy)pho-
sphoryl)oxy)methyl isopropyl carbonate (I-60)
##STR00085##
[0375] To a solution of
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
dihydrogen phosphate (1.00 g, 1.64 mmol, 1.0 eq) in dimethyl
sulfoxide (10 mL) was added chloromethyl isopropyl carbonate (2.17
mL, 16.4 mmol, 10 eq) and diisopropylethylamine (2.71 mL, 16.4
mmol, 10 eq). The solution was stirred at room temperature for 2
days. The reaction mixture was purified by reverse phase HPLC
(C-18, water/acetonitrile with 0.1% formic acid) to give the title
compound (309 mg, 26%) as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 11.6 (s, 1H), 8.37 (s, 1H), 8.25 (s, 1H), 8.03
(s, 1H), 7.95 (s, 1H), 7.57-7.51 (m, 1H), 6.81-6.79 (m, 1H), 5.97
(d, J=10.8 Hz, 2H), 5.65 (d, J=10.8 Hz, 2H), 4.93-4.87 (m, 1H),
4.27-4.21 (m, 1H), 3.57 (q, J=7.2, 6.8 Hz, 2H), 3.41-3.35 (m, 1H),
2.32-2.22 (m, 4H), 1.93-1.84 (m, 2H), 1.52-1.43 (m, 2H), 1.33-1.24
(m, 9H). MS m/e: Calculated 725.18; Found 726.2 (M+H).sup.+.
[0376] The following exemplary compounds were prepared using the
methods of Examples 4-18. Characterization data for these
additional compounds are provided below.
I-6:
2-(1-(acetyl-L-leucyl)-1H-pyrazol-4-yl)-N-(3-(3,6-difluoropyridin-2-y-
l)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
##STR00086##
[0378] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.78 (1H, s,
pyrazoleH-3 or H-5), 8.50 (1H, s, thiazoleH-5 or pyrazoleH-5), 8.36
(1H, s, pyrazoleH-3 or H-5), 8.14 (1H, s, thiazoleH-5 or
pyrazoleH-5), 7.65 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or H-5),
6.91 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 6.11 (1H,
d, J 9.0 Hz, NHCOCH.sub.3), 5.88 (1H, m, COCHNHCO), 4.27 (1H, tt, J
11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.56 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.30 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.22 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.08 (3H, s, COCH.sub.3),
1.89 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.86-1.76 (2H,
m, 2H of CHCH.sub.2CH(CH.sub.3).sub.2), 1.65 (1H, m, 1H of
CHCH.sub.2CH(CH.sub.3).sub.2), 1.33 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.22 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 1.07
(3H, d, J 6.0 Hz, 1.times.CH.sub.3 of CH(CH.sub.3).sub.2), 0.97
(3H, d, J 6.5 Hz, 1.times.CH.sub.3 of CH(CH.sub.3).sub.2); m/z: 677
[M+Na].sup.+, 655 [M+H].sup.+ (found [M+H].sup.+, 655.2623,
C.sub.31H.sub.36F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
655.2621).
I-7: 1-methylcyclopropyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
##STR00087##
[0380] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.73 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5 or pyrazoleH-3, H-5), 8.50 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5 or pyrazoleH-3, H-5), 8.33 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5 or pyrazoleH-3, H-5), 8.13 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5 or pyrazoleH-3, H-5), 7.66 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 6.88 (1H, ddd, J 9.0, 3.5, 2.5 Hz,
pyridineH-4 or H-5), 4.28 (1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1
or H-4), 3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.37 (1H, tt, J
10.5, 4.0 Hz, cyclohexaneH-1 or H-4), 2.30 (2H, br t, J 11.5 Hz, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 2.22 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.89 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.76 (3H, s, CH.sub.3), 1.47 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.24 (2H, m, 2H of cPrH-2, H-3),
1.23 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 0.86 (2H, m, 2H of
cPrH-2, H-3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta. -72.6,
-124.3; m/z: 598 [M+H].sup.+ (found [M+H].sup.+, 598.2035,
C.sub.28H.sub.29F.sub.2N.sub.7O.sub.4S requires [M+H].sup.+
598.2043).
I-8: 1-(isobutyryloxy)ethyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
##STR00088##
[0382] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.76 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.51 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.38 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.14 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 7.66 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 7.15 (1H, q, J 5.5 Hz,
OCH(CH.sub.3)O), 6.87 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or
H-5), 4.28 (1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.57
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.63 (1H, heptet, J 7.0 Hz,
COCH(CH.sub.3).sub.2), 2.30 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.22 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.90 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.74 (3H, d, J 5.5 Hz,
OCH(CH.sub.3)O), 1.47 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.23 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 1.21 (3H, d, J 7.0 Hz,
1.times.CH.sub.3 of (CH(CH.sub.3).sub.2), 1.21 (3H, d, J 6.5 Hz,
1.times.CH.sub.3 of CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.6 (ddd, J 27.0, 5.5, 4.0 Hz), -124.3 (ddd,
27.0, 9.5, 2.5 Hz); m/z: 658 [M+H].sup.+ (found [M+H].sup.+,
658.2553, C.sub.30H.sub.33F.sub.2N.sub.7O.sub.6S requires
[M+H].sup.+ 658.2254).
I-9:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)-2-(1-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1H-pyrazol-4-yl)t-
hiazole-4-carboxamide
##STR00089##
[0384] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.50 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.49 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.11 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.09 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 7.67 (1H, td, J 9.0,
6.5 Hz, pyridineH-4 or H-5), 6.92 (1H, dt, J 9.0, 3.0 Hz,
pyridineH-4 or H-5), 5.19 (1H, d, J 4.5 Hz, 1H of NCH.sub.2C), 4.73
(1H, d, J 4.5 Hz, 1H of NCH.sub.2C), 4.28 (1H, tt, J 11.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 3.57 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.38 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or H-4), 2.36 (3H, s,
CCH.sub.3), 2.30 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.23
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.90 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.48 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.23 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F
nmr (380 MHz, CDCl.sub.3) .delta. -73.5, -124.1 (ddd, 27.0, 9.5,
3.0 Hz); m/z: 612 [M+H].sup.+ (found [M+H].sup.+, 612.1835,
C.sub.28H.sub.27F.sub.2N.sub.7O.sub.5S requires [M+H].sup.+
612.1857).
I-10: 2-morpholinoethyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
##STR00090##
[0386] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.75 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.49 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.35 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 8.13 (1H, s, 1H of
thiazoleH-5, pyrazoleH-5, pyrazoleH-3, H-5), 7.64 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 6.86 (1H, dt, J 8.5, 3.5, 2.5 Hz,
pyridineH-4 or H-5), 4.63 (2H, t, J 6.0 Hz, COOCH.sub.2CH.sub.2N),
4.26 (1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.70, 3.68
(4H, 2d AB system, J 4.5 Hz, 4H of morpholine), 3.55 (2H, q, J 7.0
Hz, OCH.sub.2CH.sub.3), 3.36 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.84 (2H, t, J 6.0 Hz, COOCH2CH2N), 2.58,
2.57 (4H, 2d AB system, J 4.5 Hz, 4H of morpholine), 2.28 (2H, m,
2H of cyclohexaneH-2, H-3, H-5, H-6), 2.20 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.88 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.45 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.21 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.7 (ddd, J 27.0, 5.5, 4.0 Hz), -124.3 (ddd,
27.0, 11.0, 9.5 Hz); m/z: 657 [M+H].sup.+.
I-12:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1-(morpholine-4-carbonyl)-1H-pyrazol-4-yl)thiazole-4-carbox-
amide
##STR00091##
[0388] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.71 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.50 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.26 (1H, d, J 0.5
Hz,), 8.10 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
7.64 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or H-5), 6.90 (1H, ddd, J
9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 4.27 (1H, tt, J 11.5, 4.0
3.83, 3.82 (4H, 2d AB system, J 4.0 Hz, 4H of morpholine), 3.56
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.36 (1H, tt, J 11.0, 4.0 Hz,
cyclohexaneH-1 or H-4), Hz, cyclohexaneH-1 or H-4), 3.94 (4H, br s,
4H of morpholine), 2.33-2.25 (2H, m, 2H of cyclohexaneH-2, H-3,
H-5, H-6), 2.55-1.90 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.94-1.84 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.41
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.5, -124.4; m/z: 613 [M+H].sup.+ (found [M+H].sup.+, 613.2163,
C.sub.28H.sub.30F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
613.2152).
I-13:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1-((3-morpholinopropyl)carbamoyl)-1H-pyrazol-4-yl)thiazole--
4-carboxamide
##STR00092##
[0390] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.85 (1H, t, J 5.0
Hz, CONHCH.sub.2), 8.79 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.49 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.25 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.08 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 7.36 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or
H-5), 6.90 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 4.26
(1H, tt, J 12.0, 4.0 Hz, cyclohexaneH-1 or H-4), 3.85, 3.84 (4H, 2d
AB system, J 4.5 Hz, 4H of morpholine), 3.60-3.56 (2H, m,
CONHCH.sub.2CH.sub.2CH.sub.2N), 3.55 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.36 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.57-2.54 (2H, m, CONHCH.sub.2CH.sub.2CH.sub.2N), 2.51 (4H,
br s, 4H of morpholine), 2.30-2.26 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.23-2.18 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.93-1.84 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.84-1.78 (2H, m, CONHCH.sub.2CH.sub.2CH.sub.2N), 1.51-1.41 (2H, m,
2H of cyclohexaneH-2, H-3, H-5, H-6), 1.21 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.6 (ddd, J 27.0, 5.5, 4.0 Hz), -124.5 (ddd, J 27.0, 9.5, 2.5
Hz); m/z: 670 [M+H].sup.+.
I-14:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1-((3-(dimethylamino)propyl)carbamoyl)-1H-pyrazol-4-yl)thia-
zole-4-carboxamide
##STR00093##
[0392] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.80 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.49 (1H, s
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.36 (1H, t, J 5.5
Hz, pyrazoleCONH), 8.20 (1H, d, J 0.5 Hz, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.08 (1H, s, pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 7.63 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or
H-5), 6.89 (1H, ddd, J 9.0, 3.5, 2.5 Hz, pyridineH-4 or H-5), 4.26
(1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.58-3.52 (4H, m,
OCH.sub.2CH.sub.3, pyrazoleCONHCH.sub.2), 3.36 (1H, tt, J 10.5, 4.0
Hz, cyclohexaneH-1 or H-4), 2.44 (2H, t, J 6.5 Hz,
CH.sub.2N(CH.sub.3).sub.2), 2.26 (6H, s, N(CH.sub.3).sub.2),
2.30-2.18 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.93-1.83
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.79 (2H, pentet, J
6.5 Hz, NCH.sub.2CH.sub.2CH.sub.2N(CH.sub.3).sub.2), 1.51-1.41 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.21 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.6, -124.5; m/z: 628 [M+H].sup.+ (found [M+H].sup.+, 628.2628,
C.sub.29H.sub.35F.sub.2N.sub.9O.sub.3S requires [M+H].sup.+
628.2624).
I-15: 3-morpholinopropyl
4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyr-
azol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazole-1-carboxylate
##STR00094##
[0394] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.75 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.49 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.34 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.12 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.64 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 6.87 (1H, ddd, J 9.0, 3.5, 2.5 Hz,
pyridineH-4 or H-5), 4.61 (2H, 6.5 Hz, 2H of
OCH.sub.2CH.sub.2CH.sub.2N), 4.26 (1H, tt, J 11.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 3.66, 3.65 (4H, 2d AB system, J 4.5 Hz, 4H
of morpholine), 3.55 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.35
(1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or H-4), 2.52 (2H, J 7.0
Hz, 2H of OCH.sub.2CH.sub.2CH.sub.2N), 2.44 (4H, m, 4H of
morpholine), 2.30-2.24 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.24-2.17 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.05
(2H, pentet, J 6.5 Hz, OCH.sub.2CH.sub.2CH.sub.2N), 1.93-1.83 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.51-1.41 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.21 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.7 (ddd, J 28.5, 5.5, 4.0 Hz), -124.3 (ddd, J 28.0, 9.5, 2.5
Hz); m/z: 671 [M+H].sup.+ (found [M+H].sup.+, 671.2560,
C.sub.31H.sub.36F.sub.2N.sub.8O.sub.5S requires [M+H].sup.+
671.2570).
I-16:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate hydrogen chloride salt
##STR00095##
[0396] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 8.66 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.51 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.35 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.22 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.07 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 7.25 (1H, ddd, J 8.5, 3.0, 2.5 Hz,
pyridineH-4 or H-5), 6.2.times., 6.2.times. (2d, AB system, J Hz,
NCH.sub.2OCO), 4.32 (1H, tt, J 11.5, 3.0 Hz, cyclohexaneH-1 or
H-4), 3.90 (1H, d, J 4.0 Hz, COCHNH.sub.2), 3.45 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.30 (1H, tt, J 11.0, 4.0 Hz, cyclohexaneH-1 or
H-4), 2.12-2.00 (5H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6,
CH(CH.sub.3).sub.2), 1.88-1.80 (2H, m, 2H of cyclohexaneH-2, H-3,
H-5, H-6), 1.38-1.29 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.08 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 0.87 (3H, d, J 7.0 Hz,
3H of CH(CH.sub.3).sub.2), 0.83 (3H, d, J 7.0 Hz, 3H of
CH(CH.sub.3).sub.2); .sup.13C nmr (100 MHz, D.sub.6-DMSO) .delta.
168.8, 160.2, 157.6, 157.5 (d, J 236.0 Hz), 153.5 (dd, J 259.0, 4.5
Hz), 149.4, 139.5 (d, 6.5 Hz), 138.2 (t, J 14.5 Hz), 132.6 (d, 8.5
Hz), 132.3, 131.9 (dd, 22.5, 9.5 Hz), 124.4, 121.4, 120.3, 117.8,
109.2 (br d, J 34.0 Hz), 76.0, 73.6, 63.0, 60.8, 57.4, 30.9 (2C),
29.8, 18.6, 17.7, 16.1; .sup.19F nmr (380 MHz, D.sub.6-DMSO)
.delta. -73.0 (d, J 28.5 Hz), -124.1 (dd, J 27.0, 9.5 Hz); m/z: 629
[M+H].sup.+ (found [M+H].sup.+, 629.2477,
C.sub.29H.sub.34F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
629.2465).
I-17:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-prolinate hydrogen chloride salt
##STR00096##
[0398] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.48 (1H, s,
1.times.NH), 9.32 (1H, br s, 1.times.NH), 8.66 (1H, pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.51 (1H, s, pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.35 (1H, s, pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.22 (1H, s, pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.07 (1H, td, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.26 (1H, dt, J 8.5, 2.5 Hz, pyridineH-4 or
H-5), 6.24 (2H, s, NCH.sub.2OCOCHN), 4.42 (1H, tt, J 8.5, 3.5 Hz,
cyclohexaneH-1 or H-4), 3.45 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.33 (1H, tt, J 10.0, 4.0 Hz, cyclohexaneH-1 or H-4), 3.23-3.11
(2H, m, COCHNHCH.sub.2), 2.27-2.19 (1H, m, 1H of COCH(NH)CH.sub.2),
2.10-2.04 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.98-1.80
(5H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6, 3H of
COCH(NH)CH.sub.2CH.sub.2), 1.38-1.29 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.08 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F
nmr (380 MHz, D.sub.6-DMSO) .delta. -73.0 (d, J 27.5 Hz), -124.1
(dd, J 27.0, 9.5 Hz); m/z: 627 [M+H].sup.+.
I-18:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl-
)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
dihydrogen phosphate
##STR00097##
[0400] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.45 (1H, s,
NH), 8.55 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.50 (1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.30
(1H, s, pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.13 (1H, s
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.06 (1H, td, J 9.5,
6.5 Hz, pyridineH-4 or H-5), 7.24 (1H, dt, J 9.0, 2.5 Hz,
pyridineH-4 or H-5), 6.28-6.21 (1H, m, NCH(CH.sub.3)O), 4.31 (1H,
brt, J 11.5 Hz, cyclohexaneH-1 or H-4), 3.46 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.30 (1H, brt, J 10.5 Hz, cyclohexaneH-1 or
H-4), 2.10-2.03 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6),
1.88-1.78 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.77 (3H,
d, J 6.0 Hz, NCH(CH.sub.3)O), 1.38-1.29 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.08 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-72.8, -124.2; .sup.32P nmr (380 MHz, D.sub.6-DMSO) .delta. -3.3;
m/z: 624 [M+H].sup.+ (found [M+H].sup.+, 624.1610,
C.sub.25H.sub.28F.sub.2N.sub.7O.sub.6PS requires [M+H].sup.+
624.1600).
I-19:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
glycinate hydrogen chloride salt
##STR00098##
[0402] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.47 (1H, s,
NH), 8.67 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.52 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.37 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.34 (2H, br s, NH.sub.2), 8.23 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.09 (1H, td, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.27 (1H, dt, J 8.5, 2.5 Hz, pyridineH-4 or
H-5), 6.25 (2H, s, NCH.sub.2O or COCH.sub.2NH.sub.2), 4.33 (1H, tt,
J 11.5, 3.5 Hz, cyclohexaneH-1 or H-4), 3.89 (2H, s, NCH.sub.2O or
COCH.sub.2NH.sub.2), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.34 (1H, tt, J 11.0, 3.5 Hz, cyclohexaneH-1 or H-4), 2.12-2.04
(4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.91-1.80 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.41-1.29 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-72.9, -124.1; m/z: 587 [M+H].sup.+ (found [M+H].sup.+, 587.1996,
C.sub.26H.sub.28F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
587.1995).
I-20: sodium
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H--
pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
phosphate
##STR00099##
[0404] .sup.1H nmr (400 MHz, D.sub.2O) .delta. 8.05 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.86 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.55 (1H, s,
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.52 (1H, s
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.37 (1H, m,
pyridineH-4 or H-5), 6.59 (1H, m, pyridineH-4 or H-5), 6.00 (1H, t,
J 7.5 Hz, NCH(CH.sub.3)O), 3.94 (1H, m, cyclohexaneH-1 or H-4),
3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.43 (1H, m,
cyclohexaneH-1 or H-4), 2.16-2.08 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 2.07-2.00 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.69 (3H, d, J 6.0 Hz, NCH(CH.sub.3)O), 1.68-1.60 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.36-1.25 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.2O) .delta. -72.8,
-124.8; .sup.32P nmr (380 MHz, D.sub.2O) .delta. 1.2; m/z: 624
[M+H].sup.+.
I-21:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate hydrogen chloride salt
##STR00100##
[0406] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.47 (1H, s,
NH), 8.68 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.52 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.43 (2H, br s, NH.sub.2), 8.37 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.24 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.09 (1H, td, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.26 (1H, br d, J 8.5 Hz, pyridineH-4 or H-5),
6.34, 6.24 (2H, 2d AB system, J 11.0 Hz, NCH.sub.2O), 4.33 (1H, br
t, J 11.5, Hz, cyclohexaneH-1 or H-4), 3.86 (1H, s,
COCH(tBu)NH.sub.2), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.38-3.30 (1H, m, cyclohexaneH-1 or H-4), 2.12-2.05 (4H, m, 4H of
cyclohexaneH-2, H-3, H-5, H-6), 1.91-1.81 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.40-1.30 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3), 0.93 (9H, s, C(CH.sub.3).sub.3); .sup.19F nmr
(380 MHz, D.sub.6-DMSO) .delta. -72.9, -124.1; m/z: 643 [M+H].sup.+
(found [M+H].sup.+, 643.2607,
C.sub.30H.sub.36F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
643.2621).
I-23:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-amino-2-methylpropanoate hydrogen chloride salt
##STR00101##
[0408] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 8.68 (1H, s, 1H
of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.52 (2H, br s,
2.times.NH), 8.52 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.37 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.24 (1H, s, 1H of pyrazoleH-5, thiazoleH-5,
pyrazoleH-3 or H-5), 8.09 (1H, td, J 9.0, 6.5 Hz, pyridineH-4 or
H-5), 7.26 (1H, dt, J 9.0, 3.0 Hz, pyridineH-4 or H-5), 6.26 (2H,
s, NCH.sub.2O), 4.33 (1H, br t, J 12.0 Hz, cyclohexaneH-1 or H-4),
3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.34 (1H, tt, J 10.5,
3.5 Hz, cyclohexaneH-1 or H-4), 2.11-2.04 (4H, m, 4H of
cyclohexaneH-2, H-3, H-5, H-6), 1.91-1.80 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.43 (6H, s, C(CH.sub.3).sub.2),
1.41-1.30 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H,
t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -72.9, -124.1; m/z: 615 [M+H].sup.+ (found
[M+H].sup.+, 615.2343, C.sub.28H.sub.32F.sub.2N.sub.8O.sub.4S
requires [M+H].sup.+ 615.2309).
I-24:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexy-
l)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-4-oxob-
utanoic Acid
##STR00102##
[0410] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 11.71 (1H, s, NH),
8.48 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.29 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.14 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.06 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
7.63 (1H, td, J 9.0, 6.5 Hz, pyridineH-4 or H-5), 6.88 (1H, ddd, J
8.5, 3.5, 2.5 Hz, pyridineH-4 or H-5), 6.11 (2H, s, OCH.sub.2O),
4.26 (1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1 or H-4), 3.56 (2H, q,
J 7.0 Hz, OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.69 (4H, br s, COCH.sub.2CH.sub.2CO),
2.32-2.2.18 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.94-1.83
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.42 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.13C nmr (100 MHz, CDCl.sub.3) .delta.
175.8, 171.6, 159.8, 158.2, 157.5 (d, J 237.5 Hz), 153.4 (dd, J
260.5, 4.5 Hz), 150.1, 139.7 (d, J 5.0 Hz), 138.7 (t, J 14.5 Hz),
133.0 (d, J 8.5 Hz), 130.4 (d, J 5.0 Hz), 129.9 (dd, J 22.5, 9.0
Hz), 122.0, 121.8, 119.4, 118.6, 107.6 (dd, J 40.5, 5.5 Hz), 76.4,
72.4, 63.7, 61.5, 31.0, 30.9, 28.7, 28.5, 15.7; .sup.19F nmr (380
MHz, CDCl.sub.3) .delta. -72.5 dd, J 27.5, 9.5 Hz), -124.4 (ddd, J
28.5, 9.5, 2.5 Hz); m/z: 630 [M+H].sup.+ (found [M+H].sup.+,
630.1927, C.sub.28H.sub.29F.sub.2N.sub.7O.sub.6S requires
[M+H].sup.+ 630.1941).
I-28:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
2-morpholinoacetate
##STR00103##
[0412] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.50 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.31 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.17 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.06 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 7.65 (1H, td, J 9.0,
6.0 Hz, pyridineH-4 or H-5), 6.89 (1H, ddd, J 8.5, 3.0, 2.5 Hz,
pyridineH-4 or H-5), 6.13 (2H, s, NCH.sub.2O), 4.27 (1H, tt, J
11.5, 3.5 Hz, cyclohexaneH-1 or H-4), 3.73, 3.72 (4H, 2d AB system,
J 4.5 Hz, 4H of morpholine), 3.56 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.37 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or
H-4), 3.29 (2H, s, COCH.sub.2N), 2.57, 2.56 (4H, 2d AB system, J
Hz, 4H of morpholine), 2.32-2.26 (2H, m, 2H of cyclohexaneH-2, H-3,
H-5, H-6), 2.26-2.18 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.94-1.84 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.42
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.6 (ddd, J 27.0, 7.0, 2.5 Hz), -124.4 ((ddd, J 27.0, 9.5, 2.5
Hz); m/z: 657 [M+H].sup.+ (found [M+H].sup.+, 657.2432,
C.sub.30H.sub.34F.sub.2N.sub.8O.sub.5S requires [M+H].sup.+
657.2414).
I-29:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate
##STR00104##
[0414] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 11.72 (1H, s, NH),
8.49 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.31 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.16 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
8.05 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5),
7.65 (1H, td, J 9.0, 6.5 Hz, pyridineH-4 or H-5), 6.88 (1H, dt, J
8.5, 3.0 Hz, pyridineH-4 or H-5), 6.14, 6.10 (2H, 2d AB system, J
10.5 Hz, NCH.sub.2O), 4.26 (1H, tt, J 11.5, 4.0 Hz, cyclohexaneH-1
or H-4), 3.45 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.40-3.32 (2H,
m, cyclohexaneH-1 or H-4, COCHNH.sub.2), 2.33-2.25 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 2.23-2.17 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 2.05-2.01 (1H, m, CHCH(CH.sub.3)2),
1.94-1.83 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.51-1.41
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3), 0.91 (3H, d, J 7.0 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2), 0.82 (3H, d, J 6.5 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.7, -124.4; m/z: 629 [M+H].sup.+ (found [M+H].sup.+, 629.2474,
C.sub.29H.sub.34F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
629.2465).
I-30:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate benzenesulfonic acid
##STR00105##
[0416] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.47 (1H, s,
NH), 8.68 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.37 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or
H-5), 8.27 (2H, br s, NH.sub.2), 8.24 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3 or H-5), 8.09 (1H, td, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.69-7.56 (2H, m, 2H of
C.sub.6H.sub.5SO.sub.3H), 7.32-7.24 (4H, m, 3H of
C.sub.6H.sub.5SO.sub.3H, pyridineH-4 or H-5), 6.34, 6.25 (2H, 2d AB
system, J 11.0 Hz, NCH.sub.2O), 4.33 (1H, tt, J 11.5, 3.5 Hz,
cyclohexaneH-1 or H-4), 4.03 (1H, d, J 4.5 Hz, COCHNH.sub.2), 3.47
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.34 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.14-2.06 (5H, m, CHCH(CH.sub.3).sub.2, 4H
of cyclohexaneH-2, H-3, H-5, H-6), 1.90-1.80 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.41-1.30 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3), 0.89 (3H, d, J 6.5 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2), 0.86 (3H, d, J 7.0 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-72.6, -124.5; m/z: 629 [M+H].sup.+.
I-31:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
L-valinate methanesulfonic acid salt
##STR00106##
[0418] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 8.68 (1H, s, 1H
of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.53 (1H, s, 1H
of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.37 (1H, s, 1H
of pyrazoleH-5, thiazoleH-5, pyrazoleH-3 or H-5), 8.34 (2H, br s,
NH.sub.2), 8.24 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3
or H-5), 8.09 (1H, dt, J 9.0, 6.5 Hz, pyridineH-4 or H-5), 7.26
(1H, ddd, J 9.0, 3.0, 2.5 Hz, pyridineH-4 or H-5), 6.34, 6.25 (2H,
2d AB system, J 11.0 Hz, NCH.sub.2O), 4.33 (1H, tt, J 11.5, 3.0 Hz,
cyclohexaneH-1 or H-4), 4.04 (1H, t, J 5.0 Hz, COCHNH.sub.2), 3.47
(2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.38-3.30 (1H, m,
cyclohexaneH-1 or H-4), 2.31 (3H, s, CH.sub.3SO.sub.3H), 2.16-2.04
(5H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6, CHCH(CH.sub.3).sub.2),
1.91-1.80 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.40-1.30
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3), 0.90 (3H, d, J 7.0 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2), 0.86 (3H, d, J 7.0 Hz, 1.times.CH.sub.3 of
CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-73.0, -124.1; m/z: 629 [M+H].sup.+.
I-35:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate
##STR00107##
[0420] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 11.70 (1H, s, NH),
8.48 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.29 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.15 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.04 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
7.63 (1H, td, J 9.0, 6.5 Hz, pyridineH-4 or H-5), 6.86 (1H, ddd, J
9.0, 3.0, 2.5 Hz, pyridineH-4 or H-5), 6.13, 6.08 (2H, 2d AB
system, J 10.5 Hz, NCH.sub.2CO), 4.25 (1H, tt, J 11.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 3.54 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.35 (1H, tt, J 11.0, 4.0 Hz, cyclohexaneH-1 or H-4), 3.20 (1H, s,
COCH(C(CH.sub.3).sub.3)NH.sub.2), 2.32-2.24 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 2.24-2.16 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.93-1.82 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.50-1.40 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.20 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3), 0.89 (9H, s, C(CH.sub.3).sub.3); .sup.19F nmr
(380 MHz, CDCl.sub.3) .delta. -72.6, -124.4; m/z: 643 [M+H].sup.+
(found [M+H].sup.+, 643.2595,
C.sub.30H.sub.37F.sub.2N.sub.8O.sub.4S requires [M+H].sup.+
643.2621).
I-36:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate benzenesulfonic Acid
##STR00108##
[0422] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.74 (1H, s,
NH), 8.68 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.37 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.29 (2H, m, 2.times.NH.sub.2), 8.25 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.09 (1H, dt, J 9.5,
6.5 Hz, pyridineH-4 or H-5), 7.59-7.56 (2H, m, 2H of
C.sub.6H.sub.5SO.sub.3H), 7.32-7.23 (4H, m, 3H of
C.sub.6H.sub.5SO.sub.3H, pyridineH-4 or H-5), 6.34, 6.26 (2H, 2d AB
system, J 11.0 Hz, NCH.sub.2CO), 4.33 (tt, J 11.5, 3.5 Hz,
cyclohexaneH-1 or H-4), 3.91 (1H, br s,
COCH(C(CH.sub.3).sub.3)NH.sub.2), 3.47 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.34 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1 or
H-4), 2.12-2.05 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6),
1.92-1.80 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.41-1.30
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0
Hz, OCH.sub.2CH.sub.3), 0.93 (9H, s, C(CH.sub.3).sub.3); .sup.13C
nmr (100 MHz, D.sub.6-DMSO) .delta. 168.5, 160.2, 157.5 (d, J 234.0
Hz), 157.5, 153.5 (d, J 258.0 Hz), 149.4, 148.9, 139.6 (d, J 7.5
Hz), 138.1 (d, J 14.5 Hz), 132.6 (d, J 9.0 Hz), 132.4 (d, J 3.0
Hz), 128.7, 128.0, 125.9, 124.4, 121.4, 120.3, 117.9, 76.0, 73.7,
63.0, 60.8, 33.7, 30.9 (2C), 26.4, 16.1; .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -72.9, -124.1; m/z: 643 [M+H].sup.+.
I-37:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
4-(morpholinomethyl)benzoate
##STR00109##
[0424] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 11.73 (1H, s, NH),
8.50 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.42 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.18 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.06 (1H, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 8.02
(2H, d, J 8.0 Hz, 2H of C.sub.6H.sub.4), 7.64 (1H, dt, J 9.0, 6.5
Hz, pyridineH-4 or H-5), 7.42 (1H, d, J 8.0 Hz, 2H of
C.sub.6H.sub.4), 6.85 (1H, m, pyridineH-4 or H-5), 6.34 (2H, s,
NCH.sub.2CO), 4.27 (1H, tdd, J 11.5, 4.0, 3.5 Hz, cyclohexaneH-1 or
H-4), 3.70, 3.69 (4H, 2d AB system, J 4.5 Hz, 4H of morpholine),
3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.54 (2H, s,
C.sub.6H.sub.4CH.sub.2N), 3.37 (1H, tt, J 10.5, 4.0 Hz,
cyclohexaneH-1 or H-4), 2.42 (4H, br s, 4H of morpholine),
2.32-2.26 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.26-2.18
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.94-1.84 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.52-1.42 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.22 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, CDCl.sub.3) .delta.
-72.5, -124.4; m/z: 733 [M+H].sup.+.
I-39:
(1R,2R)-2-(((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxy-
cyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methox-
y)carbonyl)cyclohexane-1-carboxylic acid
##STR00110##
[0426] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 12.25 (1H, br s,
OH), 11.47 (1H, s, NH), 8.57 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3, H-5), 8.52 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3, H-5), 8.34 (1H, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3, H-5), 8.19 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3, H-5), 8.08 (1H, dt, J 9.0, 6.5 Hz,
pyridineH-4 or H-5), 7.27 (1H, dt, J 8.5, 2.5 Hz, pyridineH-4 or
H-5), 6.13, 6.05 (2H, 2d AB system, J 11.0 Hz, NCH.sub.2O), 4.33
(1H, tt, J 11.5, 3.5 Hz, cyclohexaneH-1 or H-4), 3.47 (2H, q, J 7.0
Hz, OCH.sub.2CH.sub.3), 3.35 (1H, tt, J 11.0, 3.5 Hz,
cyclohexaneH-1 or H-4), 2.78-2.40 (1H, m, cyclohexane dicarboxylic
acid H-1 or H-2), 2.12-2.04 (4H, m, 4H of cyclohexaneH-2, H-3, H-5,
H-6), 1.97-1.82 (1H, m, 1H of cyclohexane dicarboxylic acid H-1 or
H-2), 1.90-1.81 (4H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6, 2H of
cyclohexane dicarboxylic acid H-3, H-4, H-5, H-6), 1.65 (2H, br s,
cyclohexane dicarboxylic acid H-3, H-4, H-5, H-6), 1.39-1.30 (2H,
m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.27-1.17 (4H, m, 4H of
cyclohexane dicarboxylic acid H-3, H-4, H-5, H-6), 1.10 (3H, t, J
7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.6-DMSO)
.delta. -72.8, -124.2; m/z: 684 [M+H].sup.+ (found [M+H].sup.+,
684.2416, C.sub.32H.sub.35F.sub.2N.sub.7O.sub.6S requires
[M+H].sup.+ 684.2410).
I-40:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
(S)-2-amino-3,3-dimethylbutanoate methanesulfonic acid salt
##STR00111##
[0428] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 12.47 (1H, br s,
NH), 8.68 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.37 (1H, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5),
8.30 (2H, br s, NH.sub.2), 8.25 (1H, s, 1H of pyrazoleH-5,
thiazoleH-5, pyrazoleH-3, H-5), 8.09 (1H, dt, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.27 (1H, dt, J 8.5, 2.5 Hz, pyridineH-4 or
H-5), 6.34, 6.26 (2H, 2d AB system, J 11.0 Hz, NCH.sub.2O), 4.33
(1H, tt, J 11.5, 3.5 Hz, 1H of cyclohexaneH-1 or H-4), 3.90 (1H, d,
J 4.5 Hz, COCH(C(CH.sub.3).sub.3)NH.sub.2), 3.47 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.39-3.31 (1H, m, cyclohexaneH-1 or H-4), 2.30
(3H, s, CH.sub.3SO.sub.3H), 2.12-2.04 (4H, m, 4H of cyclohexaneH-2,
H-3, H-5, H-6), 1.90-1.80 (2H, m, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 1.40-1.30 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.10
(3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 0.93 (9H, s,
C(CH.sub.3).sub.3); .sup.13C nmr (100 MHz, D.sub.6-DMSO) .delta.
168.5, 160.2, 157.6, 157.5 (d, J 236.0 Hz), 155.7 (dd, J 260.0, 4.5
Hz), 149.4, 139.5 (d, J 6.5 Hz), 138.2 (t, J 14.0 Hz), 132.6 (d, J
8.5 Hz), 132.4, 124.4, 121.4, 120.3, 117.9, 76.0, 73.7, 65.4, 63.0,
60.8, 33.7, 30.9 (2C), 26.4, 16.1; .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -72.9, -124.0; m/z: 643 [M+H].sup.+.
I-42:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4S)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1-((2S,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetra-
hydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
##STR00112##
[0430] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.47 (1H, s,
NH), 8.66 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.32 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.14 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.08 (1H, td, J 9.5, 6.5 Hz, pyridineH-4 or H-5), 7.26 (1H,
dt, J 8.5, 2.5 Hz, pyridineH-4 or H-5), 5.30 (1H, d, J 6.0 Hz,
OH-2), 5.23-5.21 (2H, m, H-1, OH-3), 5.09 (1H, d, J 5.5 Hz, OH-4),
4.61 (1H, t, J 5.5 Hz, OH-6), 4.33 (1H, br t, J 11.5 Hz, cHexH-1 or
H-4), 3.79 (1H, td, J 9.0, 6.0 Hz, H-2), 3.70 (1H, dd, J 11.0, 5.5
Hz, 1.times.H-6), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.45-3.32 (3H, m, cHexH-1 or H-4, H-3, 1.times.H-6), 3.24-3.21 (1H,
m, H-4), 2.12-2.04 (4H, m, 4H of cHexH-2, H-3, H-5, H-6), 1.91-1.81
(1H, m, 2H of cHexH-2, H-3, H-5, H-6), 1.40-1.31 (2H, m, 2H of
cHexH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3);
.sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta. -72.8, -124.2; m/z:
662 [M+H].sup.+ (found [M+H].sup.+, 662.2219,
C.sub.29H.sub.33F.sub.2N.sub.7O.sub.7S requires [M+H].sup.+
662.2203).
I-43:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4R)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetra-
hydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thiazole-4-carboxamide
##STR00113##
[0432] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.49 (1H, s,
NH), 8.59 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.33 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.17 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.09 (1H, td, J 9.5, 6.0 Hz, pyridineH-4 or H-5), 7.28 (1H,
dt, J 8.5, 2.5 Hz, pyridineH-4 or H-5), 5.70 (1H, d, J 4.0 Hz,
H-1), 5.15 (1H, br s, 1.times.OH), 4.93 (2H, br m, 2.times.OH),
4.54 (1H, br s, 1.times.OH), 4.39 (1H, t, J 3.5 Hz, H-2), 4.33 (1H,
br t, J 11.5 Hz, cHexH-1 or H-4), 3.91 (1H, dd, J 7.0, 3.0 Hz,
H-3), 3.63 (1H, d, J 10.0 Hz, 1.times.H-6), 3.58-3.52 (2H, m, H-4,
1.times.H-6), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.45-3.42
(1H, m, H-5), 3.35 (1H, m, cHexH-1 or H-4), 2.12-2.04 (4H, m, 4H of
cHexH-2, H-3, H-5, H-6), 1.92-1.81 (2H, m, 2H of cHexH-2, H-3, H-5,
H-6), 1.40-1.31 (2H, m, 2H of cHexH-2, H-3, H-5, H-6), 1.10 (3H, t,
J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.6-DMSO)
.delta. -72.7, -124.2; m/z: 662 [M+H].sup.+ (found [M+H].sup.+,
662.2195, C.sub.29H.sub.33F.sub.2N.sub.7O.sub.7S requires
[M+H].sup.+ 662.2203).
I-49:
1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl-
)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl
hydrogen phosphate tris salt
##STR00114##
[0434] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.46 (1H, s,
NH), 8.51 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.49 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.28 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.07 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.06 (1H, dt, J 10.0, 6.5 Hz, pyridineH-4 or H-5), 7.28 (1H,
dt, J 8.5, 2.5 Hz, pyridineH-4 or H-5), 6.12 (1H, dq, J 9.0, 6.0
Hz, NCH(CH.sub.3)OP), 4.32 (1H, br t, J 11.5 Hz, cyclohexaneH-1 or
H-4), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3), 3.44 (6H, s,
C(CH.sub.2OH).sub.3), 3.35 (1H, tt, J 10.5, 3.5 Hz, cyclohexaneH-1
or H-4), 2.12-2.05 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6),
1.91-1.81 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.66 (3H,
d, J 6.0 Hz, NCH(CH.sub.3)OP), 1.40-1.30 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.32P nmr (380 MHz, D.sub.6-DMSO) .delta.
0.2; .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta. -72.6, -124.4;
m/z: 624 [M+H].sup.+.
I-50:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
glycinate benzenesulfonic acid salt
##STR00115##
[0436] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 11.47 (1H, s,
NH), 8.67 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.53 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.37 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.24 (1H, s, 1H of pyrazoleH-5, thiazoleH-5, pyrazoleH-3,
H-5), 8.23 (2H, br s, NH.sub.2), 8.09 (1H, dt, J 9.5, 6.5 Hz,
pyridineH-4 or H-5), 7.59-7.56 (2H, m, 2H of
C.sub.6H.sub.5SO.sub.3H), 7.32-7.25 (4H, m, 3H of
C.sub.6H.sub.5SO.sub.3H, pyridineH-4 or H-5), 6.26 (2H, s,
NCH.sub.2CO), 4.34 (1H, tt, J 11.5, 3.5 Hz, cyclohexaneH-1 or H-4),
3.92 (2H, br s, COCH.sub.2NH.sub.2), 3.47 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.39-3.33 (1H, m, cyclohexaneH-1 or H-4),
2.12-2.05 (4H, m, 4H of cyclohexaneH-2, H-3, H-5, H-6), 1.91-1.80
(2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.41-1.30 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.6-DMSO) .delta.
-73.0, -124.1; m/z: 587 [M+H].sup.+.
I-56:
4-((4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexy-
l)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methoxy)-4-oxob-
utanoic acid tris salt
##STR00116##
[0438] .sup.1H nmr (400 MHz, D.sub.2O) .delta. 7.52 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.49 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.16 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.13 (1H, s, 1H of
pyrazoleH-5, thiazoleH-5, pyrazoleH-3, H-5), 7.13-7.07 (1H, m,
pyridineH-4 or H-5), 6.24 (1H, br d, J 8.0 Hz, pyridineH-4 or H-5),
5.69 (2H, s, NCH.sub.2O), 7.39 (1H, br t, J 11.5 Hz, cyclohexaneH-1
or H-4), 3.59 (6H, s, 3.times.CCH.sub.2OH), 3.55 (2H, q, J 7.0 Hz,
OCH.sub.2CH.sub.3), 3.37 (1H, brt, J 10.5 Hz, cyclohexaneH-1 or
H-4), 2.54 (2H, t, J 6.5 Hz, 2H of COCH.sub.2CH.sub.2CO), 2.39 (2H,
t, J 6.5 Hz, 2H of COCH.sub.2CH.sub.2CO), 2.12-2.04 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 2.15-1.98 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.55-1.44 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.32-1.21 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.10 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz, D.sub.2O) .delta. -73.4,
-124.7; m/z: 630 [M+H].sup.+.
I-68:
N-(3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-py-
razol-4-yl)-2-(1H-pyrazol-4-yl)thiazole-4-carboxamide Citric Acid
Cocrystal
##STR00117##
[0440] .sup.1H nmr (400 MHz, D.sub.6-DMSO) .delta. 8.53 (1H, s,
thiazoleH-5 or pyrazoleH-5), 8.29 (3H, s, pyrazoleH-3, H-5,
thiazoleH-5 or pyrazoleH-5), 8.08 (1H, td, J 9.0, 6.0 Hz,
pyridineH-4 or H-5), 7.29 (1H, ddd, J 9.0, 3.0, 2.5 Hz, pyridineH-4
or H-5), 5.14 (0.5H, br s, COH), 4.33 (1H, tt, J 11.5, 3.5 Hz,
cyclohexaneH-1 or H-4), 3.47 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.35 (1H, m, cyclohexaneH-1 or H-4), 2.74, 2.64 (3H, 2d AB system,
J 15.5 Hz, 3.times.0.5 CCH.sub.2CO.sub.2H), 2.08 (4H, m, 4H of
cyclohexaneH-2, H-3, H-5, H-6), 1.85 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.35 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6),
1.10 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3); .sup.19F nmr (380 MHz,
D.sub.6-DMSO) .delta. -73.0, -124.2; m/z: 500 [M+H].sup.+.
I-69:
(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)--
1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)methyl
dihydrogen phosphate bis(tris(hydroxymethyl)aminomethane) salt
##STR00118##
[0442] .sup.1H nmr (400 MHz, D.sub.2O) .delta. 7.89 (1H, s,
thiazoleH-5 or pyrazoleH-5), 7.80 (1H, s, thiazoleH-5 or
pyrazoleH-5), 7.45 (1H, s, pyrazoleH-3 or H-5), 7.44 (1H, s,
pyrazoleH-3 or H-5), 7.33 (1H, m, pyridineH-4 or H-5), 6.53 (1H, d,
J 9.0 Hz, pyridineH-4 or H-5), 5.51 (1H, d, J 6.5 Hz, NCH.sub.2OP),
3.93 (1H, tt, J 12.0, 3.0 Hz, cyclohexaneH-1 or H-4), 3.58 (2H, q,
J 7.0 Hz, OCH.sub.2CH.sub.3), 3.57 (12H, s,
2.times.H.sub.2NC(CH.sub.2OH).sub.3), 3.45 (1H, m, cyclohexaneH-1
or H-4), 2.14 (2H, br d, J 10.5 Hz, 2H of cyclohexaneH-2, H-3, H-5,
H-6), 2.03 (2H, br d, J 12.0 Hz, cyclohexaneH-2, H-3, H-5, H-6),
1.63 (2H, m, 2H of cyclohexaneH-2, H-3, H-5, H-6), 1.32 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.11 (3H, t, J 7.0 Hz,
OCH.sub.2CH.sub.3); .sup.31P nmr (162 MHz, D.sub.2O) .delta. 1.05;
.sup.19F nmr (380 MHz, D.sub.2O) .delta. -72.8 (d, 26.0 Hz), -124.7
(dd, J 27.0, 9.5 Hz); m/z: 610 [M+H].sup.+ (found [M+H].sup.+,
610.1432, C.sub.24H.sub.26F.sub.2N.sub.7O.sub.6PS requires
[M+H].sup.+ 610.1444).
I-70: benzyl
((S)-1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl-
)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)-4-methyl-1-oxop-
entan-2-yl)carbamate
##STR00119##
[0444] .sup.1H nmr (400 MHz, CDCl.sub.3) .delta. 8.78 (1H, s, 1H of
pyrazoleH-3, H-5), 8.50 (1H, s, thiazoleH-5 or pyrazoleH-5), 8.35
(1H, s, 1H of pyrazoleH-3, H-5), 8.14 (1H, s, thiazoleH-5 or
pyrazoleH-5), 7.65 (1H, td, J 9.0, 6.0 Hz, pyridineH-4 or H-5),
7.35-7.30 (5H, m, C.sub.6H.sub.5), 6.90 (1H, ddd, J 9.0, 3.0, 2.5
Hz, pyridineH-4 or H-5), 5.66 (1H, m, NCHCO), 5.50 (1H, d, J 9.0
Hz, NH), 5.14, 5.11 (2H, 2d AB system, J 12.5 Hz,
OCH.sub.2C.sub.6H.sub.5), 4.27 (1H, tt, J 11.5, 4.0 Hz,
cycohexaneH-1 or H-4), 3.56 (2H, q, J 7.0 Hz, OCH.sub.2CH.sub.3),
3.37 (1H, tt, J 10.5, 4.0 Hz, cyclohexaneH-1 or H-4), 2.29 (2H, br
d, J 12.0 Hz, 2H of cyclohexaneH-2, H-3, H-5, H-6), 2.22 (2H, m, 2H
of cyclohexaneH-2, H-3, H-5, H-6), 1.89 (2H, m, 2H of
cyclohexaneH-2, H-3, H-5, H-6), 1.82 (2H, m,
CHCH.sub.2CH(CH.sub.3).sub.2), 1.65 (1H, m,
CHCH.sub.2CH(CH.sub.3).sub.2), 1.47 (2H, m, 2H of cyclohexaneH-2,
H-3, H-5, H-6), 1.22 (3H, t, J 7.0 Hz, OCH.sub.2CH.sub.3), 1.07
(2H, br d, J 5.5 Hz, 1.times.CH(CH.sub.3).sub.2), 0.96 (3H, d, J
6.0 Hz, 1.times.CH(CH.sub.3).sub.2); .sup.19F nmr (380 MHz,
CDCl.sub.3) .delta. -72.5 (d, J 27.5 Hz), -124.4 (dd, J 27.0, 9.5
Hz); m/z: 769 [M+Na].sup.+, 747 [M+H].sup.+ (found [M+H].sup.+,
747.2885, C.sub.37H.sub.40F.sub.2N.sub.8O.sub.5S requires
[M+H].sup.+ 747.2883).
Example 19
[0445] The purpose of the project was to evaluate several salts of
compound I-18. Salts were prepared using 10 bases (two charge
ratios for NaOH and KOH). Suitable solvents include, but are not
limited to, methanol, DMSO/acetone (1:4 or 4:1), ethyl acetate,
THF/water (9:1) or a combination thereof. The salts were isolated
by centrifugation and dried under vacuum. Optionally, the salts
also may be heated to dry and/or remove at least a portion of
residual solvent.
[0446] 1) A disodium salt was obtained by mixing 1 equivalent of
I-18 with 2 equivalents of NaOH in a solvent at room
temperature.
[0447] 2) A dipotassium salt was obtained by mixing 1 equivalent of
I-18 with 2 equivalents of KOH in a solvent at room
temperature.
[0448] 3) A magnesium salt was obtained by mixing equimolar amounts
of I-18 and magnesium hydroxide in a solvent at room
temperature.
[0449] 4) A calcium salt was obtained by mixing equimolar amounts
of I-18 and calcium hydroxide in a solvent at room temperature.
[0450] 5) An ammonium salt was obtained by mixing equimolar amounts
of I-18 and ammonium hydroxide in a solvent at room
temperature.
[0451] 6) An arginine salt was obtained by mixing equimolar amounts
of I-18 and arginine in a solvent at room temperature.
[0452] 7) A lysine salt was obtained by mixing equimolar amounts of
1-18 and lysine in a solvent at room temperature.
[0453] 8) A choline salt was obtained by mixing equimolar amounts
of I-18 and choline in a solvent at room temperature.
[0454] 9) A tris salt was obtained by mixing equimolar amounts of
I-18 and tromethamine in a solvent at room temperature.
[0455] 10) A meglumine salt was obtained by mixing equimolar
amounts of I-18 and meglumine in a solvent at room temperature.
[0456] 11) A monopotassium salt was obtained by mixing equimolar
amounts of I-18 and KOH in a solvent at room temperature.
[0457] 12) A monosodium salt was obtained by mixing equimolar
amounts of I-18 and NaOH in a solvent at room temperature.
[0458] All salt hits were characterized by XRPD, TGA and DSC. The
stoichiometric ratio was determined by 1H NMR or HPLC/IC.
Characterization results of salt hits and freeform forms were
listed in Table 5.
TABLE-US-00005 TABLE 5 Characterization results of initial salts
Weight loss DSC endotherm Molar ratio Speculated Salt Hits (%,
temp.) (peak,.degree. C.) (base/free acid) form K Salt 3.1 (to
150.degree. C.) 170.3, 248.1 0.7:1 Anhydrate/ Hydrate K Salt 5.3
(to 140.degree. C.) 94.6*, 174.0* 1.1:1 Hydrate .sup. 6.7
(140.degree. C.~240.degree. C.) K Salt 4.0 (to 130.degree. C.)
101.7*, 168.5* 1.0:1 Hydrate .sup. 4.7 (130.degree. C.~230.degree.
C.) K Salt 5.9 (to 125.degree. C.) 100.6, 149.0 1.4:1 Anhydrate
Arginine Salt 2.1 (to 190.degree. C.) 130.7, 216.1 1.2:1 Anhydrate
Choline Salt 5.1 (to 160.degree. C.) 67.7, 158.7, 195.0 0.8:1
Anhydrate Choline Salt 3.3 (to 160.degree. C.) 67.2, 159.4, 195.7
NA Anhydrate/ Hydrate Tris Salt 1.2 (to 150.degree. C.) 61.3, 174.3
1.1:1 Channel hydrate Tris Salt 2.4 (to 140.degree. C.) 63.0,
135.2, 175.6 0.9:1 Channel hydrate Na Salt) 5.5 (to 240.degree. C.)
97.6, 176.4, 195.0 1.5:1 Anhydrate/ .sup. 6.0 (110.degree.
C.~240.degree. C.) Hydrate Na Salt 13.5 (to 250.degree. C.) 109.9,
183.1, 226.0 1.6:1 Anhydrate/ Hydrate Na Salt 6.1 (to 150.degree.
C.) 66.6, 110.7, 200.7 1.6:1 Anhydrate/ Hydrate Ammonium Salt 3.0
(to 115.degree. C.) 97.9, 160.2, .sup. 0.6:1.sup.# Anhydrate/ .sup.
2.6 (115.degree. C.~200.degree. C.) 192.9, 238.8 Hydrate Arginine
Salt) 4.0 (to 160.degree. C.) 80.8, 119.4, 1.0:1 Anhydrate/ 145.1,
177.1 Hydrate Lysine Salt 5.0 (to 140.degree. C.) 69.3, 175.4,
227.3 0.7:1 Anhydrate/ Hydrate Mg Salt 11.7 (to 230.degree. C.)
69.4, 116.4, 183.2 .sup. 1.0:1.sup.# Anhydrate/ Hydrate Ca Salt 6.9
(to 180.degree. C.) 114.0*, 190.5* .sup. 0.8:1.sup.# Anhydrate/
Hydrate *Onset temperature. .sup.#Solid could not be dissolved
completely before HPLC and IC test, so the stoichiometric ratio was
for reference only.
[0459] Based on the above, a potassium salt, arginine salt, choline
salt and tris salt were selected for further evaluation.
TABLE-US-00006 TABLE 6 Characterization of evaluation salts TGA
weight loss DSC endotherm Molar ratio Salt form (%, temp.)
(.degree. C., peak) (base/API) K salt 6.6 (to 220.degree. C.) 199.8
.sup. 1:1 Arginine salt 3.3 (to 190.degree. C.) 131.6, 217.1 .sup.
1:1 Choline salt 2.3 (to 160.degree. C.) 64.3, 186.7 0.9:1 Tris
salt 5.8 (to 150.degree. C.) 156.5, 176.2 1.1:1
Hygroscopicity Evaluation
[0460] To investigate the solid form stability as a function of
humidity, DVS isotherm plot of the K salt, Arginine salt, Choline
salt and Tris salt were collected at 25.degree. C. between 0 and
95% RH. The DVS plot of the K salt is shown in FIG. 20. The water
uptake at 70% RH was 0.42%, and increased dramatically to 16.5% at
95% RH. The DVS plot of Arginine salt is shown in FIG. 21. A water
uptake of 1.43% was observed at 80% RH, indicating Arginine salt
was slight hygroscopic. The DVS plot of Choline salt is shown in
FIG. 22. The water uptake at 70% RH was 3.66%, and increased
dramatically to 32.4% at 95% RH. The DVS plot of Tris salt is shown
in FIG. 23. The water uptake at 70% RH was 6.06%, and increased
dramatically to 39.5% at 95% RH.
Physical and Chemical Stability
[0461] The physical and chemical stability of the K salt, Arginine
salt, Choline salt and Tris salt were evaluated under conditions of
25.degree. C./60% RH and 40.degree. C./75% RH for 1 week. Each
sample was added into 3 mL glass vials, sealed by parafilm with
several holes, and kept under tested condition. After one week,
samples was taken for XRPD and HPLC purity test. All the
characterization data are summarized in Table 7.
TABLE-US-00007 TABLE 7 Summary of physiochemical stability
evaluation 25.degree. C./60% RH/1 week 40.degree. C./75% RH/1 week
Initial purity Purity/Initial Form Purity/Initial Form Salt (area
%) purity (%) change purity (%) change K salt 97.27 99.0 No 99.1
Yes Arginine salt 95.91 99.4 No 99.6 No Choline salt 98.70 100.0 No
99.1 No Tris salt 96.06 100.6 No 98.9 No
[0462] The XRPD patterns showed that no form change was observed
after storage under the two conditions for the Arginine salt,
Choline salt and Tris salt. For the K salt, no form change was
observed under 25.degree. C./60%.sub.0RH while a form change was
observed under 40.degree. C./75%.sub.0RH. For both the K salt and
Arginine salt, a slight purity decrease was observed under both
conditions after 1 week. For Choline salt and Tris salt, no HPLC
purity decrease was observed under 25.degree. C./60%.sub.0RH while
a purity decrease was observed under 40.degree. C./75%.sub.0RH.
Impurities summary for all salt hits are shown in Tables 8-11. The
peak at RRT=1.17 corresponds to I-1, the parent compound of I-18
that is formed by hydrolysis. Decrease in purity of I-18 salt is
typically correlated with a corresponding increase in I-1 parent
impurity level.
TABLE-US-00008 TABLE 8 Impurity summary of the potassium salt Area
(%) # Peak RRT Initial 25.degree. C./60% RH 40.degree. C./75% RH 1
1.00 97.27 96.26 96.40 2 1.14 <0.04 <0.04 0.05 3 1.17 1.33
2.14 1.80 4 1.40 0.23 0.25 0.39 5 1.44 0.21 0.30 0.24 6 1.70 0.18
0.27 0.24 7 1.72 0.77 0.78 0.83 8 1.81 <0.04 <0.04 0.04
TABLE-US-00009 TABLE 9 Impurity summary of the arginine salt Area
(%) # Peak RRT Initial 25.degree. C./60% RH 40.degree. C/75% RH 1
0.77 <0.03 0.03 0.04 2 1.00 95.91 95.31 95.50 3 1.13 <0.03
0.06 0.06 4 1.17 2.39 2.68 2.48 5 1.35 <0.03 0.06 0.11 6 1.45
0.44 0.50 0.47 7 1.71 0.73 0.74 0.73 8 1.73 <0.53 0.61 0.60
TABLE-US-00010 TABLE 10 Impurity summary of the choline salt Area
(%) # Peak RRT Initial 25.degree. C./60% RH 40.degree. C./75% RH 1
0.77 0.03 0.04 0.04 2 1.00 98.70 98.66 97.81 3 1.13 0.06 0.06 0.06
4 1.17 0.75 0.58 1.31 5 1.35 <0.03 0.10 0.14 6 1.45 0.06 0.07
0.11 7 1.71 0.06 0.05 0.08 8 1.73 0.33 0.46 0.46
TABLE-US-00011 TABLE 11 Impurity summary of the tris salt Area (%)
# Peak RRT Initial 25.degree. C./60% RH 40.degree. C./75% RH 1 0.77
<0.03 <0.03 0.03 2 1.00 96.06 96.61 95.03 3 1.13 0.07 0.06
0.06 4 1.17 1.87 1.63 2.69 5 1.45 0.37 0.35 0.47 6 1.71 0.86 0.80
0.88 7 1.73 0.76 0.55 0.84
[0463] In view of the many possible embodiments to which the
principles of the disclosed invention may be applied, it should be
recognized that the illustrated embodiments are only preferred
examples of the invention and should not be taken as limiting the
scope of the invention. Rather, the scope of the invention is
defined by the following claims. We therefore claim as our
invention all that comes within the scope and spirit of these
claims.
* * * * *